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Abstract
Oncogene-induced senescence (OIS) is an irreversible G1 cell cycle arrest triggered by 
aberrant expression of oncogenes. The arrest observed during senescence is 
implemented mainly through activation of p53 and the upregulation of the cyclin- 
dependent kinase (CDK) inhibitors, p l6 INK4a and p21CIP1. In vivo OIS may act as a 
barrier to neoplastic transformation, and bypass of OIS is a prerequisite for 
tumorigenesis.
In this work the role of OIS in thyroid carcinogenesis was investigated by in 
combination of in vitro and in vivo approaches.
We found that the expression of different thyroid tumour-associated oncogenes (BEAT, 
RAS, RET and TRK) in human primary thyrocytes triggers senescence, as 
demonstrated by the presence of OIS hallmarks. For instance, cells appeared flatted and 
enlarged; they displayed senescence-associated P-galactosidase activity (SA-P-Gal), 
senescence associated heterochromatic foci (SAHF), and high expression levels of the 
CDK inhibitors p lb 1^ 43 and p21CIP1 and p53. Additionally, using RNA-interference 
strategy we directly assessed the individual contribution of p lb 114^ 3 in BRAFV600E- 
induced senescence. In our experimental setting the inactivation of p lb 1^ 43 did not 
have any impact on oncogene-induced senescence suggesting the possibility that 
pl6iNK4a may cooperate with other factors in triggering senescence.
A major consequence of oncogene activation is the secretion of a plethora of proteins 
including growth factors, cytokines, and chemokines. Some of these secreted proteins 
are known to be regulators of OIS. For example, IGFBP7 is recently proposed as a 
mediator of BRAFY600E-induced senescence in melanocytes.
We showed that IGFBP7 gene is frequently downregulated in Papillary thyroid tumour 
(PTC); restoration of its expression in a PTC-derived, IGFBP7-negative cell line affects
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growth properties, migration and invasion, and this is associated to the induction of 
apoptosis. Thus, our results implicate IGFBP7 as a tumour suppressor protein in thyroid 
tumours. Additionally, we investigated the possible involvement of IGFBP7 in our 
cellular senescence model. Our data indicate that IGFBP7 expression is not changed 
during OIS.
We also established and characterized OIS inducible system in our cellular model; we 
transduced human primary thyrocytes with a retroviral vector carrying an activated 
form of RAS oncogene coupled to the ligand binding domain of the estrogen receptor. 
Upon addition of 4-hydroxytamoxifen (4-OHT), we observed a robust induction of 
senescence, including significantly reduced incorporation of BrdU and high levels of 
pl6iNK4a? p21CIP1, and p53. Moreover, we assessed the relative importance of tumour 
suppressor proteins, p lb 1^ 43 and p53 in mediating OIS in H-RASG12V transfected 
thyrocytes. Surprisingly, silencing of p53 expression did not alter the growth arrest 
induced by H-RASG12V, whereas p lb 1^ 43 seems to be the dominant effector of 
senescence in this experimental setting, as its specific inactivation delays the onset of 
senescence.
We also found that senescence induced by H-RASG12V is associated with activation of 
inflammatory transcriptome including IL8 and its receptor CXCR2. We reported that 
knocking down the chemokine receptor CXCR2 either IL8 prevents H-RASG12V cells 
from undergoing OIS.
To translate information from in vitro experiments to a clinic setting, senescence 
markers identified in cultured cells were used to detect OIS in a panel of thyroid 
tumours characterized by different aggressiveness. Our immunohistochemical analysis 
showed that the expression of OIS markers is upregulated at early stages of the thyroid 
tumour and lost during tumour progression. These evidences support the notion that
12
OIS may counteract oncogenic activity in thyroid tumours, and its escape allows thyroid 
tumour progression.
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CHAPTER 1
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Chapter 1 -  Introduction
1.1 Thyroid cancer
Thyroid cancer is the most common malignant tumour of endocrine system, accounting 
for approximately 1% of all newly diagnosed cancer cases. Its worldwide incidence has 
increased significantly over the last few decades, albeit it is limited to the papillary type 
of thyroid cancer and is mostly due to tumours of small size (less than 1 cm, termed 
microcarcinoma) (Davies and Welch, 2006; Albores-Saavedrea et al., 2007). It is not 
yet clear if such increase is a true biological issue or if it is a result of improvement in 
the diagnostic tools, for example increased access to high resolution imaging 
(particularly ultrasonography) and increased use of fine-needle aspiration biopsy. 
However, it has been proposed that other factors also contribute to the fast-growing 
number of new thyroid cancer cases, including the exposure to radiation during medical 
procedures (Mettler et al., 2007), the obesity (Kitahara et al., 2011) as well as the 
increase in pathological detection of incidental papillary thyroid cancer (Grodski et al., 
2008). Mortality rates, in contrast to incidence rates, are stable or decreasing (Davies et 
al., 2002; La Vecchia et al., 2010). The 10-year relative survival rate is very good, 
ranging from 90% in differentiated thyroid cancer (Hundahl et al.,1998) to 74% in 
medullary thyroid cancer while it is dramatically short, less than 1 year, in case of 
anaplastic thyroid cancer which represents one of the most aggressive malignant 
tumours.
Patients with differentiated thyroid cancer are cured by surgery, adjuvant radioactive 
iodine therapy and THS suppression (Samaan et al., 1992). However, some of these 
patients cannot be cured because tumours are unresctable, or fail to absorb radioiodine, 
or, in rare cases, they progress from differentiated to poorly differentiated carcinoma.
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Anaplastic thyroid carcinomas are very difficult to treat; surgery is not often technically 
feasible due to the local invasion of the contiguous anatomic structures (Hag et al., 
2005).
Thyroid cancer is a unique and fascinating model that includes several histotypes 
characterized by peculiar biological and clinical features.
Significant knowledge in molecular mechanisms of thyroid carcinogenesis has been 
achieved in the past few years. This improved knowledge has provided new insights 
into thyroid cancer aetiology and has offered novel diagnostic tools and prognostic 
markers that could improve the management of patients with thyroid cancer.
1.1.1 Histological classification
The vast majority of thyroid tumours arise from thyroid follicular epithelial cells, 
whereas 3-5% of cancers derive from parafollicular or C cells. The follicular cell- 
derived cancers comprise papillary carcinoma (about 80% of the cases), follicular 
carcinoma (10%), poorly differentiated carcinoma (4-6%), and anaplastic carcinoma (2- 
5%). Tumours, originating from C cells, are known as medullary carcinomas (5-10%). 
Papillary and follicular histotypes are also referred as differentiated thyroid carcinomas. 
Poorly differentiated carcinoma and anaplastic carcinoma, much less frequent, can 
develop de novo or derive through the process of stepwise dedifferentiation of papillary 
and follicular carcinoma (Nikiforov and Nikiforova, 2011) (Figure 1.1).
Papillary thyroid carcinoma (PTC)
PTC is the most frequent thyroid tumour type and the most common paediatric thyroid 
malignancy (Davies and Welch, 2006). It is associated with external radiations; an 
increased incidence has been observed after nuclear Chernobyl accident, overall in 
children, who are much more sensitive to the tumorigenic effect of external irradiation, 
because of the high degree of replication of thyroid cells (Nikiforov, 2006).
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PTCs characteristically spread to regional lymph nodes, in fact cervical lymph node 
metastases are very frequent at the time of diagnosis.
Classic PTC is microscopically characterized by a papillary architecture and a 
population of follicular cells with “ground glass” nuclei and irregularities of nuclear 
contours, including grooves and nuclear pseudoinclusions. Psammona bodies, which 
represent a typical PTC feature, are found in at least 50% of cases: they are rounded and 
concentrically laminated calcifications, which can be present within the tumour stroma, 
in the tip of the papillae or in lymphatic spaces.
The prognosis of classic PTC is excellent and influenced by patient age, tumour size 
and presence of distance metastasis.
In addition to classic PTC, also known as not otherwise specified (NOS), several 
histological variants, differing in morphological pattern as well as in prognosis have 
been described. The most common are papillary thyroid microcarcinoma, follicular, 
oncocytic, clear cells, diffuse sclerosing, tall cell, columnar cell, solid and cribriform 
(Sherman, 2003). For most of them the prognosis is similar to classic PTC, whereas for 
some histotypes such as tall cell, columnar cell and solid variant, the outcome is worse. 
These rare variants are characterized by an aggressive behaviour, with the primary 
tumour often presenting with extrathyroid extension and vascular invasion. Papillary 
thyroid microcarcinoma (PTMC) represents a particular variant of papillary thyroid 
carcinoma and it is very common in the general population, accounting for up to 30% of 
all papillary carcinoma. It is defined as a tumour measuring < lcm in diameter and it is 
considered the early stage of PTC, exhibiting architectural, cytological and behavioural 
features of papillary lesions, often found incidentally. It has an indolent course and very 
favourable prognosis despite the presence of multifocality within the thyroid and 
synchronous nodal local-regional spread (Sakorafas et al., 2005).
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Follicular thyroid carcinoma (FTC)
FTC is characterized by evidence o f follicular cell differentiation but lacking the 
diagnostic features of PTC. It is usually encapsulated and solitary (Sobrinho Simoes et 
al., 2004). FTC is more common in regions of iodine insufficiency and metastasizes 
almost exclusively via the blood stream (Delellis et al., 2004). Compared to PTC, 
cervical lymph nodes involvement is less common at diagnosis while distant metastases 
can be found in 20% of the cases, lung and bone being the most involved sites. 
Invasiveness of the capsule and vascular invasion are the microscopic characteristics of 
FTC.
Hurthle cell carcinoma (HCC) is a rare variant of FTC. It differs from conventional 
FTC in biological and clinical behaviour, leading some groups to classify HCC as a 
distinct pathologic entity. It is defined as a tumour composed of 75% or greater Hurthle 
cells with complete capsular-or vascular-invasion (Rosai et al., 1992). The tumour cells 
are typically characterized by an abundant granular, eosinophilic cytoplasm derived 
from the presence of a large number of mitochondria. Moreover, HCC presents cervical 
lymph node in 30% of the cases, and distant metastases can also occur.
FTC is generally considered a more aggressive disease with a poorer prognosis when 
compared with PTC; 50% of patients with a widely invasive FTC die, whereas patients 
with a minimally invasive FTC have a survival expectance similar to that of a normal 
population matched for age and sex (Sobrinho-Simoes et al., 2011).
Poorly differentiated thyroid carcinoma (PDTC)
PDTC is a rare tumour with higher incidence in areas having iodine deficiency. It 
behaves intermediately between differentiated (PTC and FTC) and anaplastic 
carcinoma. It can be the terminal stage of the dedifferentiation process of PTC or FTC 
or can grow ex novo (Pilotti et al., 1997). PDTC can appear as a unique rapidly growing 
thyroid with or without cervical node involvement. Distant metastases can be also
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present. Three different histological patterns have been described: insular, trabecular 
and solid (Sobrinho-Simoes, 1996). They are similar for features including increased 
mitotic activity, necrosis, and capsular and vascular invasion. The mean 5-year survival 
of FTC patients is less than 50% (Sobrinho-Simoes et al., 2005).
Anaplastic thyroid carcinoma (ATC)
ATC is the most aggressive and lethal form of thyroid cancer. It carries a dismal 
prognosis, with a median survival of 4 to 12 months from the time of diagnosis. ATC 
can arise de novo or from preexisting differentiated thyroid cancer. At the clinical level, 
it is characterized by a large thyroid mass, rapidly growing and infiltrating surrounding 
tissues and muscles. The larynx (13%), oesophagus (44%) and trachea (46%) may also 
be involved in up to 70% of the patients. Systemic metastases disease can also occur at 
presentation or during the course of the illness with lung being the most common site 
(80%), followed by bone (6-15%) and brain (5-13%) (Mclever et al., 2001). The clinical 
course of the disease can be so rapid that surgical procedures performed are often 
useless.
Papillary
carcinom a
Poorly
d ifferentiated
carcinom a
A naplastic
carcinom a
Follicular cell
Follicular
carcinom a
Follicular
ad en om a
Figure 1.1 Multistep oncogenesis in thyroid cancer. The follicular cells give rise to a broad spectrum 
of tumours which display very distinctive phenotypic, biological and clinical features. (Adapted from 
Nikiforov and Nikiforova, 2011)
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Medullary thyroid cancer (MTC)
MTC arises from parafollicular or C cells that produce calcitonin, and predominately 
develops as a sporadic tumour in about 60% of the cases, whereas it is hereditary in 
40% of the cases. MTC is the principal disease feature of multiple endocrine neoplasia 
type 2 (MEN2), an autosomal dominantly inherited cancer syndrome caused by 
activating germ-line mutations in the RET proto-oncogene (Ball et al., 2000).
MTC is typically located at the junction of the upper third and the lower two-thirds of 
the thyroid lobes. On histological examination, MTC consists in sheets of spindle- 
shaped, round or polygonal cells separated by fibrous stroma. The nuclei are usually 
uniform in shape with rare mitotic figures. The cytoplasm is eosinophilic with a finely 
granular appearance (Hedinger et al., 1988; Rosai et al., 1992).
Metastatic dissemination to both central and latero-cervical lymph nodes occurs at 
similar high frequencies. Distant metastases are the main cause of MTC-related death. 
They are usually diffuse and multiple in involved organs and simultaneously affect 
multiple organs, such as the liver, lungs and bones (Moley and DeBenedetti, 1999; 
Guignat et al., 2001).
The survival of MTC patients strongly correlates with stage at diagnosis. The 10-year 
survival rate is approximately 65%. Some clinical features are related to a lower 
survival. These include older age, male gender, extent of local tumour and presence of 
distant metastases (Bhattacharyya, 2003).
1.1.2 Genetic alterations in thyroid cancer
Thyroid cancer initiation and progression occur through gradual accumulation of 
various genetic and epigenetic alterations, including activating and inactivating somatic 
mutations, alteration in gene expression patterns.
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Moreover, thyroid cancer represents a type of neoplasia in which critical genes are 
frequently mutated via two distinct molecular mechanisms: point mutation or 
chromosomal rearrangement. The former is a result of single nucleotide change within 
the DNA chain, whereas the latter represents a genetic abnormality with breakage and 
fusion of parts of the same or different chromosomes.
Most mutations in thyroid cancer involve the effectors of the MAPK and PI3K-AKT 
pathways (Figure 1.2). The mutated genes that affect these signalling networks encode 
cell membrane receptor tyrosine kinases RET and NTRK1 and intracellular signal 
transducers BRAF and RAS. These typically mutually exclusive mutations occur in 
approximately 70% of patients with PTC (Kimura et al., 2003). In FTC, in addition to 
mutation of RAS, another common event is PAX8/PPARy rearrangement (Dwight et 
al., 2003) (Figure 1.7). Thyroid cancer progression and dedifferentiation involve a 
number of additional mutations that affect the PI3K-AKT pathway and other cell 
signalling pathways.
R eceptor
tyrosine
k in ase
BRAF
MAPK
pathway
MEK
mTOR
Figure 1.2 The main signalling pathways involving in thyroid cancer. MAPK and PI3K-AKT 
pathways are involved in propagation of signals from various cell membrane receptor tyrosine kinase into 
the nucleus, and they regulate multiple cell process including proliferation, differentiation and survival. 
(Adapted from Nikiforov and Nikiforova, 2011)
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1.1.2.1 RET
The RET prooncongene is located in the pericentromeric region of chromosome 
10qll.2 and comprises 21 exons (Pasini et al., 1995). RET encodes a receptor tyrosine 
kinase, which is expressed in neuroendocrine cells (including thyroid C cells and 
adrenal medullary cells), neural cells, urogenital tract cells and testis germ cells. RET 
protein is structured with an extracellular portion (which contains four cadherin-like 
repeats, a calcium binding site, and a cysteine-rich region), a transmembrane portion, 
and an intracellular portion, which two tyrosine kinase subdomains that are involved in 
the activation of several intracellular signal transduction pathways (Ishizaka et al., 
1989) (Figure 1.3).
RET
cadherin dom ain
cysteine dom ain
^  cell m em brane
TKi
TK2
RET 9 (1,072 aa) 
RET 43 (1,106 aa) 
RET 51 (1,114aa)
Figure 1.3 Schematic representation of the RET tyrosine kinase. The extracellular region comprises 
four cadherin domains and a cysteine-rich domain. A single transmembrane region spans the cell 
membrane, and the two tyrosine kinase domains (TKI and TK2) are located in the intracellular region. 
The three isoforms of RET are indicated. (Adapted from de Groot JW, 2006)
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A tripartite cell-surface complex is necessary for RET signalling. One of four glial 
derived neurotrophic factor (GDNF) family ligands, GDNF, neurturin, artemin, or 
persephin, binds RET in conjunction with one of four glycosylphosphadylinositol- 
linked co-receptors designated as GFRa 1, 2, 3, and 4. It has been demonstrated that 
GDFN interacts with GFRal, whereas neurturin, artemin, and persephin preferentially 
bind GFRa2, GFRa3, or GFRa4, respectively (Airaksinen et al., 1999). Ligand 
stimulation leads to activation of the RET receptor with dimerization and subsequent 
autophosphorylation of intracellular thyrosine residues, which serve as docking sites for 
adaptor proteins that link the signal from the receptor to the main signal transduction 
pathways (Santoro et al., 2004). At least 18 of these specific phosphorylation sites have 
been identified. For example, phosphorylated Y981 constitutes the major binding site of 
v-src sarcoma viral oncogene homolog (Src), which is essential for neuronal survival. 
Src is also necessary for RET signalling through focal adhesion kinase (FAK), an 
important mediator of tumour cell migration and metastases. Tyrosine 1015 is a binding 
site for phospholipase C (PLC)-y, which activates protein kinase C (PKC) enzymes 
(Andreozzi et al., 2003). PCK enzymes, in turn, cause RET phosphorylation but also 
down-regulate RET and its downstream signalling, thus functioning as a negative 
feedback loop to modulate RET activity. Phosphorylation of Y1062 is crucial for 
activation of major intracellular signalling pathways such as RAS/ERK, PI3K/AKT, 
p38MAPK, and Rac/JNK pathways. Y1062 is a docking site for various adaptor 
proteins, including Src-homology collagen (She), ShcC, insulin receptor substrate (IRS) 
1/2, fibroblast growth factor receptor substrate 2 (FRS2), downstream of kinase (DOK) 
1/4/5 and Enigma (Iwashita et al., 1996).
In 1990, a chimeric gene generated by the fusion of the RET tyrosine kinase domain 
and the 5’ terminal region of a new gene was reported as the first oncogene in PTC and
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was therefore denominated RET/PTC (Grieco et al., 1990) (Figure 1.5). These 
chromosomal aberrations occur in 2 to 40% of cases and are the result of double­
stranded DNA breaks with erroneous rearrangements involving the C-terminal portion 
of RET and the promoter and coding region of the N terminus of a constitutively 
expressed unrelated gene from chromosome 10 or a different chromosome (Santoro et 
al., 2006). Interestingly, all breakpoints of the RET gene occur within intron 11. All 
partner genes have in common constitutive expression in thyroid follicular cells and 
dimerization and is no longer an integral membrane protein due to the lack of a 
transmembrane domain like RET. The intact tyrosine kinase domain of RET allows the 
RET/PTC protein to bind SHC via Y1062 and thus activates the MAPK pathway. To 
date, 12 different fusion partner genes are reported to form at least 17 different RET 
hybrid oncogenes (Tallini and Asa, 2001; Saenko et al., 2003). The most prevalent 
variants of these chimeric oncogenes are RET/PTC 1 (60 to 70%) and RET/PTC3 (20 to 
30%) in which RET is fused to either CCDC6 (also known as H4) or NCOA4 (also 
known as ELE1), respectively (Nikiforov, 2002). Both of these rearrangement types are 
paracentric, intrachromosomal inversions, as all fusion partners reside on the long arm 
of chromosome 10.
Several studies reported an increase in the prevalence of RET/PTC rearrangements in 
PTC from patients with a radiation history (Fagin et al., 2004; Nikiforova et al., 2000). 
After Chernobyl accident the majority of PTCs carry RET/PTC3 and are associated 
with the solid/follicular variant of PTC, while the less frequent RET/PTC1 is associated 
with the classical and diffuse sclerosing variant (Williams, 2002).
Besides the association with ionizing radiation, there are several lines of evidence that 
indicate RET/PTC as a causative factor in the pathogenesis of PTC. RET/PTC 
transforms thyroid follicular cells in vitro (Santoro et al., 1993), and overexpression of 
RET/PTC1 and RET/PTC3 in the thyroid of transgenic mice leads to the development
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of tumours that resemble PTC (Powell et al., 1998; Santoro et al., 1996). Interestingly, 
not all transgenic mice developed thyroid tumours, suggesting that the expression of the 
oncoprotein is necessary but not sufficient for tumorigenesis. Furthermore, in 
microscopic PTC, RET/PTC expression is highly prevalent, indicating that RET/PTC is 
activated at early stages of the tumour (Sugg et al., 1998).
Although several studies failed to demonstrate correlation of RET/PTC rearrangements 
with clinicopathological features of increased mortality (Puxeddu et al., 2003; Santoro 
et al., 2002; Tallini et al., 1998), different types of RET/PTC rearrangement with 
variation in biological behaviour were described. Patients with RET/PTC1 usually show 
an indolent behaviour, whereas RET/PTC3 is associated with a more aggressive tumour 
phenotype (Basolo et al., 2002; Bongarzone et al., 1998). These observations are in 
keeping with transgenic mouse models expressing RET/PTC. Mice harbouring 
RET/PTC 1 develop thyroid lesions with morphological features of PTC that do not 
metastasize, whereas mice carrying RET/PTC3 are associated with tumour growth and 
metastases (Powell et al., 1998; Santoro et al., 1993).
RET gene is also crucial in MTC being mutated in more than 95% of MEN2 families 
and in 30-50% of sporadic MTCs (Nikiforova and Nikiforov, 2008). A spectrum of 
RET mutations has been identified in MEN2 families. In 98% of MEN2A, the 
mutations affect one of the five cysteines in the extracellular cysteine-rich domain of 
RET: codons 609, 611, 618, 629 (exon 10), and 634 (exon 11) (Eng et al., 1996). These 
mutations result in receptor dimerization and constitutive activation. The “gain 
function” mutations associated with familial MTC (FMTC) involve a broad range of 
codons including some associated with MEN2A, particularly, 609, 618, and 620, as 
well as others: 768, 790, and 791 (exon 13), 804 and 844 (exon 14), or 891 (exon 15) 
(Niccoli-Sire et al., 2001; Kouvaraki et al., 2005). Most MEN2B patients (95% of 
cases) carry the M918T mutation in RET kinase domain, causing receptor auto­
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phosphorylation and activation, resulting in a shift in substrate specificity (Hansford 
and Mulligan, 2000).
Besides mutations, other RET genetic alterations must occur at the somatic level and act 
in concert with RET mutations for the tumour to develop: duplication of the mutant 
allele or deletion of wild type allele have been reported (Huang et al., 2000).
1.1.2.2 NTRK1
NTRK1 (also named TrkA) is a tyrosine kinase receptor for the nerve growth factor 
(NGF) and is a member of the neurotrophin receptor family which also includes 
NTRK2 and NTRK3, binding to BDNF and NT3, respectively (Kaplan and Miller,
2000V/
NTRK1 regulates growth, differentiation, and programmed cell death of neurons in both 
the peripheral and central nervous system. The NTRK1 gene is located on chromosome 
lq21-22 and consists of 17 exons distributed within a 25-kb region (Greco et al., 1998). 
The NTRK1 receptor is a glycosylated protein of 140 KDa, comprising an extracellular 
portion containing Ig-like and leucine rich domains for ligand binding, a single 
transmembrane region made of 25 hydrophobic, a juxta-membrane domain, a catalytic 
domain responsible for the kinase activity and a C-terminal tail of about 15 amino acids 
(Figure 1.4). Following NGF binding, NTRK1 undergoes dimerization and 
autophorylation of five tyrosine residues (Y490, Y670, Y675, and Y785) (Figure 1.5). 
Activated receptor initiates several signal transduction cascades, including MAPK, 
PI3K, and the PLC-y pathways. These signalling networks culminate in the activation of 
transcription factors that alter gene expression (Kaplan and Miller, 2000).
26
Signal Peptide ( aa 1-32) 
Cysteine cluster ( aa 33-67) 
Leu-rich motif ( aa 68-139) 
Cysteine cluster ( aa 140-191)
Ig-like domain ( aa 192-284)
Ig-like domain ( aa 285-381)
Transmembrane region ( aa 408-433) 
Juxtamembrane region ( aa 434-509) Y490
Tyrosine kinase domain ( aa 510-775)
j — Y670, Y674.Y675
C-terminal tail ( aa 776-790) 1r — Y785
Figure 1.4 Schematic representation of NTRK1 receptor. The domains and the main tyrosine residues 
of the NTRK1 receptor are indicated.
Deregulation of NTRK1 activity is associated with several human diseases. Mutations 
affecting NTRK1 have been found in CIPA, Congenital Insensitivity to Pain with 
Anhidrosis, a rare recessive genetic characterized by loss of pain and temperature 
sensation, defects in thermal regulation and occasionally mental retardation (Indo et al., 
1996; Pierotti and Greco, 2006).
A mutation in the NTRK1 gene was identified in a patient with acute myeloid 
leukaemia. This deletion removes 75 amino acids in the extracellular domain of NTRK1 
receptor resulting in vitro transforming activity (Reuther et al., 2000).
NTRK1 was also shown to play a role in regulating neurogenic neoplasms such as 
neuroblastoma (NBL). High levels of NTRK1 are expressed in NBL with good 
prognosis which often spontaneous regression (Nakagawara et al., 1992). On the other
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hand, down regulation of NTRK1 was found in NBL with aggressive behaviour 
(Borrello et al., 1993; Nakagawara et al., 1992).
Deregulation of NGF/NTRK1 pathway, may also lead to prostate and breast cancer 
(Weeraratna et al., 2001; Descamps et al., 1998).
Several TRK oncogenes, arising from rearrangements of NTRKl gene, have been 
isolated in PTC. The NTRKl gene joins to TMP3 (Martin-Zanca et al., 1986), TPR 
(Greco et al., 1992) or TFG (Greco et al., 1995) generating chimeric oncogenes TRK, 
TRK-T1, TRK-T2 and TRK-T3, respectively. TRK-T1 and TRK-T2 are two fusion 
variants of TPR-NTRK1 (Greco et al., 1997).
In TRK the NTRKl TK domain is fused to the sequences of one isoform of the non­
muscle tropomyosin gene, TMP3, localized on chromosome Iq22-q23 (Wilton et al., 
1995).
TRK-T1 oncogene contains sequences belonging to the translocated promoter region 
(TPR) gene, encoding a filamentous protein of the nuclear protein pore complex 
implicated in nuclear protein transport (Byrd et al., 1994). TPR locus is located on 
chromosome lq25 and the mechanism leading to the formation of TRK-T1 oncogene is 
an intrachromosomal inversion inv(l)(q21-22q25) (Miranda et al., 1994). TRK-T1 
encodes a 55 kDa protein, consisting of 192 amino acids of TPR preceding the NTRKl 
portion (Greco et al., 1997).
In addition, TPR is involved in generating TRK-T2 oncogene, which contains a TPR 
portion longer by 737 amino acids than in TRK-T1 (Greco et al., 1997).
The TRK-T3 oncogene is activated by TFG (TRK Fused Gene), a novel gene localized 
on chromosome 3 (3ql 1-12) (Greco et al., 1995). Differently from the other TRK 
oncogenes, TRK-T3 is produced by a translocation involving chromosomes 1 and 3
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t(l;3)(q21-22;qll-12). The TRK-T3 protein has a molecular weight of 68 kDa and is 
made of 592 amino acids.
Somatic rearrangements of NTRKl gene in PTC occur with a significantly lower 
prevalence than RET/PTC rearrangements; they are present in about 11% of PTC and 
are rare (3.3%) in post-Chernobyl thyroid tumours (Bongarzone et al., 1998). 
Experimental evidence indicates that TRK oncogenes play a direct role and represent an 
early event in the thyroid carcinogenesis. Transgenic mice carrying TRK-T1 oncogene 
under the control of thyroglobulin promoter (Tg-TRK-Tl mice) develop thyroid 
hyperplasia and PTC (Russell et al., 2000).
Intrachromosomal
rearrangement
inversion
Interchromosomai
rearrangement
ET
translocation
FUSION GENE
Dimerization
domain
Tyrosine Kinase 
domain
Activating gene RTK gene
Figure 1.5 Mechanism of chromosomal rearrangements generating fusion transforming gene in
PTC. Inversion between genes localized on the same chromosome or translocation between genes on 
two different chromosomes generate chimeric fusion gene made of the thyrosine kinase domain o f RTK 
gene preceded by the N-terminal portion of the activating gene, containing the dimerization domain.
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1.1.2.3 Molecular mechanisms underlying chromosomal rearrangements in PTC
Chromosomal rearrangements involving either RET or NTRKl genes are a frequent 
event in tumours originating from follicular epithelial cells (up to 60% of the cases in 
PTC). This peculiarity of thyroid epithelium sets it apart from other epithelial cells 
considering that chromosomal rearrangements leading the formation of fusion 
oncoproteins are a future usually associated with mesenchymal and hematopoietic cells 
(Pierotti et al., 2001). However, the molecular mechanisms underlying the 
predisposition of thyrocytes to undergo chromosomal rearrangements are not 
completely understood.
Some reports have suggested that the spatial proximity of translocation-prone gene loci 
may favour gene rearrangements. In particular, two studies used two-colour FISH 
analysis and three-dimensional microscopy investigated in the thyrocytes nucleus the 
proximity of loci undergoing rearrangements such as RET and H4 genes forming 
RET/PTC1 (Nikiforova et al., 2000) or the NTRKl and TPR genes forming TRK-T1 
(Roccato et al., 2004). They compared interphase nuclei of thyrocytes and B-cell 
lymphoma and found that in their respective normal cells both translocation-prone gene 
loci were positioned close to their translocation partner genes suggesting that this 
spatial contiguity may facilitate the specific translocation. Another model system 
considered that the high frequency of chromosomal rearrangements in thyroid tumours 
might reflect the thyrocyte intrinsic capability to repair DNA DSBs, either spontaneous 
or induced. In particular, in vitro irradiation failed to induce apoptosis in human thyroid 
cells, but increased a DNA end-joining enzymatic activity. Therefore, following DNA 
damage, thyrocytes would more prone to DNA repair than to apoptosis, and this would 
increase the likelihood of gene rearrangements (Yang et al., 1997).
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1.1.2.4 RAS
The RAS gene product is a monomeric membrane-bound guanosine triphosphate 
(GTP)/guanosine diphosphate (GDP)-binding (G) protein that serves as a “molecular 
switch,” converting signals from the cell membrane to the nucleus. These chemical 
signals lead to protein synthesis and regulation of cell survival, proliferation, and 
differentiation. The human RAS gene family includes HRAS, KRAS, and NRAS.
Each RAS protein consists of about 190-amino-acid residues that are highly conserved 
in the N and C termini. Most of the differences between these proteins occur in the near 
C-terminal hypervariable domain of about 25 amino acids, which is presumed to be 
responsible for their different functions.
RAS cycles between the GDP-bound inactive form and the GTP-bound active form. In 
the quiescent state, RAS exists in the GDP-bound form. After binding of an external 
ligand to its receptor, dimerization of the receptor occurs, and the intrinsic receptor 
tyrosine kinase is activated. This is followed by autophosphorylation of specific 
tyrosine residues on the intracellular portion of the receptor. These phosphorylated 
tyrosine residues then bind the sequence homology 2 (SH2) domains of adaptor proteins 
such as Grb2. These adaptor proteins contain not only an SH2 domain(s) but also an 
SH3 domain(s) that binds proline-rich motifs of other proteins, such as son of sevenless 
(SOS), a guanine dissociation stimulator (GDS) of RAS. The key adaptor molecule for 
RAS is Grb-2 that consists solely of one SH2 and two SH3 domains and links the 
activated receptor to SOS. Such a complex formation recruits SOS, a cytosolic protein, 
into close proximity to RAS on the plasma membrane. The binding of SOS to RAS 
causes a change in the RAS conformation and leads to the dissociation of GDP, which 
allows RAS to bind GTP and become active. Activated RAS activates several distinct 
effectors, such as the serine-threonine kinase raf-1, phosphoinositide 3-kinase (PI3-K). 
These downstream effectors activate several distinct signalling cascades, leading to
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either activation of certain genes, such as those encoding growth factors transforming 
growth factor-a and vascular endothelial growth factor (VEGF), or changes in actin 
cytoskeleton by activating Rho family G proteins. Normally, these Ras-signaling 
cascades are only transiently activated because each normal RAS has low intrinsic 
guanine triphosphatase (GTPase) activity that gradually inactivates its own signalling 
function by hydrolyzing the bound GTP. More importantly, several distinct cytoplasmic 
GTPase-activating proteins (GAPs) stimulate the intrinsic GTPase activity of RAS, 
rapidly converting RAS from the active GTP form to the inactive GDP form.
A high frequency of RAS mutations has been found in a variety of tumour types. 
Identified mutations are limited to a very small number of sites (amino acids 12, 13, 59, 
and 61), all of which abolish GAP-induced GTP hydrolysis of the RAS proteins. Such 
single-point mutations can lead to its constitutive activation of RAS protein, with an 
impaired GTPase activity. Although they still bind GAP, there is no “o ff’ sign, since 
GTPase is no longer activated. This results in continuous stimulation of cellular 
proliferation. Mutations are frequently limited to only one of the RAS genes, and 
frequency is dependent on tissue and tumour type. Thus, RAS gene mutations are rare 
in cancers of the breast, ovary, stomach, oesophagus, and prostate; however, they are 
present in almost all adenocarcinomas of the pancreas and in 50% of colon and thyroid 
cancers. Mutations in colon and pancreatic cancers are found only in the KRAS gene. In 
cancers of the urinary tract and bladder, mutations are primarily in the HRAS gene; 
mutations are in the NRAS gene in leukaemia. Thyroid carcinomas are unique in having 
mutations in all three RAS genes.
In thyroid cancer, NRAS codon 61 and HRAS codon 61 mutations are most common. 
RAS mutations are found in a variety of thyroid tumours, including 10-20% of PTC, 
40-50% of FTC and 20-40% of PDTC and ATC (Suarez et al., 1990). Among papillary
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carcinoma, all tumours that harbour a RAS mutation grow forming neoplastic follicles 
and no papillary structures and are, therefore, diagnosed as the follicular variant of 
papillary carcinoma (Motoi et al., 2000). RAS mutations are also reported in 20-40% of 
benign follicular adenomas. The finding of this mutation in benign adenomas as well as 
in follicular-patterned carcinomas suggests that RAS may serve as a precursor for RAS- 
positive follicular carcinomas and the follicular variant of PTC (Namba et al., 2000). 
Furthermore, RAS mutations may predispose differentiated cancers to dedifferentiation 
and anaplastic transformation (Basolo et al., 2000; Garcia-Rostan et al., 2003). The 
close relationship between RAS mutations and the loss of tumour differentiation is also 
supported by studies in transgenic mice showing that the expression of NRAS-Q61K in 
thyrocytes can drive the formation of tumours that undergo differentiation and 
neoplastic progression (Vitagliano et al., 2006).
Remarkably, oncogenic RAS not only correlates with the loss of tumour differentiation 
but also with the presence of distant metastases and poor prognosis (Garcia-Rostan et 
al., 2003; Manenti et al., 1994). It is conceivable that RAS activation may be 
insufficient to induce malignant growth but may predispose to acquire further genetic or 
epigenetic alteration leading to a fully transformed phenotype.
1.1.2.5 BRAF
The BRAF gene is located on human chromosome 7q24 and encodes a cytosolic serine- 
threonine protein kinase that is expressed in many human cells, including thyroid 
follicular cells (Kondo et al., 2007). The wild-type (wt) BRAF is activated at the plasma 
membrane through a complex process that involves RAS activity, phosphorylation 
events, and protein-lipid interactions resulting the most potent activator of MAPK 
signalling pathway. Upon activation by RAS binding and recruitment to the cell 
membrane, BRAF activates the protein kinase MEK, which, in turn, activates the
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protein kinase ERK and consequent effectors of MAPK cascade. All together they form 
a molecular axis crucial in the regulation of gene expression, cell proliferation, and 
differentiation (Leicht et al., 2007; Raman et al., 2007).
BRAF is comprised of three homologous regions, CR1, CR2 and CR3. CR1 has all the 
elements for BRAF membrane recruitment. These include a RAS binding domain 
(RBD) that binds to the active RAS-GTP, and a cysteine rich domain (CRD) that 
stabilizes its interaction with RAS. CR2, the N-terminal regulatory domain, contains a 
conserved phosphorylation site at S259 that serves as a regulatory binding site for 
protein 14-3-3, an essential dimeric cofactor for BRAF kinase activity. The N-terminal 
domain also acts as autoinhibitor of the C-terminal kinase domain and helps to maintain 
BRAF in an inactive state in the absence of extracellular stimuli. CR3, the C-terminal 
kinase catalytic domain, serves as the catalytic portion of the BRAF kinase domain 
(Leicht et al., 2007). BRAF exhibits a characteristics bilobar structure (McKay and 
Morrison, 2007). The inactive conformation of BRAF involves the simultaneous 
binding of 14-3-3 to phosphorylated sites S365 and S729 (Dhillon and Kolch, 2004). 
The activated wt BRAF is phosphorylated at site S446, leading to a maximally 
negatively charged amino region. Extracellular signals act on RAS-GTP to induce a 
thyrosine kinase receptor and initiate the activation sequence. Pre-activated BRAF is 
recruited to the plasma membrane where it is fully activated, first as two protein 
phosphatases (PP1 and PP2A) dephosphorylate the N-terminal 14-3-3-binding sites, and 
second by phosphorylation of the BRAF kinase domain, converting it to its active form 
(Dhillon and Kolch, 2004; Ikenoue et al., 2003). Importantly, oncogenic RAS 
phosphorylates two conserved sites of BRAF (T598 and S601) (Zhang and Guan, 
2000). This event not only renders BRAF constitutively active, but also induces 
ERK1/2 activation, causing cell transformation (Figure 1.6).
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Figure 1.6 Schematic representation of the BRAF protein kinase. The three conserved regions CR1, 
2, 3 are highlighted. CR1 and CR2 are regulatory domains and CR3 is the catalytic domain. The Ras- 
binding domain (RBD) and Cystein-rich domain (CRD) are located in CR1. The N-region, Glycine-rich 
loop and activation segment are located in CR3. S446 in the SSDD motif is constitutively phosphorylated. 
Phosphorylation of residues T599 and S602 results in BRAF activation. (Adapted from Michaloglou et al., 
2007)
Constitutive activation of RAS-ERK signalling pathway is common to numerous 
cancers. More than 30 mutations of the BRAF gene associated with human cancers 
have been described. In 2002 Davies et al. identified an oncogene widespread amongst 
human cancers, mutant BRAFV600E. This BRAF point mutation involves a thymine to 
adenine substitution at nucleotide position 1799, which results in a valine-to-glutamate 
replacement at residue 600 (Val600Glu). The V600E mutation strongly enhances BRAF 
kinase activity that over-activates the MAP kinase pathway (Davies et al., 2002). 
BRAFv600E is expressed in different human cancer cell lines including melanoma 
(Tuveson et al., 2003), colorectal cancer (Ikenoue et al., 2003), and thyroid cancer 
(Xing, 2007).
BRAFY600E is the most common genetic lesion in PTC, being detected in about 29 to 
69% of cases and is highly prelevant in PTC with classical histology and in tall cell
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variant tumours (69-71%) (Xing, 2007). Controversial relationship between BRAFV600E 
and the potential aggressiveness of PTCs has been described. Some studies show a 
positive correlation between BRAFv600b and advanced PTCs, characterized by poorer 
outcomes, extrathyroidal extension, and lymph nodal metastasis, while others do not. 
PTCs carrying BRAFY600E mutation exhibit decreased expression of genes involved in 
thyroid hormone biosynthesis, including sodium iodine symporter (NIS), decreased 
ability to trap radioiodine and consequent treatment failure (Frasca et al., 2008). 
Furthermore, BRAFV600E is also found in PDTC and ATC, suggesting that this mutation 
may be involved in progression of thyroid cancer from PTCs to poorly differentiated 
and undifferentiated phenotypes (Nikiforova and Nikiforov, 2008).
Interestingly, BRAFV600b is also the most common genetic alteration in PTMC which is 
generally considered to have a very low risk of progression and/or recurrence (Kim et 
al., 2005; Trovisco et al., 2005). Recent studies showed that even in PTMC, BRAFv600b 
was significantly associated with extrathyroidal extension, high tumour stage, and lack 
of tumour capsule (Lupi et al., 2007). These results suggest that BRAFv600b may also 
confer a higher risk of tumour progression and invasiveness versus the wild-type in 
PTMC, potentially serving as a predictive indicator of aggressive behaviour in PTMC. 
Transgenic mice with thyroid-specific expression of BRAFv600b developed PTC closely 
recapitulating those seen in human tumours, thus supporting the role of mutant BRAF 
in tumour initiation and differentiation, as well as its correlation with tumour 
characteristics (Knauf et al., 2005). It has been recently demonstrated that BRAFv600E 
localizes to mitochondria and exerts an antiapoptotic effect, independent from kinase 
activity, which is not abrogated by BRAF inhibitors (Lee et al., 2011).
Recently, another mechanism of BRAF oncogene activation has been reported in post- 
Chemobyl thyroid carcinomas. This new BRAF alteration derives from a fusion of the 
first eight exons of the A-kinase anchor protein 9 (Akap9) gene with the c-terminal-
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encoding region of BRAF (Ciampi et al., 2005). The Akap9 fusion gene of this 
rearrangement is intriguing since it is interacting with the type II regulatory subunit of 
the cAMP-dependent protein kinase A.
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Figure 1.7 Genetic alterations in thyroid cancer. Common mutational mechanisms in thyroid cancer 
are point mutations, such as those in the RAS and BRAF genes, and chromosomal rearrangements, such 
us RET/PTC, TRK and PAX8/PPARy. Genetic alterations and association with the different histological 
types of thyroid tumours are shown.
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1.1.2.6 Other molecular events
In the last few years gene expression analysis studies have identified several genes, 
involved in different cellular processes, which might be important in the molecular 
pathogenesis and the malignant progression of thyroid cancer. Distinct alterations in 
gene expression have been observed in PTC and others types of thyroid cancer. For 
instance, Huang et al. undertook the first study of PTC gene expression profile. Respect 
to normal thyroid tissue they observed upregulation of many genes involved in cell 
adhesion, motility and cell-cell interaction, including MET, TIMP1, LAMB3, CITED 1, 
LGALS3. Conversely, they found downregulated genes responsible for specialized 
thyroid function such as thyroid hormone synthesis (Huang et al., 2001). These results 
are consistent with the fact that most malignant thyroid tumours are hypofunctioning in 
trapping iodine and producing thyroid hormone. Genes underexpressed in PTC also 
included tumour suppressor and fatty acid binding proteins. Therefore, despite its 
clinical heterogeneity, PTC is characterized by consistent and specific molecular 
changes and behaves as a homogeneous group in terms of gene expression (Frattini et 
al., 2004; Huang et al., 2001). Moreover, some of the differentially expressed genes 
have been proposed as useful PTC markers (Huang et., 2001).
Different gene expression profiles have been observed between PTC and FTC: a 
combination of five genes was proposed to distinguish PTC from FTC. PTCs showed 
overexpression of CITED 1, IGFBP6 and CLDN10, whereas FTCs did not express 
CLDN10 and displayed a decreased expression of IGFBP6, CAV1 and CAV2 (Aldred 
et al., 2004).
The relationship between the presence of thyroid cancer histotype-specific mutations 
and gene expression profiles of tumours is complex. However, several studies described 
the gene expression profile changes with the presence of different mutations that 
contribute to thyroid cell carcinogenesis. As mentioned above, PTC is associated with
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well defined genetic lesions i.e. BRAF mutations and RTK rearrangements. 
Independent expression studies showed differences in gene expression between BRAF- 
positive PTCs and those with RTK rearrangements (Frattini et al., 2001; Giordano et al., 
2005). These results could suggest that although RTK and BRAF act along the same 
signal transduction pathway, their activity occurs at different levels, leading to the 
regulation of different gene sets.
Alteration in gene expression as result of aberrant methylation of gene promoter regions 
or histone modification also occurs in thyroid cancer (Xing et al., 2007). These 
epigenetic events can alter the function of tumour suppressor genes and thus contribute 
to activation of important signalling pathways, such as PI3K-AKT and MAPK 
cascades. Changes in epigenetic regulation might also result in downregulation of 
thyroid-specific genes during tumour progression and dedifferentiation. 
Hypermethylation of tumour suppressor genes, including TIMP3, DAPK, SLC5A8, was 
associated with tumour aggressiveness and BRAF mutation in PTC (Hu et al., 2006). 
Despite the numerous gene expression studies, validated by different approaches, only a 
few data addressing the role of differentially expressed genes in the pathogenesis of 
thyroid tumours have been produced yet. Nevertheless, such studies are important for a 
deeper understanding of molecular mechanisms underlying thyroid carcinogenesis, and 
they could also identify possible new strategies for therapeutic intervention.
1.1.3 Thyroid cancer and inflammation
The relationship between inflammation and thyroid cancer is not yet completely 
understood. Like others tumours, thyroid cancer is influenced by and modulates 
inflammation. For instance, thyroid cancer often has an inflammatory cell infiltrate 
including lymphocytes, macrophages, dendritic cells and mast cells. The role of these 
cells is complex and the effect can be either pro- or anti-tumorigenic, depending on the
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specific cell population, as demonstrated by several studies. Specifically, the presence 
of lymphocytes, which belong to the adaptive branch of immunity, is significantly 
higher in neoplastic than in non-neoplastic lesions (Okayasu, 1997). However, 
lymphocytic infiltration seems to confer protection against cancer progression. In fact, 
numerous studies indicate that PTC with high number of infiltrating and proliferating 
lymphocytes are associated with less extensive disease at diagnosis and improved 
disease free-survival. Conversely, thyroid carcinomas with poor prognosis, such as 
PDTCs and ATCs, are characterized by a strongly reduced lymphocytic infiltration 
compared with PTCs, thus suggesting that these cells may play a protective role in 
thyroid cancer (Ugolini et al., 2007). On the other hand, the presence of macrophages 
and mast cells, belonging to innate immunity, correlates with tumour progression and 
poor prognosis (Scarpino et al., 2000). In particular, the macrophage component termed 
“tumour-associated-macrophages (TAMs), which is closely mixed with cancer cells 
plays a key role in thyroid tumour progression. In fact, studies show that ATCs display 
a very dense network of interconnected TAMs characterized by elongated thin ramified 
cytoplasmic extensions in direct contact with intermingled cancer cells (Caillou et al., 
2011).
Oncoproteins typically express in PCTs, such as RET/PTC, RAS, and BRAF, trigger a 
proinflammatory program in thyrocytes including the expression of cytokines, 
chemokines and their receptors (Borrello et al., 2005; Melillo et al., 2005). These 
molecules have a dual effect in thyroid cancer. By acting in an autocrine way, they can 
enhance proliferation, survival and invasiveness of thyroid cells. But, they can also 
induce, in a paracrine manner, remodelling of the tumoral stroma by recruiting 
inflammatory, immune, endothelial cells. For instance, several studies have 
demonstrated that activated RET, in its different forms, leads to expression of a number 
of inflammatory mediators in different cell environments. For example, RET/PTC1
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oncogene, when exogenously expressed in primary normal human thyrocytes, induces 
the expression of a large set of genes involved in inflammation and invasion, including 
those encoding chemokines (CCL2, CCL20, CXCL8, and CXCL12), chemokine 
receptors (CXCR4), cytokines (IL1B, CSF-1, GM-CSF, and G-CSF), matrix-degrading 
enzymes (metalloproteases and uroki-nase-type plasminogen activator and its receptor), 
and adhesion molecules (L-selectin) (Borrello et al., 2005). These RET/PTC1-induced 
genes were also expressed in specimens of PTC suggesting a direct link between a 
transforming oncogene involved in the pathogenesis of a human tumour and the 
activation of a proinflammatory network in the primary human cells originating that 
tumour. Molecules activated by RET/PTC 1 in human thyrocytes is likely to contribute 
to the tumour. This is in line with another work showing the up-regulation of some 
chemokines (CXCL1, CXCL10, and CCL2) and of CXCR4 in a rat thyroid cell line 
expressing RET/PTC and suggesting a chemokine role in proliferation and invasion 
(Melillo et al., 2005). As a consequence, not only oncoproteins, but also inflammatory 
molecules are promising targets for novel thyroid cancer therapeutical strategies.
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1.2 The limited lifespan of normal somatic cells
Cellular senescence was formally described more than 40 years ago when Hayflick and 
Moorhead showed that normal cells had a limited ability to proliferate in culture. In 
fact, they observed that human primary fibroblasts, isolated from embryonic lung tissue, 
initially exhibited robust proliferation and after many population doublings (PDs), they 
underwent a gradual decline in proliferate rate. Eventually, all cells lost the ability to 
divide (after 50-80 PDs), despite the abundance of growth and nutrients and ample 
room for expansion. This finite proliferative lifespan is known as the “Hayflick limit”. 
The process, which describes this cellular condition of ceased proliferation, is termed 
cellular senescence (Hayflick, 1965).
Subsequent studies showed that senescence was not specific to human fibroblasts, it 
was described in cultures established human mammalian species and in a variety of cell 
types including keratinocytes (Rheinwald and Green, 1975), vascular smooth muscle 
cells (Bierman, 1978), lens cells (Tassin et al., 1979) and lymphocytes (Tice et al., 
1979).
The work by Hayflick gave birth to the idea that normal somatic cells possessed a 
“mitotic clock” that dictates their maximum lifespan, which constitute a protective 
mechanism against unlimited cell proliferation essential for tumorigenesis. Nowadays, 
cellular senescence is an important mechanism for preventing the proliferation of 
potential cancer cells. In addition to suppressing tumorigenesis, cellular senescence 
might also promote tissue repair and fuel inflammation associated with the ageing and 
cancer progression (Campisi et al., 2001).
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1.2.1 Characteristics of senescent cells
Senescent cells display important and unique properties that distinguish them from cells 
undergoing other types of proliferative arrest.
In contrast to quiescence, a form of cell cycle arrest that can be reverted in the presence 
of appropriate physiological signals, the hallmark of cellular senescence is its 
irreversible nature. Once senescent cells arrested growth, they cannot re-enter the cell 
cycle despite adequate growth conditions (Campisi and d’Adda di Fagagna, 2007). 
Although cells reach a state in which they can no longer initiate replication, this 
happens asynchronously so that at any given moment in mitotic cultures, the population 
is a heterogeneous mixture of senescent and non-senescent cells, that are at various 
stages in their proliferative life (Cristofalo and Sharf, 1973). Early passage cultures 
consist primarily of cells that exhibit short cell cycle periods. With successive 
subcultivations, the percentage of cells in the population that exhibit longer generation 
times and those unable to proliferate, increases. Successful progression through the cell 
cycle involves the synthesis of the new DNA that can be quantified by 5- 
bromodeoxyuridine (BrdU) incorporation assay. Senescent cells fail to incorporate 
BrdU because they are arrested predominantly at G1 phase and do not progress to S 
phase for DNA synthesis. However, senescent cells remain metabolically active, as 
evidenced by changes in the pH of the growth medium.
Senescence, like apoptosis, is a cellular response to stress, and plays an important role 
in suppressing tumorigenesis. But, whereas senescence prevents the growth of damaged 
or stressed cells, apoptosis quickly eliminates them. Interestingly, senescent cells 
acquire resistance to apoptosis induced by several stimuli (Chen et al., 2000; Hampel et 
al., 2004).
It is not clear which factors direct the choice of cells between apoptosis and senescence; 
it may depend on cell type and on the intensity, duration and nature of the damage.
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Moreover, the balance between proapoptotic and antiapoptotic proteins may also be 
important (Rebbaa et al., 2003; Seluanov et al., 2001). The mechanisms by which 
senescent cells resist apoptosis are not completely understood. They are most probably 
related to their common regulator, the p53 tumour suppressor protein. This resistance, 
in some cells, might be associated with the expression changes in proteins, which are 
key executioners for committing apoptotic death (Marcotte et al., 2005). In others, p53 
might transactivate genes that arrest proliferation rather than those that induce apoptosis 
(Jackson and Pereira-Smith, 2006). This could partly explain why senescent cells are so 
stable in culture, and why they increase with age in vivo.
Cellular senescence is also accompanied by morphological and structural changes. 
Upon entering the state of senescence, cells become large and flat (Serrano et al., 1997). 
Moreover, they exhibit an increase in the number of lysosomes and Golgi, appearance 
of vacuoles in the cytoplasm and endoplasmic microfilaments and an increase in the 
size of the nucleus and nucleoli. However, the molecular mechanisms underlying such 
morphological alterations in senescent cells have not been elucidated.
Senescence associated p-galactosidase activity detectable at pH 6.0 is the most 
frequently used senescence marker (Dimri et al., 1995). Its induction in senescent cells 
is due to an increase in GLB1 expression, the gene encoding lysosomal p-D- 
galactosidase. Fibroblasts, obtained from patients with autosomal recessive Gmi- 
gangliosidosis, which have defective lysosomal P-galactosidase, fail to express SA-p- 
Gal even though they undergo senescence. These results confirmed that SA-p-Gal 
activity is an outcome rather than a cause of the senescent cells and is due to an 
expansion of the lysosomal compartment. Importantly, this activity can be uncoupled 
from senescence (Lee et al., 2006). For instance, SA-P-Gal activity increases also in 
non-senescent cells following serum starvation, oxidative treatment with H2 O2 or 
contact inhibition (Severino et al., 2000). For these reasons, SA-P-Gal is not
senescence-specific; therefore it must be used in conjunction with additional markers 
(Cristofalo, 2005).
Another common feature of senescence is the widespread nuclear heterochromatization; 
senescence is accompanied by profound chromosome condensation, so that each 
chromosome forms a punctate heterochromatic domain, called a senescence-associated 
heterochromatin focus (SAHF) that is detectable by DNA staining dye, 4’,6-diamidino- 
2-phenylindole (DAPI). When stained with DAPI normal human cells exhibit a 
relatively diffuse distribution of DNA through the nucleus. The chromatin from cells 
with SAHF appears much more compact than the chromatin in normal interphase 
growing cells. Moreover, these foci are enriched in markers of heterochromatin such as 
heterochromatin protein 1 (HP1) and Lys 9 tri-methyl on histone H3 (H3K9me3) and 
exclude euchromatic markers, such acetylation of histone H3 on lysine 9 (H3K9Ac) or 
tri-methylation on lysine 4 (H3K4me3). SAHFs are also characterized by depletion of 
histone HI and enrichment in at least two other proteins, namely the histone variant 
macroH2A and high mobility group A (HMGA) proteins. Paradoxically, the presence of 
HMGA proteins in chromatin is normally associated with gene activation, cell 
proliferation and cell transformation. Thus, it was a surprise when SAHFs were shown 
to be enriched in HMGA proteins and that these proteins contribute to senescence 
(Narita et al., 2003).
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F ig u re  1.8 T h e  sen escen t p h e n o ty p e . Premature senescence can be observed in young cells under a 
number of physiological stresses including expression of oncogenes (oncogene-induced senescence). 
Replicative senescence is described as the growth arrest in response to prolonged passaging. Both lead to 
a senescent phenotype with morphologic and functional characteristics, which are listed in the right box. 
SA-P-Gal activity (upper panel) and SAHF formation (middle panel) of IMR90 fibroblasts transfected 
with empty vector or RAS oncogene, as well as cells in late passage, are shown. Enlarged image of DAPI 
stained chromatin foci is shown in the lower panel. (Adapted from Narita et al., 2003)
As transcription in heterochromatin is generally low, the idea was launched that the 
senescence-associated heterochromatization contributes to shutting down transcription 
of proliferation-associated genes. Consistent with this, the promoters of several E2F 
target genes acquire increased binding of heterochromatin-associated proteins (Narita et 
al., 2003).
Since the discovery of SAHF, several studies have dissected the events that eventually 
culminate in the formation of SAHF observed in senescent cells (Adams, 2007). An 
essential step in the initiation phase of chromosome condensation is the translocation of
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HIRA (histone chaperon) and HP1 to promyelocytic leukaemia nuclear bodies (PML 
bodies), another senescence effector. Currently, the exact function of PML bodies, and 
how PML bodies are involved in senescence program are not clear; it has been 
suggested that PML bodies are sites for macromolecular assembly and posttranslational 
modifications of proteins. These subnuclear organelles are thought to serve as a staging 
ground for formation of histone chaperones complex, HIRA/ASF1A, which are 
incorporated into chromatin and play an essential role in SAHF formation (Zhang et al., 
2005).
Senescence phenotype exhibits a specific gene expression profile, including changes in 
cell-cycle regulators (Mason et al., 2004; Shelton et al., 1999; Trougakos et al., 2006; 
Yoon et al., 2004). Two cell-cycle inhibitors that are often expressed by senescent cells 
are the cyclin-dependent kinase inhibitors (CDKIs) p21 (also termed CDKNla, p21CIP1, 
Wafl) and p i6 (also termed CDKN2a or p l6 INK4a). Senescent cells also repress genes 
that encode proteins involved in cell cycle; some of them are E2F targets (for example, 
replication-dependent histones, c-FOS, cyclin A, cyclin B and PCNA) (Pang and Chen, 
1994; Seshandri and Campisi, 1990). Interestingly, amongst the genes whose expression 
is upregulated during senescence there are a myriad of secreted proteins, which are the 
basis of the so-called senescence-associated secretory phetotype (SASP) (Coppe et al., 
2008; Rodier et al., 2009) or senescence-messaging secretome (SMS) (Kuilman and 
Peeper, 2009). Many of these factors contribute to reinforce senescence: the 
plasminogen activator inhibitor (PAI)-l is necessary and sufficient for the induction of 
senescence (Kortlever et al., 2006); insulin-like growth factor binding 7 (IGFBP7) was 
shown to mediate senescence induced by oncogenic BRAF (Wajapeyee et al., 2008). 
Equally, pro-inflammatory cytokines and chemokines such as IL-8, CXCL1, IL-6 and 
their receptors have an indispensable role in the establishment and maintenance of the 
senescence arrest (Acosta et al., 2008; Kuilman et al., 2008). In addition to these
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tumour-suppressing functions, increasing evidence also points to a tumour-promoting 
role of these secreted factors. SASP factors can boost up cancer progression by 
stimulating proliferation (Krtolica et al., 2001; Coppe et al., 2008), inducing epithelial 
to mesenchymal transition (EMT) and promoting angiogenesis (Nickoloff et al., 2004). 
These two opposing effects of SASP can be reconciled: the tumour-suppressing role 
generally functions in a cell-autonomous manner (by enforcing senescence), whereas its 
tumour-promoting actions are mediated by cell-non-cell-autonomous mechanisms, 
altering the microenvironment. Thus, secreted factors affect not only the cells producing 
them (autocrine effect), but also the neighbouring cells (paracrine effect) (Kuilman and 
Peeper, 2009) (Figure 1.8).
1.2.2 Causes of cellular senescence
1.2.2.1 Replicative Senescence
Induction of cellular senescence by prolonged in vitro culturing has been termed 
replicative senescence, reflecting its onset after a defined number of cell divisions. The 
timed nature of this cell cycle arrest suggests the existence of a counting mechanism, 
and this is indeed the case. The extreme ends of chromosomes, i.e. telomeres, are 
subject to attrition due the fact that DNA polymerase fails to completely replicate the 
lagging strands, a phenomenon called the end-replication problem that is a major reason 
why normal cells do not proliferate indefinitely (Olavnikon, 1971; Watson, 1972). 
Telomere erosion can be prevented or even reverted by telomerase. This enzyme 
contains a catalytic protein component (telomerase reverse transcriptase; TERT) and a 
template RNA component, and adds telomeric DNA repeats directly to the chromosome 
ends (Collins and Mitchell, 2002). Its activity is low or absent in most human somatic 
cells, so telomeres become progressively shorter with every round of cell division 
(Masutomi et al., 2003). It is thought that telomere shortening triggers DNA damage
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response, thereby activating a checkpoint mediated by the p53 pathway that contributes 
to either senescence or apoptosis (D’Adda di Fagagna et al., 2003; Takai et ah, 2003)., 
Telomere length therefore functions as a mitotic clock, counting the number of cell 
divisions that human somatic cells undergo (Harley et ah, 1990). In this regard, 
introduction of telomerase extends the replicative life span of normal human cells 
(Bodnar et ah, 1998). Although telomerese expression is strictly regulated in normal 
human somatic cells, in tumour cells its expression is frequently deregulated (Neumann 
and Reddel, 2002). Since telomerase is specifically required for most human cancer 
cells to bypass senescence, it is clear that telomere maintenance is essential for cellular 
immortality and thus telomerase offers a possible therapeutic target in human cancer. 
However, some immortalized cell lines and tumours can also elongate their telomere 
through another mechanism termed alternative lengthening of telomeres (ALT). It was 
discovered in some cancer cell lines in which telomere lengths were maintained in the 
absence of telomerase activity. The ALT mechanism seems to depend on recombination 
in which single-stranded telomere ends invade double-stranded telomeric DNA, use it a 
template for synthesis of new telomeric DNA and thereby elongate themselves (Cesare 
and Reddel, 2010).
1.2.2.2 Oncogene-induced senescence
Not only prolonged passaging in culture, but also other types of imposed stress can lead 
to the induction of cellular senescence. For instance, oxidative stress, DNA damage and 
chromosome perturbation can all induce this response, in different cell types (Campisi 
and D’Adda di Fagagna, 2007). Somewhat counterintuitively, senescence can be 
implemented in primary cells also upon expression of an activated oncogene and this 
process has been termed oncogene-induced senescence (OIS) (Figure 1.9). It was first 
observed when an oncogenic form of RAS, a cytoplasmic transducer of mitogenic
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signals, was expressed in normal human fibroblasts (Serrano et al., 1997). 
Subsequently, other members of the RAS signalling pathway such as RAF, MEK, MOS 
and BRAF can induce cellular senescence (Dimri et al., 2000; Lin et al., 1998; 
Michaloglou et al., 2005). Conversely, the loss of PTEN, which is an inhibitor of the 
same pathway, also leads to senescence establishment (Chen et al., 2005). Since RAS 
transduction pathways relay their signals to the nucleus to regulate proliferation, the 
activation of several pro-proliferative nuclear proteins also induces senescence: 
increased expression of E2F transcription factors, key regulators of Gl/S cell-cycle 
transition triggers cellular senescence.
Time-course studies have revealed that the expression of the oncogenic form of H-RAS 
(H-RASG12V) in normal fibroblasts leads to a biphasic response. RAS drives an initial 
hyperproliferation phase in which cells proliferate faster than the control cells. This in 
keeping with the mitogenic functions of this signal transducer molecule. However, this 
burst of proliferation is transient and is quickly followed by a proliferation slow down 
and the eventual establishment of cellular senescence (D’Adda di Fagagna, 2008).
In this context, OIS is therefore a tumour suppressor mechanism that restricts the 
proliferation of a cell that expresses high levels of an aggressive oncogene.
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Figure 1.9 Senescence is a tumour suppressive mechanism. Two main mechanisms, senescence and 
apoptosis, act to prevent the proliferation of altered cells. Senescence can be triggered by several different 
stimuli, including telomere erosion, oxidative stress and others forms of DNA damage. Activation of 
oncogenes can also trigger senescence, highlighting the importance of senescence as a tumour suppressor 
mechanism. (Adapted from Gil and Peters, 2006)
1.2.3 Two pathways to senescence
During cell cycle progression, checkpoints ensure that cells are “ready” to progress to 
the next phase and that no defects during DNA replication or chromosome segregation 
are accumulated. Moreover, two DNA damage checkpoints, during G l/S  and G2/M 
assure that cells that acquired DNA breaks or other forms of DNA damage, do not 
progress through the cell cycle. Arresting the cell cycle allows cells to repair these 
defects. If the damage is irreparable due to excessive or continuous DNA damage, cells 
may enter senescence or undergo apoptosis. Alternatively, accumulation o f DNA 
alterations may result in genomic instability leading to cell transformation and 
oncogenesis (Malumbres and Barbacid, 2009).
Misregulation of cyclin-dependent kinases (CDKs) whose activity requires binding of 
regulatory subunits known as cyclins, is at the heart of the cell cycle defects that can 
lead to unscheduled proliferation. In unstressed cells at G l, the phase proceeding the
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DNA replication phase, mitogenic signals are sensed by D-type cyclins that 
preferentially bind CDKs 4 and 6. Activation of the CDK4/6-Cyclin D complexes 
results in partial inactivation of the retinoblastoma protein (RB) and retinoblastoma-like 
proteins (RBL) 1 and 2 (pi 07 and p i30). This allows expression of E-type cyclins that 
bind to and activate CDK2, which will further phosphorylate RB proteins thereby 
inactivating them. Inactivated RB releases E2F transcription factors that will induce 
transcription of genes necessary for DNA replication and cell cycle progression 
(Weinberg, 1995) (Figure 1.10).
If cells encounter various stresses, such as telomere uncapping or expression of 
oncogene, two main pathways are triggered that converge on modulation of CDK 
activity and are responsible for senescence onset. These pathways are controlled by the 
tumour suppressor proteins p53 and pRB, they interact but can independently halt cell- 
cycle progression and they also respond to different stimuli. In addition, depending on 
the cell type and species of origin, there are differences in the propensity with cells 
engage one or the other pathway, and in the ability of each pathway to induce 
senescence.
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Figure 1.10 Two pathways to senescence. A) In unstressed cells and in the presence of mitogenic 
signals, activation of the CDK4/6-Cyclin D complexes results in partial inactivation of RB family 
proteins. This allows the expression of E-type cyclins that bind to and activate CDK2, which will further 
phosphorylate RB proteins, thus inactivating them. Inactive RB releases E2F transcription factors that 
activate transcription of genes necessary for entry into S-phase. B) Senescence-inducing signals usually 
engage either the p53 or the p 16INK4a-retinoblastoma protein (RB) tumour suppressor pathways. p53 is 
negatively regulated by HDM2, which facilitates its degradation. HDM2 is negatively regulated by ARF. 
Active p53 establishes senescence in part by inducing the expression of p21CIP1, a cyclin-dependent 
kinase (CDK) inhibitor that suppresses the phosphorylation and hence, the inactivation of RB. 
Engagement of pl6-Rb pathway also results in inhibition of RB phosphorylation and inactivation, by 
inhibition CDK4/6. RB halts cell proliferation by inhibiting the activity of E2F, and thereby suppressing 
expression of genes required for cell-cycle progression.
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The p53 pathway is activated by DNA damage response mediated by ATM/ATR, and 
by the ARF protein. ATM/ATR are protein kinases that activate p53 mainly by 
phosphorylation whereas ARF activates p53 by inhibiting HMD2 an ubiquitin E3 ligase 
that targets p53 for degradation. Active p53 induces the expression of p21, a cyclin- 
dependent kinase (CDK) inhibitor that belongs to the Cip/Kip or CDKN1 family.
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p21 inhibits cell cycle progression mainly through the inhibition of CDK2. However, it 
is known to interact with both CDK4/6-Cyclin D complexes and CDK2-Cyclin E 
complexes resulting in the suppression of phosphorylation and, hence, inactivation of 
pRB (Sherr and Roberts, 1999). Senescence signals that engage pl6-pRB pathway 
generally do so by inducing the expression of p i6, another CDK inhibitor that belongs 
to the INK4a or CDKN2 family, p i6 binds to CDK4 and 6 and inhibits their ability to 
interact with D-type cyclins, which is the early and essential step in the phosphorylation 
of pRB. Thus, p i6 maintains pRB in its active, growth-inhibitory state. In turn, pRB 
halts cell proliferation by suppressing the activity of E2F, a transcription factor that 
stimulates the expression of genes that are required for cells cycle progression (Sherr 
and McCormick, 2002).
1.2.3.1 The DNA damage response (DDR)
Several stresses that can lead to senescence converge on a DNA damage response 
(DDR). Telomeres consist of nucleoprotein complexes that cap the end of chromosomes 
and protect them from degradation or fusion. The progressive telomere shortening 
eventually causes chromosome ends to be recognized as DNA breaks, which 
consequently activates a DDR and enforces replicative senescence (Verdun and 
Karlseder, 2006).
Induction of p53 in response to DNA damage is coordinated by the serine/threonine 
protein kinase ataxia telangiectasia mutated (ATM) and the ataxia telangiectasia and 
Rad3-related (ATR). These modify a large number of substrates, including signal- 
amplifying checkpoint kinases CHK1 and CHK2, whose engagement is favoured by 
mediator proteins, such as 53BP1, MDC1 and BRCA1, and chromatin modifiers such as 
y-H2AX. These signals converge on p53 and lead to p21 induction, halting cell-cycle 
progression (Figure 1.11).
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F ig u re  1.11 T h e  D N A  d a m a g e  re sp o n se . Double strand breaks are recognized by the MRN complex 
(composed by MRE11, RAD50 and NBS1) and lead to the activation of the kinase ataxia-telangiectasia 
mutated (ATM) and subsequent amplification of the response by recruitment of other DNA damage 
signalling proteins. ATM phosphorylates several proteins including MDM2, MDM4, p53 and 
checkpoint-2 (CHK2), which phosphorylates p53 and other proteins. Single strand breaks become coated 
with replication protein A (RPA) that attracts ATM and Rad3-related (ATR)-interacting protein (ATRIP) 
complex which phosphorylates the 9-1-1 complex (constituted by RAD9, RADI and HUS1) further 
activating ATR. Active ATR phosphorylates p53, MDM2, checkpoint-1 (CHK1) and other substrates. 
The DNA damage response ultimately results in activation of effector molecules such as p53, CDC25 or 
structural maintenance of chromosomes (SMC1). Activated p53 will induce expression of several genes 
involved either in cell cycle arrest or apoptosis. (Adapted from Campisi and d’Adda di Fagagna, 2007)
Like replicative senescence, OIS is often associated with activation of the DDR 
(Bartkova et ah, 2006; Di Micco et al., 2006; Mallette et ah, 2007). This is linked to 
DNA replication stress that might result from impaired or inappropriately activated 
origins of replication, although the exact mechanism has not yet been fully established 
(D’Adda di Fagagna et al., 2003). These findings raise the possibility that the DDR and 
OIS are causally linked. Indeed, RNA interference-mediated depletion of different DDR 
signal transduction components, including ATM and CHK2, allows for rescue o f OIS 
(Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 2007).
RAD17
CHK2
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How then does the DDR contribute to OIS? For instance, in analogy to replicative 
senescence, the DDR could activate p53. Indeed, in all the settings where interference 
with the DDR allows a bypass from senescence, induction of the arrest is accompanied 
by p53 activation. This strongly suggests that the DDR and p53 function in a single 
signal transduction cascade. The close link between the DDR and p53 activation has 
other important implications with regard OIS. If all type of OIS would rely on DDR 
signalling for their onset and/or maintenance, one would expect that OIS is always 
accompanied by p53 activation. However, this is not the case in mice and in the context 
of several human senescent cells, suggesting that DDR activation is not a universal 
feature of OIS and that is involved in certain, but not all, OIS settings.
1.2.4 Occurrence of cellular senescence in vivo
During the paste decade cellular senescence has been shown to occur and to be 
important in vivo. Senescent cells, identified by senescence-associated markers, are 
found in many renewable tissues in humans and murine model (Michaloglou et al., 
2005; Collado et al., 2005; Braig et al., 2005; Chen et al., 2005).
In line with theories that senescence in vitro is a correlate of ageing, several studies 
have provided direct evidence that senescent cells accumulate in ageing individuals 
(Campisi, 2005). It has been reported that in skin samples from human donors, there 
was an age-dependent increase in SA-p-GAL activity in dermal fibroblasts and 
epidermal keratinocytes (Dimri et al., 1995).
Moreover, it has been proposed that senescence can also contribute to age-related 
pathology. Atherosclerosis is accompanied by an induction of SA-P-GAL activity and 
telomere shortening (Minamano et al., 2002; Foreman and Tang, 2003).
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In osteoarthritis senescent cells are also observed (Price et al., 2002).
Recently, also beneficial aspects of replicative senescence have been uncovered. In a 
mouse model of liver fibrosis, senescent cells are found, as evidenced by positivity for 
SA-p-GAL activity, p lb 11^ 48, p53, p21CIP1 and HMGA1 (Krizhanovsky et al., 2008). 
These senescent cells derive from activated hepatocellular stem cells and limit the 
progression of fibrosis, supporting the speculation from Hayflick’s experiments that 
replicative senescence limits tumorigenesis. The observation of senescent cells has been 
extended to many premalignant lesions or benign tissues induced by different activation 
or tumour suppressor inactivation in human and mouse.
Human melanocytic nevi, which frequently harbour activating BRAF or NRAS 
mutations, display several characteristics of senescence. Nevi are benign tumours that 
rarely progress towards melanoma, which is accompanied by the implementation of a 
long-term proliferation arrest in these lesions. In line with this, nevi contain very few 
cells that stain positively for the proliferation marker Ki-67. Instead, they display 
elevated expression of p l6 INK4a and SA-P-Gal senescence markers (Michaloglou et al., 
2005). Similarly, human prostatic intraepithelial neoplasia (PIN) lesions as well as 
human colon adenoma express markers of senescence (Acosta et al., 2008; Kuilman et 
al., 2008).
Cellular senescence in vivo can also be triggered by the loss of a tumour suppressor 
gene. The tumour suppressor NF1 encodes a RAS GTPase activating protein that is a 
negative regulator of RAS activity. It has been shown that the absence of NF1 results in 
hyperactivated RAS signalling and the formation of neoplastic lesions, known as 
neurofibromas, which display markers of senescence (Courtois-Cox et al., 2006).
The observation of senescent cells has also been reported in mouse models. Serrano and 
colleagues described a “knock-in” mouse model in which oncogenic RAS was 
expressed at a physiologic level. Unexpectedly, most RAS-expressing cells in these
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mice remained normal for a long period with no apparent defects in differentiation or 
signs of unchecked proliferation. Lung adenoma did emerge, but only after a long 
latency period. In these adenomas, a low proliferative index was accompanied with 
elevated levels of SA-P-Gal and increased expression of senescence markers (Collado 
et al., 2005). Similarly, RAS-driven mouse T-cell lymphomas entered senescence after 
drug therapy, when apoptosis was blocked. Senescence has also been observed in lung 
tumours and melanocytic nevi when using mice with endogenous BRAFV600E (Dankort 
et al., 2007; Dhomen et al., 2009). To study the role of BRAFY600E in non-small-cell 
lung cancers (NSCLCs) its expression was targeted to the lungs. At eight weeks 
BRAFV600E-expressing mice displayed benign adenomas, which accumulated some 
senescence-associated markers. Interestingly, no adenocarcinomas were detected after 
six months in BRAFV600E-expressing mice (Dankort et al., 2007). Similarly, transgenic 
expression of BRAFV600E in the melanocytic lineage drives the formation of nevi with 
several signs of senescence (Dhomen et al., 2009).
Pandolfi and co-workers found that cellular senescence can be triggered in vivo not only 
by oncogene activation, but also by inactivation of tumour suppressor. Loss of the 
tumour suppressor Pten, a phosphatase that opposes PI3K activity in murine prostate 
cells leads to the formation of PIN lesion with features of senescence (Chen et al., 
2005).
1.2.4.1 Cellular senescence as a barrier to tumorigenesis
Tumorigenesis is a multistep process, in which a normal cell acquires mutations that 
allow it to avoid replicative and oncogene-induced senescence. These mutations 
typically occur in the p53 and pl6-pRB pathways. By restricting cell proliferation and 
thereby impeding the accumulation of mutations, senescence acts as an important 
tumour suppressor mechanism. The first evidence derived from the analysis of
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senescence in tumours is its close association with the pre-malignant stages of 
tumorigenesis. In fact, the identification of senescent cells was obtained from lung 
adenomas, pancreatic intraductal neoplasia, PIN lesions and melanocytic nevi, which 
are premalignant tumours (Collado et al., 2005; Chen et al., 2005; Michaloglou et al., 
2005). By contrast, senescence was absent in their corresponding malignant stages. 
Nonetheless, there are several evidences in which loss of senescence appears to be a 
crucial, albeit insufficient, step in the development of cancer. For example, genetically 
engineered mice that are deficient in a histone methyltransferase or p53 contain cells 
that fail to senescence in response to appropriate stimuli; these mice are cancer-prone 
(Braig et al., 2005; Chen et al., 2005; Donehower et al., 1992). Similarly, cells from 
patients with Li-Fraumeni syndrome, which carry mutations in p53 or CHK2, abrogate 
senescence and allow progression to malignant stages (Shay et al., 1993). These 
observations point to a causal link between loss of senescence and malignant 
transformation. All this evidence strongly suggests a role of senescence as a barrier to 
tumour progression, as a physiologic response that cells must overcome in order to 
divide indefinitely and develop into tumours (Figure 1.12).
However, it is not clear whether malignant tumours emerge from a senescent cell upon 
acquisition of an escape mutation or expand from a clone that a priori bypassed 
senescence. In addition, genetic defects that inactive senescence are necessary but 
insufficient for malignant tumorigenesis. In fact, the inactivation of p lb 1^ 43, p21CIP1 or 
even p53 or pRB increases the replicative lifespan of human cells but does not 
transform them per se (Di Micco et al., 2006; Brown et al., 1997); thus, additional 
mutations might be required to establish cancer cells that eventually expand as a 
clinically relevant tumour mass (Figure 1.13).
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Figure 1.12 Senescence as a barrier to tumorigenesis. Premalignant lesions usually comprise of a 
heterogeneous population of tumour cells, some undergoing apoptosis (purple) others senescence (blue). 
These lesions may remain restricted in growth or if cells are able to override tumour suppressive 
mechanisms, tumour progression to a malignant state will be favoured. (Adapted from Collado and 
Serrano, 2006)
1.2.4.2 Cellular senescence as anticancer therapy
In light of the increasing evidence that senescence protects humans and other organisms 
against cancer, the idea to restore this process in tumour cells in which it has become 
deficient, represents an attractive therapeutic approach.
As mentioned above, senescence induced by oncogene activation or inactivation of 
tumour suppressor genes must be evaded for tumours to progress to malignancy, which 
is often associated with inhibition of senescence regulators. Considering the critical role 
of p53 in senescence onset and common occurrence of p53 mutations in cancer cells, 
p53 is an attractive target for reactivation of senescence in cancer cells. The feasibility 
of such an approach has been recently demonstrated. In a mouse model of 
hepatocellular carcinoma, reactivation of p53 in these tumours triggers senescence 
response and subsequent immune cell infiltration, which leads to clearance of tumour 
cells (Xue et al., 2007). Likewise, restoration of p53 in p53-deficient mouse models of 
lymphoma and osteosarcoma leads a rapid tumour regression (Ventura et al., 2007). In 
this context, the artificial expression of p53 induces senescence selectively in tumour
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cells, leaving normal tissue completely unaffected. Thus, these models support the idea 
that drugs targeted at restoring p53 in tumours might be an effective manner to restrict 
tumour growth by inducing senescence and promoting tumour cell clearance. Such p53- 
restoring drugs are currently being developed and some of their preliminary results 
suggest that senescence could be an important outcome in cancer therapy (Efeyan et al., 
2007; Kumamoto et al., 2008).
In addition to restoration of tumour suppressor genes, oncogene inactivation offers 
another possible intervention to induce senescence in cancer cells. Suppression of c- 
Mcy oncogene causes rapid regression accompanied by senescence in several tumours 
including hepatocellular carcinoma, lymphoma and osteosarcoma (Wu et al., 2007). 
These studies serve as proof of principle for the premise that reactivation of senescence 
is an efficient way to intervene with cancer.
Moreover, senescence-inducing drugs, attacking tumour cells, might prove effective 
alone or in combination with classic therapeutic approaches, and might reduce the 
toxicity of chemotherapy. It has been shown that primary murine lymphomas respond to 
chemotherapy by engaging a senescence program controlled by p53 and p lb 1^ 43 and 
this correlated with a better prognosis following chemotherapy (Schmitt et al., 2002). 
Senescence markers have been observed also, in biopsies from patients with lung, breast 
or prostate cancer after chemotherapy (Roberson et al., 2005; te Poele et al., 2002; 
Coppe et al., 2008). This therapy-induced senescence is associated with treatment 
success.
However, it is conceivable that some cancer cells in a senescence-like state might 
remain as “dormant” tumour cells and therefore represent a dangerous potential for 
tumour relapse. The mechanisms that allow tumour cells to overcome this terminal 
arrest might contribute to anticancer drug resistance and tumour relapse.
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In vivo observations suggest that escaping from drug-induced senescence is responsible, 
at least in part, for treatment failure.
As mentioned above, senescent cells secrete a complex mixture of secreted and 
extracellular factors usually referred to as the SASP or SMS. These components 
establish or reinforce the cell cycle arrest and contribute to tumour suppression by 
signalling to and recruiting the immune system (Acosta et al., 2008; Kuilman and 
Peeper, 2009). Secreted factors and their receptors are prototypic druggable molecules. 
Thus, it is feasible to manipulate components of the senescence secretome for 
prosenescence therapies. Despite increased knowledge on SASP composition and the 
existence of recombinant proteins, small molecules and antibodies to target these 
factors, there are not yet examples of prosenescence cancer therapies that use 
components of the senescence secretome, at either the experimental or the preclinical 
stage. A word of caution must be added as some factors of senescence secretome may 
also display protumorigenic activities stimulating malignant phenotype in nearby 
tumour cells (Coppe et al., 2008).
Overall, prosenescence therapies could be a new weapon for the fight against cancer.
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Figure 1.13 A model for tumour progression. Acquirement of an oncogenic mutation in normal cells 
can trigger three types of response. An antiproliferative response can be activated, leading to apoptosis or 
senescence. Alternatively, in the absence of an immediate response, the mutation-driven cell proliferation 
may produce a lesion. At this stage, both apoptosis and senescence might be activated. In the absence of 
appropriate defence mechanisms, continued growth with additional genetic events may lead to a 
malignant lesion.
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Aim of the thesis
Oncogene induced senescence (OIS) acts as an important tumour suppressor 
mechanism. Overcoming senescence and acquiring a limitless replicative potential has 
been proposed to be one of the key events required for malignant transformation. In the 
last few years a flood of studies showed evidence of senescence in a plethora of benign 
lesions in mice and human. However, the underlying mechanisms that control 
senescence as well as the key players that are mechanistically involved remain poorly 
understood.
The aim of this work is to investigate the role of OIS in tumours originating from the 
thyroid epithelium. We provided evidence that the activation of thyroid tumour- 
associated oncogenes (BRAF, RAS, RET and TRK) triggers senescence in human 
primary thyrocytes as demonstrated by the presence of several hallmarks of senescence. 
With the aim to increase our understanding of the molecular principles of thyroid 
tumour progression we dissected the signalling transduction pathways and molecules 
regulating senescence in our cellular model. To achieve these goals, we combined 
classical biochemical and genetic approaches with more advanced techniques including 
loss-of-function RNA interference strategy and high content analysis. We next extended 
our findings obtained in vitro in humans examining a panel of thyroid lesions 
characterized by different aggressiveness.
In a nutshell, our data in vitro and in vivo demonstrated that OIS serves as a potent 
tumour suppressor mechanism limiting thyroid cancer progression.
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CHAPTER 2
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Chapter 2 - IGFBP7: an oncosuppressor gene in thyroid 
carcinogenesis
The insulin-like growth factor (IGF) axis plays a key role in the growth, differentiation, 
and proliferation of mammalian cells (Poliak et al., 2004). It consists of two growth 
factors (IGF-I and IGF-II), their receptors (IGF-IR and IGF-IIR), a group of IGF- 
binding proteins (IGFBP) and IGFBP proteases. IGF signalling, mediated by interaction 
with IGF-Rs, is modulated by IGFBPs, which influence IGF bioavailability (Burger et 
al., 2005). When bound to IGFs, IGFBPs function by regulating their transport between 
intra- and extra-vascular spaces and by interaction with their receptors (Zapf, 1995), 
resulting in prolonging IGF-I/II half life and precluding their mitogenic activity 
(Stewart and Rotwein, 1996).
Insulin-like growth factor-binding protein 7 (IGFBP7), also known as mac25 or IGFBP- 
related protein-1 (IGFBP-rPl) is a secreted protein belonging to the IGFBP family 
which includes six proteins (IGFBP-1 to IGFBP-6) that bind IGFs with high affinity 
and a group of ten IGFBP-related proteins (IGFBP-rPs) that bind IGFs with low affinity 
(Burger et al., 2005). IGFBP7 binds IGFs with low affinity, but recognizes insulin with 
high affinity, and thereby modifies its metabolism, distribution, and ability to bind to 
the insulin receptor (Yamanaka et al., 1997). IGFBP7 has also IGF/insulin independent 
actions (Kato, 2000). IGFBP7 is expressed in an ubiquitous fashion in normal tissues 
(Degeorges et al., 2000) and is inactivated by proteolytic processing (Ahmed et al., 
2003). A large body of evidence suggests that IGFBP7 functions as an oncosuppressor 
gene in human prostate, breast, lung and colorectal cancer, as it regulates cell 
proliferation, cell adhesion, cellular senescence and angiogenesis (Akaogi et al., 1996; 
Sprenger et al., 1999; Wilson et al., 2002; Burger et al., 2005; Ruan et al., 2006; Chen et 
al., 2007; Sato et al., 2007).
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IGFBP7 is silenced by promoter hypermethylation in several neoplastic tissues, 
including colorectal and gastric cancers (Ahmed et al. 2003; Kanemitsu et al. 2000; Lin 
et al. 2007).
More recently, IGFBP7 has been shown to mediate senescence in melanocytes, and to 
suppress melanoma growth in vivo by inducing apoptosis (Wajapeyee et al., 2008). 
Studies in mouse models have proposed IGFBP7 as a therapeutic agent for treatment of 
metastatic melanoma and colorectal tumours carrying RAS or BRAF mutations 
(Wajapeyee et al., 2009). However, the critical role of IGFBP7 in mediating 
BRAFV600E-induced senescence in melanocytes has been challenged recently (Scurr et 
al., 2010).
In this work we investigate the role of IGFBP7 in PTC aiming to increase our 
understanding of molecular mechanisms underlying thyroid carcinogenesis. Analysis of 
expression levels in microarray datasets highlighted that IGFBP7 was dowregulated in a 
consistent fraction of PTC, with respect to normal thyroid. To address the functional 
consequences of IGFBP7 downregulation we used the PTC-derived NIM1 cell line, in 
which the expression of IGFBP7 is lacking. Exposure to soluble IGFBP7 protein or 
restoration of IGFBP7 expression by cDNA transfection reduced growth rate, 
migration, anchorage independent growth and tumorigenicity of NIM1 cells. We 
provide evidence that the effects of IGFBP7 are related to apoptosis. Overall, our data 
suggest that IGFBP7 gene exerts an oncosuppressor role in thyroid epithelial 
carcinogenesis.
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2.1 Results
2.1.1 Expression of IGFBP7 in PTC
To examine the biological relevance of IGFBP7 in papillary thyroid carcinogenesis, its 
expression level in normal thyroid tissues or thyroid carcinomas was first analyzed on 
cDNA microarray data produced in our laboratory (Ferrario et al., 2008). As shown in 
Figure 2.1 A, in comparison to IGFBP7 gene expression level in normal thyroid (9 
samples), IGFBP7 transcripts were significantly downregulated in both FTC (11 
samples) and PTC (31 samples) histotypes with a p-value <0.05. Downregulation of 
IGFBP7 affected a consistent fraction of PTC cases, with 16 out of 31, including 80% 
of tall cell (TC) variants, displaying expression levels lower than the lowest level of 
normal samples. To further analyze the role of IGFBP7 in PTC we used three 
independent, publicly available datasets of microarray gene expression data of thyroid 
PTC samples, all obtained using Affymetrix HG-U133 series platforms. In the Vasko 
dataset (Vasko et al., 2007), which included normal thyroid and microscopically 
dissected intratumoral samples of PTC from four patients, both central and invasive 
regions displayed reduced expression of IGFBP7 transcripts (p<0.01) with both 
201162_at and 201163_at probe sets, in comparison to the normal region (Figure 2.IB). 
In the Giordano dataset (Giordano et al., 2005) significantly reduced expression of 
IGFBP7 (p<0.05) was observed in the TC variants (10 TC out of 26 total PTC) when 
compared to normal thyroid with one of the two probe sets (201162_at). Even for the 
second probe set, however, 40% of TC variants displayed hybridization values lower 
than the lowest level of normal samples (Figure 2.2A). In the He dataset (He et al., 
2005), PTC displayed a reduced IGFBP7 expression when compared to unaffected 
thyroid tissues from the same patients in 5 out of 9 cases with both probe sets 
(201162_at and 201163_at) but did not reach statistical significance (Figure 2.2B).
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Overall these results suggest that expression of IGFBP7 is downregulated in a 
consistent fraction of PTC with respect to normal thyroid.
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Figure 2.1 IGFBP7 gene expression levels in PTC in two different data sets. Data are reported as 
scatter plots of log2 values and median is recorded. A) Our data set: FTC and PTC thyroid carcinoma 
presented a significantly lower IGFBP7 expression as compared with normal thyroid samples. IGFBP7 
relative expression values were measured as log2 ratio between expression level of the specimen and that 
of the reference. * = p<0.05 by Kruskal-Wallis followed by multiple comparisons post-tests.
B) Vasko dataset: central and invasive area of PTC display reduced expression of IGFBP7 when 
compared to the normal thyroid in paired tissue samples. Expression values relative to the two different 
IGFBP7 probe sets (201162_at, left panel and 201163_at, right panel) are shown. ** = p<0.01 by one-way 
ANOVA followed by multiple comparisons post-tests.
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Figure 2.2 Two different data sets showing IGFBP7 gene expression levels in PTC. A) Giordano 
dataset: 51 PTC samples including 26 classic PTC types, 15 follicular variants (FV), 10 tall cell variants 
(TC) and 4 normal thyroid tissues were compared. B) He dataset: PTC samples from 9 patients showed 
reduced IGFBP7 expression when compared to unaffected thyroid tissue samples. Expression values 
relative to the two different IGFBP7 probe sets (201162_at, left panel and 201163_at, right panel) are 
shown.
2.1.2 Expression analysis of IGFBP7 in thyroid tumour cell lines
To further explore the role of IGFBP7 in thyroid carcinogenesis we investigated its 
expression in several thyroid tumour cell lines, including PTC-derived (TPC1, NIM1, 
BCPAP and K l) and ATC-derived (BHT and KAT4) cell lines. Except for TPC1, 
which carries the RET/PTC1 oncogene, all the other cell lines harbour the BRAFV600E 
mutation. As control the melanoma SKMEL-31 cell line, known to express IGFBP7, 
was used (Wajapeyee et al., 2008). As IGFBP7 is a secreted protein, its presence in the 
conditioned medium (CM) was investigated. For each cell line an aliquot of CM
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corresponding to 4x105 cells was analyzed by Western blot with anti-IGFBP7 
antibodies. Expression of IGFBP7 protein was strong in BCPAP, K1 and BHT cell 
lines, reduced in TPC1 and KAT4, and undetectable in NIM1 cell line (Figure 2.3A). 
The lack of expression of IGFBP7 in NIM1 cells was due to the absence of the relative 
mRNA, as demonstrated by RT-PCR (Figure 2.3B). Treatment with the demethylating 
agent 5-Aza-2’Deoxycitidine (5-Aza-dC) restored the IGFBP7 mRNA expression, 
indicating that the lack of IGFBP7 protein in NIM1 cells is caused by promoter DNA 
hypermethylation.
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2.1.3 IGFBP7 reduces NIM1 cells growth rate
To investigate the potential pathogenic role of IGFBP7 in PTC, we produced an in vitro 
model of thyroid cancer based on the restoration of the IGFBP7 expression in NIM1 
cells. The latter, derived from a PTC, harbour the BRAFV600E mutation and are 
tumorigenic in nude mice (Zeki et al., 1993). As first approach, we determined the 
growth rate of NIM1 cells exposed to CM from K1 cell line, expressing IGFBP7 
(Figure 2.4A), or to their own CM. The experiment reported in Figure 2.4A shows that 
growth rate of NIM1 cells exposed to IGFBP7-containing medium is reduced with 
respect to control. The reduction was evident at day 2, and accounted for 47% at day 4. 
To verify whether the inhibitory effect of the K1 CM is due to the presence of IGFBP7 
we performed an immunodepletion with anti-IGFBP7 antibodies. Although the 
immunodepletion did not remove completely IGFBP7 from K1 CM (Figure 2.4A, 
inset), we observed a partial restoration of the NIM1 cells growth.
We next investigated the effect of restoration of IGFBP7 expression in NIM1 cells by 
cDNA transfection. To this end, NIM1 cells were transfected with a plasmid expression 
vector containing the IGFBP7 cDNA in frame with myc epitope or the empty vector, 
and selected in G418. NIM1 cells transfected with IGFBP7 expression vector produced 
G418-resistant colonies smaller than those obtained with the empty vector (Figure 
2.4B), supporting the notion that IGFBP7 protein negatively regulates NIM1 growth 
rate. Several NIM1-IGFBP7 clones were isolated and analyzed; in 6 out of 12 the 
expression of the IGFBP7 protein was detected at variable levels in the CM (Figure 
2.4C). The growth rate of three clones expressing different level of IGFBP7, namely 
NIM1-I2, NIM1-I11, and NIM1-I13 was determined (Figure 2.4D). For all the clones a 
growth decrease with respect to parental NIM1 cells was observed, and such decrease 
correlated with the expression level of IGFBP7 protein. In fact at day 5, growth rate was 
reduced of 39% forN IM l-Ill, of 59% forNIM1-I13, of 66% forNIMl-I2.
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Overall these data demonstrate that IGFBP7 negatively regulates growth of thyroid 
tumour cells.
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2.1.4 IGFBP7 reduces anchorage-independent growth and migration of NIM1 cells
Tumour cells display the capability to grow in the absence of adhesion. We wondered 
whether this feature in NIM1 cells is affected by IGFBP7 by performing soft agar assay. 
For these experiments we used clones NIM1-I2, NIM1-I5 and NIM1-I13, all producing 
high but variable levels of IGFBP7 protein (Figure 2.4C); as control, the NIM1-EV 
clone, transfected with empty vector, was used. As shown in Figure 2.5A, the colonies 
formed by NIM1-IGFBP7 clones were smaller than those formed by the control cells. 
In addition, NIM1-IGFBP7 clones formed colonies with efficiency reduced with respect 
to the control; reduction accounted to 82 % for NIM1-I2, 67% for NIM1-I5, and 75% 
for NIM1-I13 (Figure 2.5B).
We next analyzed the migration capability of NIM1-IGFBP7 clones by the wound 
healing assay; as control, the NIM1-EV clone was used. The wound healing was 
monitored between 4 and 24 hours, and the wound closure rate was calculated 4 and 8 
hours after scratching (Figure 2.6). All the NIM1-IGFBP7 clones showed reduced 
wound healing capability with respect to empty vector transfected NIM1 cells. Such 
reduction ranged from 30% to 35% 4 hours after scratching, and from 31% to 51% 8 
hours after scratching. The wound of control cells was completely healed after 8 hours 
(Figure 2.6), whereas for NIM1-IGFBP7 clones the scratch was not yet closed within 24 
hours.
2.1.5 IGFBP7 reduces tumorigenicity of NIM1 cells
We next asked whether re-expression of IGFBP7 could affect the in vivo growth of 
NIM1 cells. To this end, NIM1-IGFBP7 clones and NIM1 cells were injected into nude 
mice at two different cell concentrations (Table 2.1). In mice injected with 2xl06 cells, 
tumour growth was observed in 3/3 mice injected with NIM1 cells, whereas no tumour 
growth occurred in those injected with NIM1-IGFBP7 clones. When 5xl06 cells were
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injected, no take was observed in mice xenografted with NIM1-I2 cells. In mice 
injected with NIM-I5 and NIM1-113 cells, 3/3 takes were observed, but regression 
occurred in 1/3 animal for each clone; in the remaining animals tumours grew slower 
than NIM 1 tumours.
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Figure 2.6 Effect of IGFBP7 re-expression on migration capability of NIM1 transfected and control 
cells. Migration of NIM1-IGFBP7 clones (NIM1-I2, NIM1-I5, NIM1-113) and empty vector transfected 
clone (NIMl-EV) was analyzed by wound healing assay. Representative images of the wound captured at 
0, 4, 8 hours are shown. In each panel the percentage of migration, determined by dividing the migrated 
distance by the scratched distance, is indicated.
Table 2.1 In vivo tumour growth3
Cell line 2x106 cells 5x l06 cells
Tumor-bearing
mice
Tumor-bearing
mice Regression Days at 0. lg Days at lg
NIM1 3/3 6/6 0/6 <8 11(7-40)
NIM 1-12 0/3 0/3 - - -
NIM 1-15 0/3 3/3 1/3 <8 22,41
NIM1-I13 0/3 3/3 1/3 <8 14,59
aNIMl-IGFBP7 clones and parental NIM1 cells were inoculated subcutaneously into the left flank of 
athymic nude mice. Tumor growth was monitored twice a week from day 8 to day 60.
2.1.6 IGFBP7 impairs cell cycle progression and modulates ERK activation, p21 
and p53 expression
To explore the mechanisms by which IGFBP7 negatively regulates the growth of NIM 1 
cells we performed cell cycle phase distribution of transiently transfected NIM1 cells 
through flow cytometric analysis. As shown in Figure 2.7A, re-expression of IGFBP7 in 
NIM1 cells increased the percentage of cells in G1 (84%) compared with the empty 
vector transfected NIM1 cells (65%) with a consequent decrease of the percentage of 
cells in S phase (8% in NIM1-IGFBP7 versus 24% in control) as evaluated by DNA 
content analysis (Figure 2.7A). The G1 arrest caused by IGFBP7 was associated with a 
strong decline of phospho-ERK (pERK) levels and an up-regulation of p53 and p21 
tumour suppressors (Figure 2.7B). IGFBP7-transfected NIM1 cells compared to the 
control displayed 70% reduction of pERK levels, and an increase of p53 and p21 
expression of 49% and of 54%, respectively, as assessed by densitometric analysis 
(Figure 2.7B).
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Figure 2.7 Analysis of cell cycle, ERK activation, p53 and p21 levels in NIM1-IGFBP7 transfected 
cells. Cells were transfected with either empty vector (vector) or IGFBP7 expression vector (IGFBP7), 
and analyzed 3 days after transfection. A) Quantification of the percentage of cells in different stages of 
the cell cycle as analyzed by flow cytometry assay. The data represent the average of three independent 
experiments. B) Western blot analysis with the antibodies against phosphorylated ERK or ERK, p53 and 
p21. p-Actin was used for normalization of gel loading. Band intensity was assessed by densitometry to 
evaluate the ratio between phosphorylated ERK and total ERK, p53 and P-Actin, p21 and P-Actin.
2.1.7 IGFBP7 mediates cell growth suppression through induction of apoptosis
We next wondered whether the effects induced by IGFBP7 in NIM1 cells could be 
related to apoptosis. To this end, we analyzed the capacity of IGFBP7 to induce 
apoptosis, alone or in combination with TRAIL, a proapoptotic agent effective in NIM1 
cells, by determining the levels of cleaved PARP. We observed that IGFBP7 transiently
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transfected NIM1 cells exhibited higher levels of cleaved PARP compared with empty 
vector transfected cells (Figure 2.8A). Exposure to TRAIL (50ng/ml for 5 hours) 
generated a higher induction of apoptosis in IGFBP7 transfected NIM1 cells with 
respect to the control (Figure 2.8A), suggesting that IGFBP7 may cooperate with other 
stimuli in inducing apoptosis. These observations were also confirmed by analyzing the 
levels of cleaved PARP in NIM1-IGFBP7 clones (Figure 2.8B). In clone NIM1-I2, 
expressing the highest amount of IGFBP7 protein (Figure 2.4C), cleaved PARP was 
observed in untreated cells, and it was strongly induced by TRAIL treatment. Clones 
NIM1-I5 and NIM1-I13, both expressing lower amount of IGFBP7 protein with respect 
to NIM1-I2, displayed low levels of cleaved PARP, which increased after TRAIL 
exposure. In the control cells, cleaved PARP was detectable after TRAIL treatment, but 
to a lesser extent with respect to NIM 1-15 and NIM 1-113 in the presence of TRAIL.
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Figure 2.8 Detection of apoptosis in NIM1-IGFBP7 transfected and control cells. Untransfected or 
transiently transfected cells (A) or NIM1-IGFBP7 and NIMl-EV clones (B), treated or not with TRAIL 
(50 ng/ml for 5 hours) were analyzed for the expression of cleaved PARP by Western blot with cleaved 
PARP antibodies. P-Tubulin was used for normalization o f gel loading. Band intensity was assessed by 
densitometry to evaluate the ratio between cleaved PARP and P-Tubulin.
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2.2 Discussion
We have shown that IGFBP7 protein exerts a negative regulation on thyroid tumour 
cells. By analysis of gene expression data produced in our laboratory we have detected 
significant reduction of IGFBP7 gene expression in both FTC and PTC. Down 
regulation of IGFBP7 gene in PTC compared to normal thyroid was also observed in 
different, publicly available gene expression datasets. This in silico analysis even 
indicated that IGFBP7 downregulation is associated to the TC variant of PTC.
Silencing of IGFBP7 gene in melanoma was originally found associated with the 
BRAFY600E mutation (Wajapeyee et al., 2008). However, such correlation was not 
confirmed by subsequent studies showing loss of IGFBP7 expression regardless of 
BRAF status (Schrama et ah, 2009; Wajapeyee et al., 2009). In colorectal cancer loss of 
IGFBP7 has been associated to BRAFy600b mutation by two different studies (Hinoue et 
al., 2009; Suzuki et al., 2010). Our gene expression analysis indicates the absence of 
correlation between loss of IGFBP7 and BRAFY600E mutation in thyroid carcinoma. In 
keeping with this, among 5 cell lines carrying the BRAFY600E mutation, only 2 showed 
downregulation of IGFBP7 expression.
To determine whether IGFBP7 contributes to thyroid carcinogenesis we used the NIM1 
cell line, derived from a PTC carrying the BRAFY600E mutation, in which the expression 
of IGFBP7 gene is abrogated by promoter hypermethylation. Several lines of evidence^ 
suggest that restoration of IGFBP7 in NIM1 cells interferes with cell growth. Reduction 
of growth rate was in fact detected in NIM1 cells exposed to soluble IGFBP7 and in 
clones obtained by stable transfection with an IGFBP7 expression vector. We provided 
also evidence that IGFBP7 interferes with other tumour cell properties, such as 
anchorage-independent growth and migration capability: both of them were reduced in 
NIM1 clones stably expressing the IGFBP7 protein.
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In vivo experiments showed that restoration of IGFBP7 expression reduces the NIM1 
cells capability to induce tumour formation in mouse xenografts.
IGFBP7 negatively regulates NIM1 cell growth by triggering apoptosis. Concomitantly 
to growth inhibition and attenuation of ERKs signalling, we observed upregulation of 
p53 and p21, which led to G1 arrest and apoptosis in IGFBP7-expressing NIM1 cells. 
Altogether our data propose IGFBP7 as a tumour suppressor in thyroid carcinogenesis. 
As mentioned in chapter 1, IGFBP7 has been identified as a mediator of oncogene- 
induced senescence in benign nevi. Loss of IGFBP7 expression accounts for 
uncontrolled proliferation of melanoma; addition of IGFBP7 to melanoma cells inhibits 
ERK signalling and activates apoptosis (Wajapeyee et al., 2008). The capacity of 
IGFBP7 to induce apoptosis has been also demonstrated in cell lines derived from 
different tumour types, such as colorectal, prostate, lung (Chen et al., 2007; Ruan et al., 
2007; Sprenger et al., 1999). More recently, IGFBP7 has been proposed as an 
efficacious agent for treating malignancies that are dependent on BRAF-MEK-ERK 
signalling (Wajapeyee et al., 2009).
Our study provides evidence that apoptosis is also involved in the suppressor effects of 
IGFBP7 in thyroid tumour cells. In our experimental system IGFBP7 was capable to 
induce apoptosis and to potentiate the apoptotic effect of TRAIL. The mechanisms of 
apoptosis are highly complex, involving energy dependent cascade of molecular events. 
Two main apoptotic signalling pathways have been delineated: the intrinsic and 
extrinsic pathways. TRAIL has been shown to mediate the extrinsic pathway of 
apoptosis by binding to two transmembrane receptors, TRAILR1 and TRAILR2 (Wang 
and El-Deiry, 2003). However, the intrinsic pathway involves mitochondria and is 
triggered and controlled by members of the Bcl-2 protein family. Both pathways 
converge at caspase 3, leading to activation of others proteases, including PARP 
(Taylor et al., 2008).
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In light of this crosstalk, further studies on the involvement of which signalling 
cascades leading PARP cleavage might be important for a better characterization and 
understanding of cellular apoptotic events induced by IGFBP7. Moreover, the capacity 
of IGFBP7 to induce senescence in primary cells and apoptosis in tumour cells supports 
the notion that cancer cells that have bypassed senescence are in general more 
susceptible to apoptosis (Lowe et al. 2004).
The molecular events underlying thyroid cancer initiation and progression have been in 
part elucidated. Nevertheless, a role for tumour suppressor genes in thyroid 
carcinogenesis has not been assessed yet. Several recent studies highlight the power of 
gene expression analysis as a tool for the identification, among others, of putative 
oncosuppressor genes. In the last few years, in fact, some genes identified as 
downregulated in the context of gene expression studies, were classified as tumour 
suppressors by functional studies, as their re-expression modulated transformed 
properties of thyroid carcinoma cell lines. Restoration of MT1G (Ferrario et al., 2008), 
CBX7 (Pallante et al., 2008), ABI3BP (Latini et al., 2008), TIMP3 genes (Anania et al., 
2011), or IGFBP7 (present study) in thyroid tumor cell lines lacking their expression 
affected cell growth and transformed properties.
The downregulation of IGFBP7 gene expression in PTC raises the attractive hypothesis 
that oncogene-induced senescence might represent a relevant mechanism in thyroid 
carcinogenesis. The involvement of IGFBP7 in mediating senescence in our cellular 
system is reported in chapter 3.
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2.3 Materials and methods
2.3.1 Microarray datasets and statistical analysis
The expression of IGFBP7 was examined on microarray datasets containing normal 
thyroid tissues and PTC. One dataset, generated in our laboratory from cDNA 
microarray hybridization, contains the expression profile data of 45 thyroid samples 
collected at the Department of Pathology of our Institute. Sample collection includes: 9 
normal thyroid tissues, 11 FTC and 34 PTC. The PTC collection (24 classical types and 
10 TC variants) consists of cases carrying BRAFv600b mutation (12 samples), RET/PTC 
rearrangements (7 samples), TRK rearrangements (2 samples), none of the above 
genetic lesions (13 samples). The details of gene expression analysis have been 
previously reported (Ferrario et al. 2008). The other datasets are publicly available and 
all derived from experiments using HG-U133 series microarrays (Affymetrix, Santa 
Clara, CA, USA). These datasets contained data obtained from: a) 51 PTC samples 
(including 26 classical types, 15 follicular variants, 10 TC variants) and 4 normal 
thyroid tissues (Giordano et al. 2005); among PTC samples, 25 carry the BRAFv600E 
mutation, 6 RAS mutations, 1 RET/PTC rearrangement; 19 samples none of the above 
genetic lesions; b) paired PTC and unaffected thyroid tissue samples from 9 patients 
(He et al. 2005); c) paired central and invasive region of PTC and normal tissue from 4 
patients (Vasko et al. 2007). RMA normalized data were extracted from the NCBI Gene 
Expression Omnibus database (GSE3467 for the He dataset and GSE6004 for the 
Vasko dataset) or from the author’s website (Giordano dataset). All IGFBP7 probe sets 
were considered for expression analysis. Statistical analysis and graphs were generated 
using GraphPad Prism version 5.0. Comparison between two groups was performed by 
the non parametric Mann-Whitney or, in case of matched samples by Wilcoxon tests.
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Comparison between three or more groups was performed by ANOVA followed by 
multiple comparisons post-tests. A p-value <0.05 was considered significant.
2.3.2 RNA extraction and RT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA), according 
to the manufacturer’s instructions. One microgram of RNA was retro-transcribed using 
SuperscriptHI (Invitrogen, Carlsbad, CA) with random examers. Quality of RT 
reactions was monitored by PCR amplification of the housekeeping gene 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) using primers 5’- 
ACCATCTTCCCAGGAGCGAGAT-3 ’ and 5 ’ -GGC AGAG AT GAT GACCCTTT-3 ’, 
producing a 142 nucleotides fragment. After a denaturation at 94°C for 2 min, 35 PCR. 
cycles were performed (94°C for 1 min, 54°C for 1 min, 72°C for 1 min), followed by a 
final extension at 72°C for 2 min. For IGFBP7 amplification the following primers were 
used: 5’-TGGGTGCTGGTATCTCCTCT-3’ and 5’-TATAGCTCGGCACCTTCACC­
S’, producing a 154 nucleotides fragment. After a denaturation at 95°C for 7 min, 35 
PCR cycles were performed (95°C for 1 min, 56°C for 40 s, 72°C for 1 min) followed 
by a final extension at 75 °C for 5 min. PCR reactions were performed in a total volume 
of 20 pi containing 15 ng of single strand cDNAs, lxPCR buffer, 1.0 mM MgCk, 200 
pM each dNTP, 0.5 pM each primer and 0.25U of AmpliTaq-Gold polymerase 
(Applied Biosystem, Foster City, CA, USA). PCR products were separated on 2% 
agarose gel.
2.3.3 IGFBP7 expression vector preparation
The IGFBP7 cDNA was obtained from HeLa cells by RT-PCR using the following 
primers: 5’-CCGGAATTCCTGCCACCGCACCCCGCCAT-3’ and 5’-
GCCCAAGCTTTAGCTCGGCACCTTCACCTT-3 ’ encompassing the IGFBP7
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coding region and containing, respectively, the EcoRI and Hindlll restriction sites 
(bold). The 923 nucleotides PCR product was digested with EcoRI and Hindlll 
endonuclease and inserted into the pcDNA3.1/mycHis(-)A vector carrying compatible 
ends. The resulting construct encodes the IGFBP7-myc fusion protein.
2.3.4 Cell culture, transfection and treatments
The following thyroid tumour cells were used: TPC1, NIM1, BCPAP and K l, derived 
from PTC; BHT and KAT4, derived from ATC; SK-MEL 31, derived from melanoma. 
All thyroid tumour cells were maintained at 37°C, 5% CO2 humidified atmosphere; Kl 
cell line was cultured in DMEM:HAM’S F12:MCDB 105 (2:1:1) with 2mM glutamine 
and 10% fetal calf serum (FCS). All the other thyroid carcinoma cell lines were 
maintained in DMEM medium containing 10% FCS, 2 mM glutamine and lOOU/ml 
penicillin/streptomycin. SK-MEL 31 cells were cultured in MEM Eagle’s supplemented 
with 10% FCS at 37°C, 10% CO2 humidified atmosphere.
Transient and stable transfection of NIM1 cells was performed using Lipofectamine 
LTX (Invitrogen, Carlsbad, CA). Cells (4xl05) were seeded in 60mm dishes, cultured 
for 24 hours and transfected with 2 pg of plasmid DNA (pcDNA3.1/IGFBP7-myc or 
pCDNA3.1-myc, as control) and 5 pi of LTX, according to the manufacturer’s 
instructions. After 48 hours transfected cells were either harvested and processed, or 
subjected to G418 (Lifetechnologies, Invitrogen, Carlsbad, CA) selection (400 pg/ml). 
After 2 weeks of selection G418-resistant colonies were either fixed and stained, or 
isolated and propagated in G418-containing medium.
For the 5-Aza-dC (Sigma Aldrich, St. Louis, MO, USA) treatment, 6x105 NIM1 cells 
were seeded in 100 mm dishes and treated with 5 pmol/L of 5-Aza-dC 24 hours later. 
After 3 days of treatment, cells were harvested and processed for RNA isolation. For 
TRAIL (Genentech Inc, USA) treatment, 4x105 cells were seeded in 60 mm dishes and
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exposed to 50 ng/ml TRAIL 24 hours later. After 5 hours of treatment both attached and 
floating cells were collected and processed for protein extraction.
2.3.5 Immunodepletion of IGFBP7
Conditioned medium (CM) from Kl cell line was collected and incubated with 2 pg/ml 
of IGFBP7 antibodies for 2 hours at 4°C with rotation. Afterwards, 1 ml aliquot was 
incubated with 50 pi of protein A agarose beads (previously washed once with PBS 
and once with serum-free medium) for 24 hours at 4°C with rotation. After 
centrifugation the supernatant was filtered through a 0.22 pM Millipore filter and added 
to the cells.
2.3.6 Growth curves
Growth curves were determined by alamarBlue® Assay (Biosource, Nivelles, Belgium). 
Cells were plated in sextuple in 96-well multiwell (400 cells/well). After adhesion of 
cells the alamarBlue reagent was added to the medium at 10% v/v. The fluorescence at 
X = 590 and 535 nm was detected every 24 hours from day 1 to day 5, using a 
microplate reader (TecanUltra Tecan Trading AG, Switzerland ). Data were normalized 
for values detected at day 1.
2.3.7 Wound healing assay
Cells (1.5xl06) were seeded into 60mm dishes and incubated until they reached 80% 
confluency. A scratch was made through the center of the plate using a micropipette tip. 
Plates were washed with PBS, reefed with complete medium, and returned to the 
incubator. Images of the wound were collected at 0, 4, 8 and 24 hours using a 
microscope magnification of xlO (LEICA, DMIRB). The migration rate was quantified
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by measuring the distance between the wound edges, and the percentage of migration 
was determined as ratio between migrated distance and scratched distance.
2.3.8 Soft agar assay
Cells (5x104) were suspended in 1.5 ml of DMEM containing 0.33% agar and 10% 
FCS, added into a layer of medium containing 0.5% agar and 10% FCS in 60mm 
dishes, and incubated for 3 weeks. After staining with p-iodonitrotetrazolium chloride 
(Sigma Aldrich, St. Louis, MO, USA) the plates were analyzed for colony number and 
size.
2.3.9 Flow cytometry assay
Cells were collected 3 days after transient transfection for DNA content analysis. Cells 
were washed twice with PBS and fixed for 24 hours in cold ethanol (70%). After two 
washes with PBS, cells were incubated in PBS containing lpg/ml RNase and 50 pg/ml 
propidium iodide at room temperature for 30 min in the dark. Analysis was carried out 
using FACSCalibur (Becton Dickinson, San Jose, CA, USA) and data analysis was 
carried out using Cell Quest software.
2.3.10 Western blot analysis
Proteins were extracted in RIPA modified buffer (20mM Tris-HCl, pH 7.4, 150mM 
NaCl, 5mM EDTA, 1% NonidetP-40) supplemented with Complete Mini EDTA-free 
protease Inhibitor Cocktail (Roche, Manheim, Germany), ImM Na3VC>4 and ImM 
PMSF. Protein samples were quantified by Bradford’s assay with BIO-RAD Protein 
Assay (Bio-Rad, Munchen, Germany). Conditioned media, obtained by incubating cells 
in serum-free medium for 24 hours, were concentrated by centrifugation at 4000 imp 
using AgilentSpin Concentrators (Agilent Technologies Inc, Wilmington, DE, USA)
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and normalized to cell number. Protein and conditioned medium samples were boiled in 
NuPAGE LDS sample buffer (Invitrogen, Carlsbad, CA) and separated on 4-12% or 
10% NuPAGE Novex Gel (Invitrogen, Carlsbad, CA) with MOPS or MES running 
buffer, respectively. Proteins were transferred onto nitrocellulose filters and 
immunoblotted with the appropriated antibodies: a-phospho-ERK (pERK), a-ERK and 
a-Cleaved PARP (Cell Signaling Technology, Beverly MA, USA); a-p21 and a- 
IGFBP7 (Santa Cruz, Biotechnology, Inc Santa Cruz, CA, USA); a-p53 (YLEM); a-|3- 
Actin and a-P-Tubulin (Sigma, Aldrich St Louis, Mo, USA). The immunoreactive 
bands were visualized using horseradish peroxidase-conjugated secondary antibodies 
followed by enhanced chemiluminescence (GE, Bio-Rad Hercules, CA, USA). The 
membranes were scanned using the Chemidoc XRS and densitometric analysis was 
performed by using Quantitative One software (Bio-Rad Hercules, CA, USA).
2.3.11 In vivo studies
Animal studies were reviewed and approved by the Ethics Committee for Animal 
Experimentation of the Fondazione IRCCS ‘Istituto Nazionale dei Tumori’ and are in 
accordance with the guidelines of the UK Coordinating Committee for Cancer Research 
(U.K.Coordinating Committee on Cancer Research 1988). Female CD-I nu/nu mice (8- 
to 9-week old) (Charles River, Calco, Italy) were injected subcutaneously into the left 
flank with 2x106 or 5xl06cells in 0.2 ml PBS volume. Tumor growth was assessed by 
evaluating tumour latency, ie days to reach 0.1 g, and by monitoring tumour weight 
(TW) twice a week. TW was estimated by the formula TW(g)=d2xD/2 where d and D 
are the shortest and the longest diameters of the tumour, respectively, measured in cm.
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Chapter 3 -  Evidence of oncogene-induced senescence in thyroid 
carcinogenesis
The acquirement of oncogenic lesions can result in abnormal proliferation and generate 
early neoplastic cells. However, this is generally not sufficient for full oncogenic 
transformation, as expansion of such cells is limited by several tumour suppressive 
mechanisms. These include telomere-induced cellular senescence, apoptosis, but also 
oncogene-induced senescence (OIS).
The role of OIS in vivo has been a matter of debate for a long time, but recent advances 
in our understanding of this process strongly point to OIS as tumour suppressive 
mechanism in several model systems (see chapter 1). OIS operates during early 
tumorigenesis and involves the activation of several tumour suppressor networks, 
including the p lh ^ ^ /p R b  and p53/p21CIP1 pathways. They keep incipient tumour cells 
in check and thereby prevent them from progressing toward malignancy. In addition to 
classical senescence players, like p i6 ^ ^  and p53, several secreted factors have 
recently been found to play an essential role in senescence including growth factors, 
cytokines, and chemokines.
In this study, we investigate the occurrence of OIS in thyroid carcinogenesis with in 
vitro and in vivo studies. We found that PTC-associated oncogenes trigger OIS in 
primary human thyrocytes, as demonstrated by lack of proliferation, changes in cell 
morphology, induction of various biomarkers including elevated senescence-associated 
(SA) p-galactosidase activity, presence of SA heterochromatic foci (SAHF) as well as 
increased expression of p i 6 ^ ^ ,  p21CIP1 and p53.
To assess whether OIS represents a barrier to thyroid cancer in vivo, we performed 
immunohistochemical staining to monitor the expression of the classical OIS hallmarks 
in panel of thyroid tumours characterized by different aggressiveness.
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A strong immunopositivity for p l6 INK4a, p21CIP1 and IGFBP7 was observed in PTMCs, 
which represent the early stage of thyroid tumorigenesis, whereas such positivity was 
progressively lost in PTCs and ATCs.
Our observations made in vitro and in vivo support the notion that OIS may counteract 
oncogenic activity in thyroid tumours, and its escape paves the way for oncogenic 
transformation and thyroid tumour progression.
3.1 Results
3.1.1 BRAFV600E induces cellular senescence in primary human thyrocytes
To evaluate the response of primary human thyrocytes to BRAFV600E, the most frequent 
oncogene in PTC, we transduced cells with a lentiviral vector carrying an activated 
BRAF allele (BRAFy600b); as control, thyrocytes infected with lentivirus encoding only 
the blasticidin resistance gene were used. After selection with blasticidin, cells were 
monitored for morphology, proliferation, and presence of senescence specific markers. 
As early as 4 days after infection, BRAFY600E-transduced thyrocytes displayed a 
spindle-shaped morphology compared to cells transduced with the empty vector (Figure
3.1 A). Concomitantly, a marked growth arrest was observed, whereas control cells 
continued proliferating. Thus, as measured 7 days after infection, thyrocytes transduced 
with BRAFY600E exhibited dramatic reduction of S phase (0.47% of cells incorporated 
BrdU, vs. 18.7% for control cells), and they accumulated preferentially in G1 phase 
(65% in cells expressing BRAFY600E vs. 51% for control cells) (Figure 3.IB).
BRAFY600E transduced thyrocytes were next analyzed for the presence of two well- 
known OIS markers: senescence-associated P-galactosidase (SA-P-Gal) activity and 
senescence-associated heterochromatic foci (SAHFs). A high portion of thyrocytes 
expressing BRAFY600E exhibited SA-P-gal activity (85%) and SAHFs (80%), whereas
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in thyrocytes transfected with the empty vector SA-p-Gal activity and SAHFs were 
detected in 8% and 3% of cells, respectively (Figure 3.1C).
The expression of BRAFV600E, of its downstream effectors ERKs, and of proteins 
involved in OIS such as p l h ^ 43, p21CIP1, p53 and HMGA2, a structural component of 
SAHFs (Narita et al., 2006), was investigated at day 7 and 14 post infection in 
oncogene and empty vector transduced thyrocytes (Figure 3.ID). BRAFY600E was 
expressed to similar levels at both time points, in large excess with respect to 
endogenous BRAF. Concomitantly, an increase of ERKs phosphorylation, with respect 
to control, was detected at day 7, and persisted at day 14. Importantly, BRAFV600E 
induced expression of p lb 1^ 43, further increased at day 14, whereas p53 and p21CIP1 
levels increased slightly only at the later time point. Moreover, elevated expression of 
HMGA2 protein was maintained up to 14 day after transduction in the BRAFV600E 
expressing cells, thus corroborating the heterochromatin changes detected by DAPI 
staining.
To rule out the possibility that OIS observed in thyrocytes could be related to the 
abnormal BRAFY600E expression levels obtained by lentiviral transduction we 
performed nucleofection of thyrocytes, thus achieving low level of expression of the 
oncoprotein (two-three times more abundant than endogenous BRAF, data not shown). 
A significant number of SA-p-Gal -positive (50%) and SAHFs-bearing (30%) cells with 
respect to control (20% and 4%, respectively) were detected (data not shown).
Taken together these results indicate that oncogenic BRAFY600E induces senescence in 
human thyrocytes, and this is associated with the activation of the MAPK pathway, 
p l6 INK4a, p21cn>1 and p53 signal transduction cascades.
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Figure 3.1 BRAFV600E induces senescence in primary human thyrocytes. Primary human thyrocytes 
were infected with a lentivirus encoding BRAFV600E oncogene or control vector. A) Representative 
photographs showing cell morphology at 4 day after infection (magnification 10X). B) Cell proliferation 
was monitored by BrdU labelling followed by FACS analysis 7 days after infection. The upper box 
identifies BrdU positive cells (S phase), the lower left box displays G0/G1 cells and the lower right box 
shows G2/M cells. The percentage of cells incorporating BrdU is indicated in the upper right of each 
graph. C) Cells were analyzed for SA-P-Gal activity (upper panel; magnification 10X) and for SAHFs 
formation (middle panel; magnification 20X) 14 days after infection. The percentage o f cells positive for 
SA-P-Gal activity or carrying SAHFs is shown. Cells enlarged to show DAPI-stained chromatin foci are 
indicated with arrows and shown in lower panel. D) Expression of the indicated proteins was determined 
by Western Blot analysis at 7 and 14 day after infection. P-actin was used as a loading control. V: empty 
vector; B: BRAFV600E
3.1.2 p l6INK4a is not strictly required for BRAFV600E induced thyrocytes senescence
To investigate whether p l6 INK4a is required for BRAFv600E-mediated senescence in 
thyrocytes, we suppressed the expression of p l6 INK4a using two independent lentiviral 
shRNA vectors (#5 and #13). Six days after infection, cells were re-transduced with a 
lentiviral vector encoding BRAFY600E, selected for expression of the oncogene, and
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analyzed 7 days later. Both shRNAs could silence p l6mK4a expression. However, 
pl6iNK4a depletion ^id affect neither the level of ERK phosphorylation induced by 
BRAFV600E, nor the basal p21CIP1 levels (Figure 3.2A). Similarly, inhibition of p i6 ^ ^  
expression did not rescue the growth arrest caused by BRAFV600E (Figure 3.2B). The 
percentage of p lb ^ ^ -n u ll  BRAFV600E thyrocytes positive for SA-P-Gal activity was 
similar to BRAFY600E cells, whereas the percentage of p l6 INK4a-null BRAFY600E 
thyrocytes with SAHFs was reduced by approximately 40% compared with BRAFY600E 
cells (Table in Figure 3.2C). These data indicated p l b ^ 43 is not sufficient to fully 
execute BRAFY600E-induced senescence in thyrocytes.
3.1.3 BRAFY600e -induced senescence does not correlate with IGFBP7 expression 
As mentioned in the chapter 2, IGFBP7 is a secreted protein recently proposed as a 
mediator of BRAFY600E-induced senescence in melanocytes (Wajapeyee et al., 2008); 
this role, however, has been questioned by other authors (Scurr et al., 2010).
In light of these evidence we wondered whether IGFBP7 is involved in BRAFY600E- 
induced thyrocytes senescence. To this end, we analyzed the expression of soluble 
IGFBP7 in thyrocytes 7 days after BRAFY600E transduction. Surprisingly, BRAFY600E- 
infected cells showed reduced levels of secreted IGFBP7 protein compared to the 
control infected cells (Figure 3.3A). To further characterize such reduction we 
performed quantitative RT-PCR (qRT-PCR) (Figure 3.3B). Also in this case, we 
observed a decrease of IGFBP7 mRNA expression in senescent cells (day 7). O f note, 
such reduction was detectable as early as one day after infection.
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Figure 3.2 Effect of p l6INK4a silencing on BRAFV600E -induced senescence in primary human 
thyrocytes. Cells were transduced with two nonoverlapping shRNA against plb1^ 43 (#5 and #13) upon 
infection with BRAFV600E encoding lentivirus. The analysis of OIS markers was performed at 14 days 
after infection with the two shpl6INK4a constructs. A) Expression of the indicated proteins was determined 
by Western Blot analysis, p-actin was used as a loading control. B) The percentage o f cells for BrdU 
incorporation is shown. C) The percentage of cells positive for each indicated markers is shown in the 
table. V: empty vector; B: BRAFV600E
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Figure 3.3 Detection of IGFBP7 expression in BRAFv0UUI1'-transduced primary human thyrocytes.
The expression of IGFBP7 in primary thyrocytes infected with control lentivirus or lentivirus expressing 
BRAFV600E was monitored by Western Blot analysis 7 days after infection (A), and by real-time RT-PCR 
analysis 1 and 7 days after infection (B). V: control vector; B: BRAFV600E. RQ: relative quantity of 
IGFBP7 mRNA normalized for HPRT housekeeping gene expression
3.1.4 Expression of oncogenic RET/PTC, TRK and H-RASG12V triggers cellular 
senescence
The evidence that BRAFY600E establishes senescence arrest in primary thyrocytes raised 
the question whether the other PTC-associated oncogenes (RET/PTC, TRK and H- 
RASG12V) have also the capability to induce senescence program. Thus, to investigate 
the effect of RET/PTC oncogenes in primary thyrocytes we used cells transduced with a 
retrovirus encoding RET/PTC1 oncogene produced in the course of a previous study, 
and shown to display an increased growth rate compared to control uninfected 
thyrocytes, as determined in analyses performed between passages 3 and 7 after 
transduction (Borrello et al., 2005). Later on, however, by extending the number of 
passages in culture with respect to the previous study we noted that RET/PTC1 -infected 
thyrocytes, at variance with control cells, ceased proliferating and showed several
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morphological abnormalities, which were not further investigated at that time. In the 
course of the present work, we re-evaluated the previous observation, taking advantage 
of frozen stocks of RET/PTC 1-transduced thyrocytes and relative controls. Here again,
10-12 passages after infection, RET/PTC 1-expressing cells ceased proliferating and 
displayed morphological features of senescence, such as extensive vacuolization. 
Moreover, SA-P-Gal and SAHFs were found in 80% and 70%, respectively of cells 
infected with RET/PTC 1, but only in 10% and 2% of control cells, respectively (Figure 
3.4A). Biochemical analysis showed slight increase of ERKs phosphorylation compared 
to control cells. In addition, a marked upregulation of p l b ^ 43, p53 and HMGA2, and a 
slight increase of p21CIP1 was observed in RET/PTC1 infected cells (Figure 3.4B).
To introduce into thyrocytes TRK and RAS oncogenes we employed the nucleofcction 
technology, based on the evidence that BRAFV600E -induced senescence in thyrocytes is 
detectable with this transfection method, as described above. Plasmid expression 
vectors carrying TRK-T3 or H-RASG12Y oncogenes, and the empty vector as control, 
were transfected by nucleofection in primary human thyrocytes. Thyrocytes transfected 
with the TRK-T3 or H-RASG12V oncogenes underwent growth arrest and displayed flat, 
enlarged morphology and massive vacuolization. Moreover, an increase of SA-p-Gal 
positive cells was detected in TRK-T3 and H-RASG12Y transfected cells (60% and 
70%), respectively, whereas in thyrocytes transfected with empty vector SA-p-Gal 
activity was observed in 10% of cells. SAHFs were detected in 40% and 50% of TRK- 
T3 and H-RASG12Y transfected thyrocytes, respectively, but only in a small fraction 
(4%) of control-transfected cells (Figure 3.5A).
Biochemical analysis was performed at day 5 and 10 post nucleofection (Figure 3.5B). 
The expression of TRK-T3 and H-RASG12Y was constant. An increase in ERK 
phosphorylation level, with respect to control cells, was induced by both oncoproteins 
at the two times points analyzed.
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Similarly, an increase of p lb 1^ 43 expression was observed. None of the oncogenes 
affected the levels of p21cn>1. A slight increase of p53 was observed in H-RASG12V 
transfected cells at day 10.
On the whole our in vitro data suggest that all the PTC-associated oncogenes are 
capable to triggering senescence in primary human thyrocytes, and this is not related to 
the oncoprotein expression level.
A B
RET 
n-ERK 
ERKtot
p l 6 INK4a
p53 
P21apl 
HMGA2 
actin
F ig u re  3 .4  S en escen ce  p ro g r a m  is in d u c e d  b y  o n co g en ic  R E T /P T C 1  in  p r im a r y  h u m a n  th y ro c y te s .
P rim ary  hum an  thy rocy tes tran sduced  w ith  re tro v ira l vec to r carry ing  R E T /P T C  1 oncogene  (B o rre llo  et 
al., 2005 ) w ere  analyzed  fo r the  p resence  o f  O IS  m arkers  a t passage  10-12; u n in fec ted  ce lls  w ere  u sed  as 
contro l. A ) A naly sis o f  ce ll m orpho logy  (upper panel; m agn ifica tion  10X ), S A -P -G al ac tiv ity  (m idd le  
panel; m agn ifica tion  10X  fo r v ec to r and  20X  fo r R E T /P T C 1) and  SA H Fs fo rm ation  (b o tto m  panel; 
m agn ifica tion  40X ). P ercen tage  o f  cells positive  fo r S A -P -G al ac tiv ity  and  SA H F s a re  show n  in  each  
pho tograph . C ells en la rged  to  show  D A P I-sta ined  ch rom atin  foc i are  ind ica ted  w ith  a rro w s and  show n  in  
low er panel. B ) W estern  B lo t analysis o f  the  ind ica ted  p ro te in s  in  u n in fec ted  o r in fec ted  ce lls , p -ac tin  w as 
m onito red  as a  load ing  contro l.
Vector RET/PTC1
§3 ‘_o
M& I
9 9
ATRK 
p-ERK 
ERK tot
p  16lNMa
p53
P21clpl
actin
Day 5 Day 10 
V T V T
Day 5 Day 10 
V R V R
RAS
Figure 3.5 Expression of TRK-T3 and H-RasG12V oncogenes triggers senescence in primary human 
thyrocytes. Primary human thyrocytes were transfected with plasmid expression vectors encoding TRK- 
T3 and H-RasG12V or empty vector by nucieofection technology. A) Cell morphology (upper panel; 
magnification 10X) 4 days after transfection, the appearance of SA-P-Gal (middle panel, magnification 
10X for vector, 20X for TRK-T3 and H-RasG12V) and SAHFs (lower panel; magnification 40X) at 10 day 
after transfection are shown. Cells enlarged to show DAPI-stained chromatin foci are indicated with 
arrows and shown in lower panel. B) Immunoblot analysis monitoring the expression of the indicated 
proteins at 5 and 10 day after transfection. P-actin was used as a loading control. V: empty vector; T: 
TRK-T3; R: H-RasG12V.
3.1.5 Analysis of OIS markers in thyroid tumour samples
To study the relevance of OIS in thyroid tumour pathogenesis we performed IHC 
analysis for the detection of OIS markers in a series of thyroid tumour samples 
characterized by increasing aggressiveness, thus recapitulating epithelial thyroid tumour 
progression. The case collection included two PTMCs, seven PTCs (six NOS, and one 
SV (Nikiforov et al., 2001)), two PDTC, and one ATC. Clinical-pathological features 
and follow-up information for these cases are reported in Table 3.1.
Vector TRK-T3 H-RASG12V
1 0 0
Table 3.1 Clinical-pathological information of thyroid tumour case collection.
Case Age Gender Tumor type Genetic
lesion
ITS/LM N Lenght o f f  ollon -up Clinical 
(months) outcome
1 55 F PTMC b r a fV600E ITS, LNM 102 NED
2 36 F PTMC b r a fV600E ITS, LNM 99 NED
3 31 F PTC NOS UN ITS 60 NED
4 69 M PTC NOS UN ITS 67 NED
5 49 F PTC NOS b r a fV600E — lost —
6 48 F PTC NOS UN ITS 64 NED
7 55 F PTC NOS UN ITS lost . . .
8 57 F PTC NOS UN ITS, LNM lost . . .
9 46 F PTCSV b r a fV600E ITS 87 NED
10 67 F PTDC b r a f V600E LNM 12 Progression
11 75 M PTCD ND ITS 12 Progression
12 54 F ATC ND LNM 6 Died of disease
13 40 F PTMC UN ITS 72 NED
14 53 M PTMC TRK ITS, LNM 80 NED
15 48 F PTMC UN ITS 81 NED
16 30 M PTMC UN ITS 84 NED
PTC: papillary thyroid carcinoma; PTMC: papillary thyroid microcarcinoma; NOS: not otherwise 
specified; SV: solid variant; PDTC: poorly differentiated thyroid carcinoma; ATC: anaplastic thyroid 
carcinoma; UN: unknown (indicate case negative for BRAFV600E mutations, and RET or TRK 
rearrangement); ND: not determined; ITS: intrathyroidal spreading; LNM: lymph node metastasis; NED: 
no evidence of disease.
Notably, for PTMC # 2 three intrathyroidal spreads and a lymph node metastasis were 
available. Sample #9 (SV) and sample #10 (PDTC) presented areas with papillary and 
solid pattern of growth, thus providing a model of “in situ” tumour progression. The 
case collection was analyzed by IHC for the expression of p lb 1^ 43 and p21CIP1, well- 
known effectors of in vitro OIS, of IGFBP7, recently proposed as a factor required for 
OIS in melanocytes, and of the proliferation marker Ki-67. The results of IHC analysis 
are reported in Table 3.2; representative pictures are shown in Figure 3.6 and 3.7.
PTMC samples showed the highest expression of p l6 INK4a, which resulted upregulated 
in tumour areas with respect to the adjacent non tumoral thyroid tissue; p lb 1^ 43 
positive cells accounted for 50-60%.
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Immunolabeling for p l6 INK4a was both cytoplasmic and nuclear. In PTMC #2 p i6 mK4a 
was expressed at similar level in all the different tumour areas analyzed, including 
lymph node metastasis. The PTCs NOS samples showed a variable extent of p l6 INK4a 
expression: one case was scored negative (< 10% of positive cells); four cases showed
11-40% of positive cells, whereas only one case displayed more than 40% positive 
cells. In general, the distribution of p l6 INK4a was scattered; we observed groups of 
positive cells within the tumour mass. The PTC SV sample was scored positive in the 
areas with papillary growth, but negative in the solid ones. With respect to PDTC 
samples the papillary areas of case #10 were positive, whereas the solid areas as well as 
case #11 were negative. No expression of p lb 1^ 43 was detected in the ATC sample. 
With respect to p21CIP1 no staining was observed in the non tumoral tissue surrounding 
the tumour area. The highest expression was detected in PTMCs, showing 30% to 70% 
of positive cells, which persisted in the different lesions of PTMC #2. PTCs NOS were 
classified as negative, except for two cases that showed 11-40% of positive cells. The 
Solid Variant sample was scored positive in papillary areas and negative in solid ones. 
In the PDTC expression of p21cn>1 was detected only in the papillary areas of sample 
#10. No expression of p21cn>1 was observed in the ATC sample.
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Table 3.2 Immunohistochemical analysis for p l6INK4a, p21CIP1, IGFBP7 and Ki-67 in thyroid 
carcinomas
p !6INK4a p21c,P1 IGFBP7 Ki-67
PTCM
1 ++ + ++ L
2 PT,RL ++ + + + + + vL
2 ITS,RL + + + + + + + vL
2 ITS,IS + + + + + + + vL
2 ITS,LL + + + + + ++ vL
2 LNM ++ +++ -H- vL
PTC
NOS
3 + + L
4 - - + L
5 + - ++ L/M
6 + -j- -]—r M
7 + - - L
8 + + - + + L
SV
9 papillary + + +/++ L
9 solid - - - ND
PDTC 
10 papillary + + + + + L
10 solid - - - H
11 - + + M/H
ATC
12 - - H
PTMC, papillary thyroid microcarcinoma; PTC, papillary thyroid carcinoma; ATC, anaplastic thyroid 
carcinoma; ATC, anaplastic thyroid carcinoma; NOS, not otherwise specified; SV, solid variant; PT, 
primary tumour; ITS, intrathyroidal spread; LNM, lymph node metastasis; RL, right lobe; LL, left lobe; 
Is, isthmus. The percentage of cells with staining for p lb ^ 43 and p21CIP1 was scored from 0 to 3: (-) 
<10% of positive cells; (1+) 11-40%; (2+) 41-70%; (3+) 71-100%. The intensity o f staining for IGFBP7 
was from: (-) to (3+): (-) negative; (+) weakly positive; (++) moderately positive; (+++) strongly positive. 
Ki-67 staining was scored as very low (vL, 1-5% positive cells), low (L, 6-10% positive cells), medium 
(M, 11-30% positive cells) and high (H, >31% positive cells). ND, not done (no material available).
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Figure 3.6 Immunohistochemical analysis of OIS markers (pl6INKJa, p21CIPI, IGFBP7) and Ki-67 in 
thyroid tumour samples. A) Representative pictures of a papillary thyroid microcarcinoma (PTMC), a 
PTC not otherwise specified (NOS) variant, a poorly differentiated thyroid carcinoma (PDTC) and an 
anaplastic thyroid carcinoma (ATC) are shown. N: normal; T: tumour. B) Papillary and solid areas of 
PDTC #10 .  C) PTC sample distinguished by the presence of lymphocyte infiltration (first panel); 
edematous papillae cores (second panel); multinucleated giant cells (third panel).
IGFBP7 showed the same trend of expression as p l6 INK4a and p21CIP1. In both PTMC 
primary tumour samples, and in the intrathyroidal and lymph node spreads o f PTCM 
#2, IGFBP7 was upregulated with respect to the adjacent non tumoral tissue. PTCs 
NOS showed variable expression levels: three cases were scored as moderately positive, 
one case as weakly, and two as negative. IGFBP7 expression was detected in the 
papillary, but not in the solid areas o f SV sample; a similar trend was observed for 
PDTC #10, whereas PDTC #11 showed weak expression, and no expression was 
detected in the ATC sample. The expression of p lb 1^ 43, p21CIP1 and IGFBP7 proteins 
was inversely correlated with the proliferative index.
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The expression of the Ki-67 proliferation marker was very low or low in PTMCs; it 
ranged from low to medium in PTC NOS and in the papillary areas of samples #9 and 
#10; it increased to medium/high and high in PDTC and ATC, respectively. In Figure 
3.6A representative pictures of PTMC, PTC NOS, PDTC, and ATC are shown; Figure 
3.6B reports the analysis of papillary and solid areas o f PDTC sample #10. 
Interestingly, in PTC samples the expression of OIS markers was often associated to 
several structures suggestive of tumour regression (Figure 3.6C) such as: i) areas with 
lymphocyte infiltration (left panel), which has been reported to play a protective role in 
thyroid cancer (Ugolini et al., 2007); ii) swelling oedematous papillae cores (middle 
panel); and iii) syncytial clusters o f tumoral cells (right panel), a frequent finding in 
PTC (Fulciniti et al., 2001), resulting from papillae apex detachment.
pl6,NK4a p21CIP1 IGFBP7 Ki-67
Figure 3.7 Immunohistochemical analysis for the expression of p l6 INK4a, p21clpl, IGFBP7 and Ki-67 in 
primary tumour (PT), homolateral (HL), controlateral (CL) and lymph-node (LN) spreads of papillary 
thyroid microcarcinoma (PTMC) # 2. The Ki-67 panel of primary tumour is the same of Figure 3.6A.
105
The first conclusion that can be drawn from the IHC analysis is that the expression of 
OIS markers is upregulated at early stages and then lost during thyroid tumour 
progression. This issue is strengthened by the evidence that in samples #9 and #10, 
which recapitulate “in situ” tumour progression, the expression of the three protein 
analyzed was detected in areas featuring papillary growth but not in the solid ones.
The highest expression of all OIS markers analyzed observed in PTMCs would suggest 
that OIS may play a role in the general indolent clinical course of this PTC variant by 
keeping proliferation under check even in the presence of intrathyroidal and lymph 
node spread, as suggested by the analysis of PTMC #2 (Table 3.1 and Figure 3.7). To 
further explore this issue we analyzed four additional PTMCs presenting intraglandular 
and/or lymph node spread (Table 3.3); due to material shortage the analysis was limited 
to Ki-67 and p l6 INK4a. As shown in Table 3.2 the primary tumours showed relative 
intense p l6mK4a expression and very low Ki-67 immunolabeling. The same pattern of 
expression was observed in the intraglandular and/or lymph node tumour foci. 
Interestingly, in none of the PTMC patients recurrence was documented in the follow- 
up period, which ranged from 72 to 102 months (Table 3.3).
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Table 3.3 Immunohistochemical analysis for p!6mK4a and Ki-67 in a small series of PTMCs
Sample  ^ANK4a. p l6 Ki-67
13 PT.Is ++ vL/L
ITS,RL ++ vL
ITS, LL + vL
14 PT.LL ++ vL
ITS, Is Na Na
LNM ++ vL
15 PT,RL ++ vL
ITS, RL Na vL
16 PT, RL ++ vL
ITS, Is Na Na
ITS, LL + vL
PT: primary tumour; ITS: intrathyroidal spread; LNM: lymph node metastasis; RL: right lobe; LL: left 
lobe; Is: isthmus. The percentage of cells with staining for p l6mK4a was scored from 0 to3: (-) < 10% of 
positive cells; (1+) 11- 40%; (2+) 41-70%; (3+) 71-100%. Ki-67 staining was scored as very low (vL, 1- 
5% positive cells), low (L, 6-10% positive cells), medium (M, 11-30 % positive cells), high (H, > 31% 
positive cells). ND: not done (no material available).
Overall our data demonstrate the presence of OIS in PTMC, and suggests that this 
mechanism maintains the indolent behaviour of this tumour type, despite multifocality 
within thyroid gland and loco-regional spread.
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3.2 Discussion
We provided evidence that OIS may represent a barrier to the progression of thyroid 
tumour. In vitro studies, using different gene transfer methods, demonstrated that all the 
oncogenes activated in thyroid tumours, namely BRAFV600E, RET/PTC1, TRK-T3, and 
H-RasG12V, are capable to induce cellular senescence in primary human thyrocytes, as 
judged by the presence of growth arrest, changes in cell morphology, accumulation of 
SA-p-Gal and chromatin modifications. Our conclusion is corroborated by the evidence 
that OIS is detectable with different oncogenes transfected with different methods and, 
thus, expressed at different levels. Differences in efficiency and onset of OIS observed 
by using the different oncogenes can be ascribed to experimental conditions and 
oncoprotein expression level, rather than to intrinsic oncogenic features.
Shading light on the molecular mechanisms responsible for the OIS onset, the 
predominant view is that aberrant levels of MAP kinase activate senescence program 
through the critical involvement of p lb ^ ^ /p R B  and p53/p21cn>1 networks (Lin et al., 
1998). In our cellular setting, PTC-associated oncogenes trigger a marked activation of 
ERKs, accompanied by a persistent induction of p lb 1^ 43, whereas we failed to observe 
any significant upregulation of p53 and p21CIP1, with exception of RET/PTC1 
expressing thyrocytes in which an increase of p53 was detected. Of note, we did not 
observe involvement of IGFBP7 in BRAFV600E-transduced thyrocytes.
The relative contribution of the plb^^V pRB and the p53/p21CIP1 pathways in 
mediating senescence program remains poorly understood. It has been shown that 
p!6iNK4a pjayS a maj or roie than p21cn>1 in the induction of senescence in many contexts 
in vitro. In some cells p l6 INK4a is solely responsible for OIS onset (Ben-Porath and 
Weinberg, 2005), whereas in other cell types it has been shown that p lb 1^ 43 alone is 
not sufficient to execute the OIS program (Haferkamp et al., 2009; Michaloglou et al., 
2005). In our experimental setting inactivation of p l6 INK4a with shRNA did not affect
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BRAFY600E-induced senescence in thyrocytes, except for a reduction of SAHFs-bearing 
cells. This raises the possibility that p i 6™ ^ may cooperate with other factors in 
triggering senescence.
The upregulation of p i6 ^ ^  observed in our analysis is in agreement with previous
• G12Vstudies, showing that the proliferation arrest induced in thyrocytes by H-Ras was 
associated with upregulation of p l6mK4a (Jones et al., 2000). In that setting, however, 
silencing of p l h ^ 43 rescued H-RasG12V expressing thyrocytes from senescence (Bond 
et al., 2004). Thus, it is worth noting that OIS program does not seem to be universal 
across cell type and genetic context.
Although initially considered as an in vitro phenomenon, OIS is now view as an 
authentic cancer barrier. As mentioned above, several groups have reported its 
occurrence in different in vivo lesions including human melanocytic nevi, human 
dermal neurofibromas, human and murine prostatic and thyroid adenomas, and murine 
lymphomas and melanoma (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; 
Courtois-Cox et al., 2006; Dankort et al., 2007; Ha et al., 2007; Kortlever et al., 2006). 
To extend our observations to an in vivo context we analyzed a panel of thyroid tumour 
samples with increasing aggressiveness: PTMC, characterized by very indolent course; 
PTC NOS, differentiated carcinoma generally associated with good prognosis; PDTC 
associated with poor prognosis; ATC, undifferentiated, very aggressive carcinoma with 
fatal outcome, mostly arising from a time-dependent dedifferentiation of differentiated 
carcinoma, in particular PTC. We analyzed the expression of p lh 1^ 43 and p21cn>1, two 
universally recognized OIS markers, and IGFBP7, a protein exerting an oncosuppressor 
role in thyroid tumours (Vizioli et al., 2010), and found involved in melanocyte OIS 
(Wajapeyee et al., 2008), although its role in this process is controversial (Scurr et al., 
2010). Collectively, the three proteins resulted upregulated in PTMCs; the PTCs 
showed a variable pattern, including loss of expression; finally, the ATC sample was
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scored negative for the all proteins. The upregulation in PTMCs and the progressive 
loss in PTCs and ATC support the notion that OIS may counteract oncogenic action in 
thyroid tumours, and its escape allows thyroid tumour progression.
Regarding IGFBP7 we have previously shown that its mRNA expression is frequently 
downregulated in PTC, and this is associated with the TC variant (Vizioli et al., 2010). 
Our IHC results are in agreement with the gene expression data, as we observed a 
progressive loss of IGFBP7 protein during thyroid tumour progression. In normal tissue 
IGFBP7 is distributed widely although with a lower expression compared with PTMC 
which showed the highest IGFBP7 levels. However, in PTC IGFBP7 expression, 
characterized by variable staining, is downregulated with respect to normal tissue. This 
is in harmony with the gene expression data (Vizioli et a l, 2010), suggesting that 
IGFBP7 may also participate in counteracting the aberrant proliferative signals of 
oncogenes. However, we did not detect induction of IGFBP7 protein in senescent 
BRAFY600E thyrocytes. This discrepancy may be explained taking into account that 
induction of IGFBP7 in vivo might result from the complex crosstalk between tumour 
and stromal cells (Kuilman et al., 2009).
Further support to the issue that OIS counteract oncogenic activation is provided by the 
evidence that in PTC samples expression of OIS markers may be associated with 
several characteristics of tumour regression, such as lymphocytic infiltration, 
oedematous papillae cores, and syncytial clusters. The presence of these features is in 
keeping with the notion that OIS triggers activation of inflammatory network and 
evokes innate immunoresponse that ultimately counteract tumour progression (Ren et 
al., 2009).
Analysis of a small series of PTMC showed consistent upregulation of p lb 1^ 43 in 
association with very low proliferative index. Of note, p l b ^ 43 expression and Ki-67 
immunolabeling remained unchanged in synchronous intrathyroidal and nodal spreads.
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In one PTMC samples the analysis of p21cn>1 and IGFBP7 was possible, showing the 
same expression level in primary tumour and intrathyroidal and lymph node foci. 
Notably, none of the PTMC patients of our series experienced recurrence during the 
follow-up period (72-102 months).
Expression of p l b ^ 43 in thyroid malignancies has been previously investigated by 
several groups. Overexpression of p lb 1^ 43 in adenomas, papillary and follicular 
tumours, and loss of expression in ATC was observed in previous works (Ball et al., 
2007; Ferru et al., 2006), suggesting that p lb 1^ 43 expression is induced in early stage 
tumours and then progressively lost during tumour progression. Similarly, 
overexpression of p21CIP1 in PTMC and progressive loss of expression with advancing 
tumour grade in PTC has been reported (Brzezinski et al., 2005), These previous reports 
together with our data suggest that the indolent course of PTMC as well as the 
characteristically slow growth of classical PTC may be explained by the persisting of 
severe limit to oncogene induced proliferation exerted by the OIS mechanism. In this 
light PTMC represents, among the variants examined, the most representative model for 
the tumour suppressor mechanism exerted by OIS. Indeed, all the foci examined across 
the thyroid and lymph nodes share the same “frozen phenotype” in terms of p l6 INK4a, 
p21CIP1 and IGFBP7.
The persistence of OIS signal in intrathyroidal and nodal spreads might explain the 
favourable prognosis of PTMC even in the presence of multifocality and lymph node 
metastasis, two features associated with lateral node recurrence, but not with increased 
risk of mortality (Hay et al., 2008).
Moreover, the constant expression of all the OIS markers analyzed and Ki-67 labelling 
across the different lesions of the same patient suggests that cells have acquired the 
capability to invade without changes in their proliferation capability.
I l l
This is in keeping with reports claiming invasion and proliferation as two distinct 
mechanisms (Gao et al., 2005), governed by different genes and pathways.
We have identified OIS as a mechanism involved in the pathogenesis of thyroid 
carcinoma by restraining the evolution of PTMC to PTC, as well as the transition of 
well differentiated and less aggressive PTC to undifferentiated and more aggressive 
variants. This raises the idea that restoration of this process in tumour cells may 
represent a therapeutic approach especially for those tumours non-responding to 
standard therapy. Moreover, a possible therapeutic strategy based on OIS restoration is 
independent from the oncogenic alteration carried by the tumour, as we have shown that 
all PTC-associated oncogenes are capable to trigger senescence program. The feasibility 
of enforced cellular senescence as therapeutic approach for thyroid as well as other 
tumour types remains to be investigated, and it will require a deeper understanding of 
the mechanisms involved in the process, as well as suitable in vitro and in vivo models.
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3.3 Materials and methods
3.3.1 Cell culture
Normal thyroid samples were obtained from patients undergoing surgery at IRCCS 
Foundation Istituto Nazionale dei Tumori (Milan, Italy). All patients gave their written 
informed consent, and the study was approved by the Independent Ethical Committee of 
IRCCS Foundation Istituto Nazionale dei Tumori. Primary thyrocyte cultures were 
obtained from normal human thyroid gland after mechanical and enzymatical 
disaggregation. For instance, the enzymatic digestion was with a solution consisting of 
collagenase at 20 units/ml, trypsin at 0.75mg/ml, and 2% heat-inactivated dialyzed 
chicken serum in Ca2+ and Mg2+-free HBSS (CTC solution). Two hours digestion at 
37°C was followed by centrifugation for 10 min at 1 x g: the supernatant was 
eliminated and cells and small fragments of tissue were seeded and maintained in 
nutrient mixture Ham’s F12 medium (custom made by Invitrogen, Paisley, UK) 
containing 5% calf serum and bovine hypothalamus and pituitary extracts (Curcio et al., 
1994). Twenty four hours later conditioned medium was collected and assayed for 
thyroglobulin (Tg) secreted in the supernatant by an immunoradiometric assay 
according to manufacturer’s instructions. Thyrocytes expressing RET/PTC1 oncogene, 
obtained from infection of primary thyrocytes with RET/PTC 1 retroviral vector, have 
been previously described (Borrello et al., 2005).
HEK293T cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM 
Gibco) supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-antimycotic (Gibco).
3.3.2 Lentivirus production and transduction
HEK293T cells (4x106) were transfected with 8 pg of BRAFV600E lentiviral construct 
(HIV-CS-CG-Blast-BRAFv600E) and 3 pg of each of the helper plasmids
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pMDLglpRRE, pHCMV-G, and pRSVrev by calcium phosphate in complete medium 
containing 25 pM chloroquine. After 6-12 hours of incubation cells were washed and 
refed with complete medium. Supernatant containing lentiviral particles was collected 
and frozen 24 hours after transfection, and subsequently added to thyrocytes for 6 hours 
in the presence of 0.8 pg/pl of Polybrene (Sigma Aldrich, St Louis, Mo, USA), 
followed by blasticidin selection (5mg/ml) after 24 hours. Three days later cells were 
harvested and plated at different densities for further analyses. The efficiency of 
transduction was monitored in parallel infections using virus expressing enhanced green 
fluorescent protein (eGFP).
3.3.3 p l6INK4a shRNA silencing
p i6 knockdown constructs were created into KH1 lentiviral vector, carrying the 
GFP reporter gene, with the following sense shRNA sequences: shpl6.5 
(TGCCCCCGGGGGAGACCCAAC), and shpl6.13 (GCCGACCCCGCCACTCTCA) 
and used for thyrocytes transduction. Transduction efficient was monitored by GFP 
expression. Six days later cells were re-transduced with lentiviruses encoding 
BRAFV600E (HIV-CSCG-BRAFv600E) and maintained under blasticidin selection for 
an additional six days.
3.3.4 Nucleofection
f t  •Human primary thyrocytes (1x10 ) were resuspended in 110 pi of Human Keratmocyte 
Nucleofector solution (Amaxa, Lonza AG Basel, Switzerland) together with 1 pg of 
plasmid DNA, transferred to the cuvette and nucleofected using Amaxa Nucleofector II 
Device (T003 program). Immediately after nucleofection, cells were resuspended in 
pre-heated complete culture medium and then seeded at different densities for further 
analyses. Cells were reefed 24 hours later and subjected to G418 (400 pg/ml) selection.
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Plasmid vectors carrying TRK-T3 and H-RASG12V oncogenes have been previously 
described (Greco et al., 1995; Pulciani et al., 1982).
3.3.5 BrdU incorporation
Cells were labeled with 10 pM BrdU for 3 hours, harvested and fixed in 75% ethanol 
for 30 min. After washing with PBS, cells were treated with RNAse A (500 pg/ml) for 
30 min, permeabilized with 5 M HC1/ 0.5% Triton for 20 min at room temperature, 
neutralized with 1M TRIS, and washed in 0.5% Tween/PBS. Incubation with primary 
anti-BrdU antibody (30 min RT) and secondary FITC conjugated antibodies (30 min 
RT) (DAKO, Seattle, WA) was followed by staining with propidium iodine (20 pg/ml) 
at 37°C for 30 min. Samples were analyzed by flow cytometry (Beeton Dickinson, San 
Jose, CA, USA).
3.3.6 Senescence-associated P-galactosidase (SA-P-Gal) assay
Adherent cells were analyzed for SA-P-Gal production using Senescence-beta- 
Galactosidase Staining Kit (Cell Signaling, Danvers, MA, USA) following 
manufacturer’s instructions. For each sample at least 200 cells were scored.
3.3.7 SAHFs formation
For the analysis of SAHFs, transfected/transduced cells growing on glass cover slips 
were fixed in 4% paraformaldehyde-2% sucrose, permeabilized with 0.1% Triton, and 
stained with Prolong Gold antifade reagent with DAPI (Molecular Probes, Invitrogen, 
Carlsbad, CA, USA). Stained nuclei were observed under a fluorescent microscope 
(Nikon Eclipse E l000). For each sample at least 100 cells were scored.
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3.3.8 Western Blotting analysis
Proteins were extracted in RIPA modified buffer (20mM Tris-HCl, pH 7.4, 150mM 
NaCl, 5mM EDTA, 1% NonidetP-40) supplemented with Complete Mini EDTA-free 
protease Inhibitor Cocktail (Roche, Manheim, Germany), ImM Na3VC>4 and ImM 
PMSF. Protein samples were quantified by Bradford’s assay with BIO-RAD Protein 
Assay (Bio-Rad, Munchen, Germany). Supernatant obtained by incubating cells in 
serum-free medium for 24 hours were concentrated by centrifugation at 4000 rmp using 
AgilentSpin Concentrators (Agilent Technologies Inc, Wilmington, DE, USA) and 
normalized to cell number. Protein and supernatant samples were boiled in NuPAGE 
LDS sample buffer (Invitrogen, Carlsbad, CA, USA) and separated on 4-12% or 10% 
NuPAGE Novex Gel (Invitrogen, Carlsbad, CA, USA) with MOPS or MES running 
buffer, respectively. Proteins were transferred onto nitrocellulose filters and 
immunoblotted with the following primary antibodies to: p lb 1^ 43 (BD Becton 
Dickinson, NJ, USA); p21CIP1, BRAF (F7), RET (C-19), TRK (C-14), IGFBP7 (Santa 
Cruz, Biotechnology, Inc, Santa Cruz, CA, USA ); p53 (YLEM); phospho-ERKl/2 (p- 
ERK), ERK1/2 , p -Actin (Sigma Aldrich, St Louis, Mo, USA); RAS (Ab3) 
(Calbiochem, San Diego, CA, USA); HMGA2 (kindly provided from G. Manfioletti, 
University of Trieste). The immunoreactive bands were visualized using horseradish 
peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence 
(GE Healthcare, Buckinghamshire, UK).
3.3.9 Real time RT-PCR
RNA was isolated with TRIzol reagent (Invitrogen Paisley, UK) from cells collected at 
day 1 and 7 post infection and purified with RNeasy purification kit (Qiagen, Valencia, 
CA, USA). Reverse transcription was performed with Superscript Reverse 
Transcriptaselll following the manufacturer’s instructions (Invitrogen). For each
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sample, 20 ng of retro-transcribed RNA were amplified in PCR reactions carried out in 
triplicate on an ABI PRISM 7900 using TaqMan gene expression assays (Applied 
Biosystem, Foster City, CA). Hs00266026_Al was used for IGFBP7 expression; 
human HPRT (HPRT-Hs99999909_Al) was used as housekeeping gene for the 
normalization among samples. Data analysis was performed using the SDS (Sequence 
Detection System) 2.2.2 software.
3.3.10 Tumour samples and immunohistochemistry
The thyroid tumour samples analyzed were selected by reviewing a larger tumour 
series available at the Department of Pathology from patients operated at IRCCS 
Foundation Istituto Nazionale dei Tumori (Milan, Italy) from 2002 to 2009. Tumours 
were classified according to the histopathological typing of the World Health 
Organization (Delellis et al. 2004). Tumour collection included: PTMC (6 cases); PTC 
NOS (6 cases); PTC SV (1 case) (Nikiforov et al. 2001); PDTC (2 cases); ATC (1 
case). Clinical pathological features are reported in Table 1. All patients gave their 
written informed consent, and the study was approved by the Independent Ethical 
Committee of IRCCS Foundation Istituto Nazionale dei Tumori.
The immunohistochemical analyses were performed on formalin-fixed, paraffin- 
embedded tissue sections of 2-pm thickness. Antigen retrieval was performed using 1 
mM citrate buffer (pH 6) or 0.25 mM EDTA (pH 8) in an autoclave at 95°C for 6-15 
minutes. Incubation with primary antibodies was performed overnight at 4°C for anti- 
p21CIP1 and anti-IGFBP7 (Santa Cruz, Biotechnology, Inc, Santa Cruz, CA, USA); for 1 
hour at room temperature for anti-human Ki-67 Antigen (Mibl) (DakoCytomation). 
Sections were then incubated for 30 minutes with biotinylated anti-goat, developed 
using 3,3’ -diaminobenzidine (DakoCytomation) as chromogen, and finally 
counterstained with hematoxylin.
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pl6iNK4a stajnjng was performed using CINtec Histologic Kit (mtm laboratories AG, 
Heidelberg, Germany) following manufacturer’s instructions.
The intensity of staining for IGFBP7 was scored from (-) negative to (3+) strong. The 
percentage of cells immunostained for p i 6™ ^ and p21cn>1 ranged from (-) <10% to 
(3+) 71-100%. Ki-67 staining was scored as very low (vL, 1-5% positive cells), low (L, 
6-10% positive cells), medium (M, 11-30 % positive cells), high (H, > 3 1%  positive 
cells).
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Chapter 4 -  H-RASG12V induces senescence in primary thyrocytes 
through p!6INK4a/pRb pathway and activation of inflammatory network
The study presented in this chapter was performed in the laboratory of Dr Jesus Gil (MRC, 
Imperial College, London) who is one of the ^ Europe’s most talented young researcher 
working in the field of oncogene-induced senescence.
An OIS inducible system, generated and well-characterized in the host laboratory, was used 
to study senescence in primary thyrocytes. A model based on thyrocytes retrovirally 
infected whit H-RASG12V and undergoing senescence upon 4-hydroxytamoxifen (40HT) 
treatment was established. To identify OIS escape mechanisms we used shRNA vectors, 
designed in the host laboratory. The analysis of OIS markers was monitored using IN Cell 
Analyzer 1000, an automated cellular imaging system for high content analysis (as deeply 
described below).
The results presented in chapter 3 reveal that all the oncogenes activated in thyroid cancer, 
namely BRAFV600E, RET/PTC 1, TRK-T3 and H-RASG12V are capable of inducing cellular 
senescence in primary human thyrocytes. Here, we focus our attention on H-RASG12V that 
is the common mutation found in PTC with follicular variant histology.
Oncogenic mutant H-RASG12V is known to transform most immortal rodent cell lines to 
tumorigenic state (Newbold and Overell, 1983). However, transformation of primary cells 
by H-RASG12V requires either a cooperating oncogene or the inactivation of tumour 
suppressors such as p l6 INK4a or p53 (Land et al., 1983).
Delineating the signalling networks that orchestrate the OIS response in our cellular model, 
we wondered whether the removal of these critical nodes can cause the senescence program
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to collapse facilitating oncogenic transformation. For this purpose, we took advantage of H- 
RASG12V-inducible system.
4.1 Results
4.1.1 Establishment and characterization of H-RASG12V-inducibIe system.
As first step, in order to establish and characterize this new system, we transduced primary 
thyrocytes with a retroviral vector carrying an activated form of RAS oncogene (H- 
RASG12V) fused with the ligand binding domain of the estrogen receptor (ER). Cells 
infected with empty vector only were kept in parallel throughout the experiments as a 
negative control. Two days after transduction, cells were selected by adding G418 for 
approximately 15 days. Upon addition of 4-hydroxytamoxifen (40HT), a time course
G12Vexperiment over 10 days was performed to monitor the effects of the activated H-RAS 
on primary thyrocytes.
By day 4, H-RASG12V transduced cells displayed changes in morphology, becoming flat 
and enlarged. No morphology changes were detected in cells transduced with empty vector 
and non 40HT-treated counterparts (Figure 4.1 A).
Expression of H-RASG12V caused a decrease in cellular density as shown by proliferation 
assay (Figure 4.IB), as well as a decrease in the percentage of cells incorporating BrdU 
(Figure 4.1C). The BrdU incorporation revealed that the H-RASG12V transduced population 
retained a lower percentage of BrdU positive cells when compared with the controls.
To further prove that the growth arrest had characteristics of senescence, cells were stained 
for senescence associated p-galactosidase (SA-p-Gal) activity, a widely used marker for 
identification of senescent cells. When H-RASG12V is activated, a higher percentage of cells
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(89%) displayed SA-p-Gal activity compared with the percentage of positive cells in 
empty vector and H-RASG12V non 40HT-treated (5% and 2% ) respectively (Figure 4. ID).
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Figure 4.1 Expression of inducible H-RASG12V triggers senescence in primary thyrocytes.
A) Bright-field pictures acquired with a lOx objective 4 days after seeding, showed morphology of thyrocytes 
transduced with empty vector or H-RASGm with (+) or without (-) 4-hydroxi-tamoxifen (40HT) treatment.
B) Samples were seeded at equal densities, fixed and stained 14 days post treatment with (+) or without (-) 
40HT. C) Samples were subjected to BrdU immunofluorescence. The percentage of positive cells was 
determined by high content analysis. Values generated at day 7 of a time-course experiment are reported. D) 
Representative images of SA-P-Gal staining (magnification 20x) are shown. Percentage of positive cells is 
indicated.
To address the mechanisms by which the inducible H-RASG12V triggered senescence in 
primary thyrocytes, we analyzed the expression of different senescence effectors by 
immunofluorescence. Activated H-RASG12V resulted in elevated expression of p l b ^ 43,
1 2 2
p53 and p21CIP1 at 7 days after 40HT treatment (Figure 4.2A-C). The levels of these 
negative regulators of cell cycle remained high during the time course.
Taking these results together we conclude that inducible H-RASG12V oncogene leads to 
senescence response in our cellular model and this is in harmony with our previous findings 
(see chapter 3).
plgINK4a
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Figure 4.2 Molecular analysis of senescence induced by expression of H-RASG12V. A-C) The levels of 
plgiNK4a^  p2 i CIP1 and p53 expressed in thyrocytes transduced with empty vector or H-RASG12V and treated 
with (+) or without (-) 40HT were analyzed by immunofluorescence and quantified by high content analysis. 
Values generated at day 7 of a time-course experiment are reported.
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4.1.2 The relative contribution of pl6INK4a and p53 pathways in H-RASG12V induced 
senescence in thyrocytes
It is conceivable that the tumour suppressors p lb11^ 43 and p53 owe, at least in part, their 
important role in cancer suppression by acting as critical mediators of oncogene-induced 
senescence. In light of this, we wondered what is the contribution of these two main tumour 
suppressors in the onset of senescence in H-RASG12V transduced thyrocytes.
To examine the requirement of p lb 1^ 43 to H-RASG12V mediated senescence we applied 
retroviral shRNA vector that specifically and efficiently suppresses the expression of 
pl6iNK4a (Figure 4.3A). Empty vector or H-RASG12V cells expressing p lb 1^ 43 shRNA, 
selected for puromycin, were plated at equal densities. The cell proliferation assay showed 
that p lb 1^ 43 depletion caused cells to bypass OIS (Figure 4.3B). To quantify the rescue 
from senescence, we performed a BrdU incorporation assay (Figure 4.3C). As measured 7 
days after adding 40HT, the percentage of H-RASG12V cells incorporating BrdU increased 
upon knockdown of p 16INK4a and reached 13% compared with 1% of p 1 b^^M ntact cells 
incorporated BrdU. Similar results were also observed following transfection of controls 
(All Stars) and pl6INK4a siRNA into thyrocytes infected with empty vector and H-RASG12V. 
The silencing of p l6INK4a expression was highly effective after sip 16 transfection as shown 
in Figure 4.3D and this resulted in an increased of BrdU incorporation in p lb ^ ^ -n u ll  H- 
RASG12V respect to pl6INK4a-positive senescent cells (10% versus 1%) (Figure 4.3E).
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Figure 4.3 Silencing of pl6INK4a with shRNA or siRNA extends cellular life span in H-RAS 
transduced thyrocytes. A) Empty vector or H-RASG12V cells were retrovirally transduced with shRNA 
targeting p i6™^ which efficiently silenced pi 6™^ expression. B) Samples were seeded at equal densities, 
fixed and stained 14 days after treatment with (+) or without (-) 40HT. C) Seven days after exposure with or 
without 40HT, samples were analyzed for BrdU incorporation via immunofluorescence. The percentage of 
positive cells was measured by high content analysis. D-E) Empty vector or H-RASG12V cells were 
transfected with 100 nM of siRNAs targeting p lO ^ 43. Four days later, the expression of plO1^ 43 and BrdU 
incorporation was assessed by immunofluorescence and quantified by high content analysis. Non-siRNA and 
scrambled siRNA (All stars) transfected cells were used as negative controls.
G12V
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Of other OIS markers analysed after shpl6 transduction, we found that the percentage of 
H-RASG12V cells positive for SA-p-Gal activity was clearly reduced in absence of p l6INK4a: 
in fact only 5% of cells stained positively for SA-p-Gal versus 89% of H-RASG12V cells 
with intact p 16INK4a (Figure 4.4A).
Moreover, elevated levels of p21CIP1 were maintained in the p l6 INK4a-null H-RASG12V 
thyrocytes (Figure 4.4B), whereas a slight decrease of p53 was observed (Figure 4.4C). 
Hence, we conclude that disruption of p l b ^ 48 allows primary thyrocytes to escape from 
H-RASG12V induced senescence.
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iG12VFigure 4.4 Primary thyrocytes transduced with shRNA against pl6INK4afail to undergo H-RAS1 
induced senescence. A) Percentage of the indicated cells positive for SA-P-Gal activity was shown. B-C) 
Expression of p21CIP1 and p53 of cells infected with shpl6 and either retrovirus expressing H-RASG12V or the 
empty vector was determined by high content analysis at 7 days after 40HT treatment. V: Vector; R: RAS.
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These results are in contrast with our previous findings described in chapter 3 in which 
suppression of p lb 1^ 43 with two independent lentiviral shRNA in BRAFV600E transduced 
thyrocytes did not alter the growth arrest induced by BRAFV600E. To determine whether this 
different cellular response after p l6 INK4a inhibition is oncogene-specific (BRAFV600E versus 
H-RASG12V) or it is due to the different method of oncogene delivery (lentiviral versus 
retroviral) resulting in a different oncogene expression, we also evaluated the role of 
pl()iNK4a in thyrocytes infected with retroviral vector encoding BRAFV600E oncogene.
To this end, cells expressing p lb 1^ 43 shRNA produced by retroviral transduction, were 
selected using puromycin prior to retroviral reinfection with oncogenic BRAFV600E.
We observed a strong suppression of p lb11^ 43 expression as shown in Figure 4.5A. 
Interestingly, knockdown of p i6 ^ ^  enabled the cells to abrogate BRAFv600E-induced 
senescence and to continue active proliferation, as demonstrated by BrdU incorporation 
(Figure 4.5B) and proliferation assays (Figure 4.5C). Moreover, in p l6 INK4a-null 
BRAFV600E thyrocytes the induction of p21cn>1 and p53 was maintained elevated (Figure 
4.5D-E).
Such an escape from BRAFV600E-induced senescence was also confirmed by sip 16 
transfection which efficiently silenced p l6mK4a expression (Figure 4.6A). In BrdU 
incorporation assay the number of cells actively replicating DNA in the presence of 
oncogenic stress increased by ~4-fold upon p lb 1^ 43 depletion with siRNA (Figure 4.6B). 
Together, these results suggest that in the absence of p 16INK4a cells retrovirally transduced 
with BRAFV600E fail to undergo senescence.
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Figure 4.5 Primary thyrocytes retrovirally transduced with BRAFV600E override senescence after 
silencing of pl6INK a. A) Cells infected with shRNA against pl6INK4a were exposed to BRAFV600E (B) or 
empty vector (V) for 7 days. The amount of pi 6INK4a was analyzed by immunofluorescence and quantified by 
high content analysis. B) Samples were analyzed for BrdU incorporation by immunofluorescence. The 
percentage of positive cells was determined by high content analysis. C) Samples were seeded at equal
densities and fixed and stained 14 days after exposure to BRAFV0Wfc. D-E) The expression o f p21cn>1 was 
assessed by immnunofluorescence and high content analysis was used for the quantification.
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Figure 4.6 sipl6 transfection in BRAFV600E expressing thyrocytes allows for OIS abrogation. A-B)
BRAFV600E or empty vector (V) cells were transfected with 100 nM of siRNAs targeting p 1 g1^ 43. Four days 
later the expression of p ^ ^ 43 and BrdU incorporation were analyzed by immunofluorescence and quantified 
by high content analysis. Non-siRNA and scrambled siRNA (All stars) transfected cells were used as negative 
controls.
G12VTo investigate the possible role of the p53 pathway activation in evasion of H-RAS 
induced senescence, we applied a shRNA vector to knockdown p53 expression using a 
retroviral delivery system. Cells were first infected with H-RASG12V oncogene or empty 
vector and then re-transduced with shRNA targeting p53 and selected for the integration of 
the construct. Seven days after adding 40HT, immunofluorescence analysis revealed a 
drop in p53 levels upon shRNA transduction, only 1% of H-RASG12V cells expressing 
shp53 and treated with 40HT displayed p53 expression compared with 26% of senescent 
H-RASG12V cells (Figure 4.7A).
However, in response to 40HT treatment, no change in cell proliferation was observed 
between p53-intact and p53-null H-RASG12V thyrocytes as evident in cell proliferation 
assay (Figure 4.7B). Moreover, in BrdU incorporation assay p53 depletion did not alter the 
growth arrest induced by H-RASG12V, only 2.5% of p53 silenced H-RASG12V cells with 
40HT had incorporated BrdU, compared with the controls (Figure 4.7C). Likewise, 
cellular senescence was initiated and maintained in the presence or absence of p53
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expression; we did not observe a significant difference in SA-p-Gal activity which 
appeared in 65% of p53-null compared to 80% in the p53 positive senescent cells, 7 days 
post 40HT treatment (Figure 4.8A). Furthermore, in p53-deficient H-RASG12V cells the 
expression of p l d ^ 43 was maintained compared to p53-intact cells (Figure 4.8B). 
Similarly, upon depletion of p53, H-RASG12V cells treated with 40HT showed p21CIP1 
expression, albeit at level less that the one detected in H-RASG12V senescent cells (Figure 
4.8C).
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Figure 4.7 p53 tumour suppressor is not required for H-RASG12V-induced thyrocytes senescence. Cells 
infected with H-RASG12V (R) or empty vector (V) were re-transduced with p53 shRNA and 
pharmacologically selected for successful integration of the construct. Non-40HT treated counterparts (R) 
and empty vector (V) were used as a negative controls. The analysis was performed 7 days after 40HT 
treatment. A) The expression of p53 was detected via immunofluorescence and quantified by high content 
analysis. B) Samples were seeded at equal densities and fixed and stained with crystal violet. C) Samples 
were analyzed for BrdU incorporation by immunofluorescence.
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Figure 4.8 Depletion of p53 has no effect on OIS markers. A) Samples were fixed and analyzed for SA-P- 
Gal activity. The percentage of positive cells is shown. B) The percentage of positive cells for p ^ ^ 43 and 
p21CIP1 expression, analyzed by immunofluorescence and quantified by high content analysis, is reported.
Similar results were also obtained after p53 siRNA transfection which resulted in a 
significant reduction of p53 levels, quantified around 80% (Figure 4.9A). We again 
observed that depletion of p53 had not effect on cell growth inhibition induced by activated 
H-RASG12V: the percentage of BrdU incorporation was not changed upon p53 silencing in 
H-RASG12V cells with 40HT (Figure 4.9B).
Together, these results indicate that p53 activation is not an essential effector of H- 
RASG12V-induced senescence in primary thyrocytes.
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Figure 4.9 Knockdown of p53 with siRNA has no impact on OIS induced by H-RASG12V in primary 
thyrocytes. A-C) H-RAS012 or empty vector cells (V) were transfected with 100 nM of siRNA targeting 
p53. Four days later the expression of p53, BrdU incorporation and p21CIP1 were analyzed by 
immunofluorescence and quantified by high content analysis.
Moreover, it is important to note that, as already observed in shRNA p53 transduction, the 
induction of p21cn>1 expression was maintained in p53 knockdown H-RASG12V cells treated 
with 40HT (Figure 4.9C), suggesting a p53-independent expression of p21CIP1. In light of 
this regulation we asked whether depletion of p21CIP1 could also influence OIS. To this end, 
the efficiency of knockdown, estimated around 60%, was assessed 5 days after sip21
Q12Y
transfection via immunofluorescence. Such a depletion did not influence H-RAS 
induced growth arrest as evident by BrdU incorporation assay. The p21cn>1-null cells 
responded to activated H-RASG12V by accumulating p53 (Figure 4.10A-C).
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Figure 4.10 Depletion of p21CIP1 expression does not allow for bypass OIS in primary thyrocytes. A-C)
H-RASG12V or empty vector (V) cells were transfected with 100 nM of siRNA targeting p21cn>1. Four days 
later the expression of p21cn>1, BrdU incorporation and p53 was analyzed by immunofluorescence and 
quantified by high content analysis.
4.1.3 Specific upregulation of IL8 and IL6 during OIS in thyrocytes
In addition to classical senescence players like p l6INK4a and p53, as described above, 
several secreted factors such as PAI 1, IGFBP7, IL6 and CXCR2 and its ligands have been 
identified as a key components of the OIS response (Kortlever et al., 2006; Wajapeyee et 
al., 2008; Kuilman et al., 2008; Acosta et al., 2008). As preliminary analysis of senescent 
secretome we performed immunofluorescence for IL6 and IL8 to determine whether the 
expression of these factors is changed during OIS in our cellular model. Interestingly, we 
observed a strong induction of IL6 and IL8 in H-RASG12V-induced senescent cells as
133
compared with H-RASG12V untreated and to cells transfected with the empty vector, 
respectively (Figure 4.11A-B).
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Figure 4.11 OIS is associated with activation of inflammatory transcriptome in primary thyrocytes. 
A-B) The levels of IL8 and IL6 expressed in thyrocytes transduced with empty vector or H-RASG12V and 
treated with (+) or without (-) 40HT were analyzed by immunofluorescence and quantified by high content 
analysis. Values generated at day 7 of a time-course experiment are reported.
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4.1.4 A critical role for IL8R (CXCR2) in mediating OIS
In light of this specific regulation, we wondered whether these cytokines are required for 
OIS in primary thyrocytes. To this end, we focused on IL8, a multifunctional chemokine 
implicated in a variety of cellular functions, including immune response, proliferation and 
tumorigenesis (Xie K, 2001). IL8 binds to two cells surface G-protein coupled receptors 
(GPCR), CXCR1 and CXCR2, respectively (Holmes We et al., 1991).
In keeping with the well-known connection between IL8 and CXCR2 for the induction and 
maintenance of OIS (Acosta et al., 2008), we found that also in our cellular model CXCR2 
expression increased during OIS compared with the non-senescent cells in which CXCR2 
levels were low. To determine whether this receptor is required for the mediation of OIS 
we used shRNA vector targeting CXCR2 which prevented H-RASG12V cells from 
undergoing senescence, although its expression was not completely depleted by shRNA 
vector (Figure 4.12A). For instance, when H-RASG12V cells treated with 40HT were plated 
at low density, depletion of CXCR2 conferred a growth advantage respect to the controls 
(Figure 4.12B). This was further illustrated by cell counting and BrdU incorporation 
assays. The cell number, quantified by high content analysis after DAPI staining, was 
duplicated upon CXCR2 depletion in H-RASG12V senescent cells (Figure 4.12C). Similarly 
the percentage of cells positive for BrdU incorporation in the presence of activated 
oncogene increased by ~4-fold upon CXCR2 knockdown (Figure 4.12D).
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Figure 4.12 Depletion of CXCR2 extends the lifespan in primary thyrocytes. Cells infected with H- 
RASG12V (R) were re-transduced with sh-CXCR2, selected for integration of the construct and treated with (+) 
or without (-) 40HT. The analysis was performed 7 days after adding 40HT. A) The levels of CXCR2 were 
detected via immunofluorescence and quantified by high content analysis. B) Cells were seeded at equal 
number and fixed and stained with crystal violet. C) Cell counting after DAPI staining was quantified by high 
content analysis. D) Samples were analyzed for BrdU incorporation by immunofluorescence.
We next determined whether depletion of CXCR2 leads to changes in the expression of IL8 
as well as in the well-known tumour suppressor genes controlling OIS. We found a 
decrease in IL8 availability (9% of activated H-RASG12V cells expressing CXCR2 shRNA 
were positive for IL8 staining compared with 25% of H-RASG12V senescent cells), as well 
as a drop in p53 levels (6% versus 15%) whereas the induction of p lb ^ ^ a n d  p21CIP1 were 
maintained when CXCR2 is depleted (Figure 4.13A-D).
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Figure 4.13 Effect of CXCR2 depletion on IL8 and tumour suppressor proteins expression. A-D)
Analysis of IL8, p ^ 11^ 43, p53 and p21CIP1 levels by immunofluorescence in H-RASG12V (R) with or without 
40HT, as a function of CXCR2 knockdown.
As CXCR2 ligand, IL8, is upregulated during senescence, we investigated its involvement 
in the process. To this end, we knockdown IL8 expression with two independent retroviral
C* 1 9VshRNAs (#1, #2) which, compared to the control, alleviated senescence in H-RAS 
treated with 40HT as shown by enhanced BrdU incorporation (3% vs 8% and 8.5% 
respectively) (Figure 4.14A-B). To determine whether IL8 depletion affected CXCR2 
activation, we analyzed the levels of CXCR2 via immunofluorescence. We observed a 
decrease of CXCR2 expression when comparing control cells with cells expressing both sh- 
IL8 (27% vs 13% and 9% respectively), suggesting that sh-IL8 confers growth advantage 
by restricting CXCR2 activity (Figure 4.14C).
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Figure 4.14 Role for CXCR2 ligand in mediating OIS. A) Cells infected with H-RASG12V (R) were re­
transduced with two independent shRNAs targeting IL8 (#1 and #2), selected for integration of the construct 
and treated with or without 40HT. The analysis of IL8 expression was performed via immunofluorescence 7 
days after adding 40HT. B) Cells infected with the indicated retroviruses and treated with or without 40HT 
were analyzed by immunofluorescence and quantified for BrdU incorporation 7 days after adding 40HT. C) 
Cells infected with the indicated vectors were subjected to CXCR2 immunofluorescence after 7 days 40HT 
treatment. The percentage of positive cells is shown.
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4.2 Discussion
We have already described in chapter 3 that H-RASG12V frequently detected in PTC, 
induces senescence in primary human thyrocytes similarly to the others PTC-associated 
oncogenes. As tool for a deeper analysis of OIS thyrocytes, here we established and 
characterized the H-RASG12V inducible system in our cellular model by transduction of 
thyrocytes with retroviral vector carrying H-RASG12V coupled to the ligand binding domain 
of the estrogen receptor. Activation of oncogene expression led to senescence-associated 
characteristics in thyrocytes.
In view of the strong evidence that H-RASG12V mediated senescence in primary thyrocytes 
through activation of both the pRb and p53 pathways, we assessed the relative contribution 
of the plb^^VpRb and the p53/p21CIP1 in the senescence program.
As reported in several studies the critical role of p53 and pRb is not universal across cells 
types. Some are significantly delayed in their onset upon inactivation of p lb 1^ 43 (Ben- 
Porath and Weinberg, 2005) while for others p53 plays a major role (Serrano et al., 2005), 
whereas yet in other setting inactivation of both is required to bypass the senescence 
response (Serrano et al., 1997).
In our experimental setting depletion of p53 by using RNA interfering strategy had not 
impact on senescence upon oncogenic stress. For instance, no change in cell proliferation, 
BrdU incorporation or SA-p-Gal activity was observed between p53-intact and p53-null 
senescent thyrocytes. Interestingly, p53 depletion did not reduce the levels of p21cn>1, 
suggesting a p53-independent expression of p21CIP1, whereas the expression of p lb 11'*’43 
was maintained. In light of this specific regulation, we next investigated the involvement of 
p21CIP1 in the OIS program. Indeed, we found that its knock down had no influence in the 
inhibition of proliferation induced by H-RASG12V.
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It is reasonable to assume that in the absence of p53, the activation of p l6INK4a/pRb 
pathway was sufficient for induction and maintenance of OIS as its depletion with 
retroviral shRNA abrogated the onset of senescence. This was illustrated by increased of 
cell proliferation and BrdU incorporation, as well as decreased in SA-p-Gal activity. Thus, 
in our experimental setting p i6 ^ ^  seems to play a dominant role supporting a model in 
which oncogenic H-RASG12V acts primarily through the p l6INK4a/pRb pathway in 
thyrocytes.
It is important to note that these results are in contrast with our previous findings presented 
in chapter 3 in which inactivation of p 16INK4a with lentiviral shRNA in BRAFV600E 
transduced thyrocytes was not sufficient to prevent induction of senescence suggesting that 
the critical role of p i6 ^ ^  in the abrogation of senescence may also depend on different 
genetic context. This is in agreement with models previously proposed by others (Serrano 
et al., 1997; Michaloglou et al., 2005). Thus, to get more insight into the reported 
differences (lentiviral BRAFv600E v s  retroviral H-RASG12V) regarding the contribution of 
pl()iNK4a we also determined the role of p lb 1^ 43 in thyrocytes infected with retroviral 
vector encoding BRAFV600E. Interestingly, we observed the abolishment of OIS by 
inactivation of p lb 1^ 43. In aggregate, the different methods of oncogene delivery resulting 
in different oncogene accumulation may vary the mechanism of senescence activation and 
may warrant the different response upon p lb 1^ 43 depletion.
In recent years, several groups have demonstrated that cells undergoing senescence produce 
increased amount of inflammatory cytokines and chemokines that play an essential role in 
the initiation and maintenance of cellular senescence (Acosta et al., 2008; Kuilman et al., 
2008).
G12VWe also observed that IL8 and its receptor CXCR2 were upregulated in H-RAS 
transduced cells.
This regulation prompted us to examine their roles in OIS. Upon depletion of CXCR2 by 
shRNA vector, senescent thyrocytes expressing H-RAS012V were able to bypass OIS in a 
p53-dependent manner. We also observed a drop of IL8 expression after CXCR2 
abrogation, suggesting that the induced IL8 is responsible for the activation of CXCR2 
during senescence. Similarly, knock down of IL8 using two independent shRNAs vectors 
allowed cells to circumvent OIS and resulted in decreased CXCR2 levels.
These findings in harmony with and extend previously model proposed by Gil and co­
workers (Acosta et al., 2008) indicate that the activation of chemokine signalling via 
CXCR2 plays an essential role in execution of cellular senescence.
The inducible OIS model allowed us to get more insight into the molecular mechanisms 
and players controlling H-RASG12v-mediating senescence. We will employed this system 
for further studies regarding the interplay between oncogene-triggered thyrocytes 
senescence and microenvironment, in particular macrophages with the aim to dissect the 
macrophage role in early stage of thyroid tumours. In order to investigate the effects of 
senescent thyrocytes on macrophage differentiation and polarization, purified peripheral 
blood-derived human monocytes from independent donors will be co-cultured with 
senescent thyrocytes or exposed to their conditioned medium in the presence of M-CSF and 
the phenotype and functional activity will be characterized. In particular we will check Ml 
and M2 associated markers (MHC II, CD206, CD 16, MSF), cytokine and chemokine 
production, functional activities (antigen presenting ability, invasion of Matrigel-coated 
membranes). We are next interested in determining whether activated macrophages either 
reinforce senescence in H-RAS012V-transduced thyrocytes or help them to bypass 
senescence, thus promoting tumorigenesis. To this end, thyrocytes at different phase of OIS 
will be co-cultured with different of activated macrophages or exposed to their CM.
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The extent of senescence in thyrocytes will be monitored over time by assessing the 
presence of senescence markers such as SA-p-Gal, SAHFs, p lh 1^ 43. Finally, it will be 
interesting to investigate in human thyroid samples PTMC the presence of the players 
identified by in vitro models including senescent thyrocytes-derived soluble factors and 
senescent thyrocytes induced infiltrating cells and their specific markers.
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4.3 Materials and methods
4.3.1 Cell culture
Human primary thyrocytes and HEK293T packaging cells were described in chapter 2.
4.3.2 Retrovirus production and transduction of target cells
HEK293T were seeded the previous day to reach a confluence of 70-80% the day of 
transfection. For each plate, 1 ml of serum-free DMEM containing 20 pg of expression 
plasmid and 10 pg of helper plasmid (gag-pol and VSV-g) was prepared. As transfection 
reagent, 75 pi of 25 KDa linear polyethylenimine (PEI 1 mg/ml) was used. The mixture was 
incubated at room temperature for 30 minutes and added drop-wise to each plate. 
Transfection efficiency was monitored the next day by the presence of Cherry fluorescent 
protein expressed from a reporter plasmid. The day after transfection, the media on the 
transduced packaging cells was replaced (6ml/plate). In parallel, the target cells, human 
primary thyrocytes were plated at a density of lx l06 cells per 10cm plate.
After 48 hours, the virus-containing supernatants were collected from packaging cells 
plates, filtered through 0.45 pm pore-sized acetate filters (Anachem) and supplemented 
with 4 pg/ml of polybrene (Sigma). The culture media of the target cells was then removed 
and replaced by the virus-containing supernatant. Infection took place 3 rounds to 
maximize the efficiency and a period of 3 hours was left between each round for virus 
production. After 3 rounds cells were refreshed.
Approximately, 2 days after infection, cells were split and subjected to the selection.
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4.3.3 Plasmids
Retrovirus encoding H-RASG12V was cloned via PCR in LXSN neo. Retrovirus encoding 
shRNAs targeting human p i6 ^ ^ ,  p53, CXCR2 and IL8 were constructed by cloning 
oligonucleotides in pRetroSuper (pRS) puro.
P M S C V b la st-B R A F v600e was used for retroviral transduction and was kindly provided by 
Daniel Peeper (NKI, Amsterdam).
The sense shRNA target sequences are as follows: 
sh-p 16INK4a GAGGAGGTGCGGGCGCTGC
sh-p53 GTAGATTACCACTGGAGTC
sh-CXCR2 GGACCGTCTACCATCCAA
sh-IL8-l TTGAACTAACAATCCTAGT
sh-IL8-2 TACAAGATTCCTGGTTAAA
4.4.4 siRNA transfection
Primary thyrocytes were transfected with 30nM siRNA in 96 wells. A 3.5% solution of 
Hiperfect transfection reagent (QIAGEN) was prepared in serum-free medium and then 
mixed with the siRNA. The mix was incubated for 30 min at room temperature and then 
added to the cells. Medium was changed on the following day and cells were fixed for 
immunofluorescence at day 4 and 5. The Cy3-labeled siGLO cyclophilin B siRNA 
(Dharmacon) was used to monitor transfection efficiency and as a negative control. A 
scrambled siRNA (All stars) were included as additional negative controls in the 
experiments.
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4.4.5 BrdU (5-Bromo-2’deoxyuridine) incorporation assay
Cells (4xl03) were plated in 96-well plates in duplicates and subsequently incubated with 
5-Bromo-2’ deoxyuridine (BrdU, 50 pM, Sigma) for 24 hours. After incubation cells were 
washed with PBS and fixed for 30 min with 4% (w/v) paraformaldehyde (Sigma). For 
immunofluorescence staining, cells were first permeabilized for 5 minutes with 0.2 (v/v) 
Triton X-100 in PBS and incubated for 30 minutes with IX (blocking solution (0.5% (w/v) 
BSA, 0.2% (w/v) fish skin gelatin). Treatment with DNase I (0.5U/pL; Sigma) in presence 
of ImM MgCb was performed simultaneously with anti-BrdU primary antibody (1:500, 
BD) for 30 minutes. Cells were washed three times with PBS and incubated with Alexa 
Fluor® 488 mouse secondary antibody (1:500, Invitrogen) for 30 minutes. Cells were 
washed three times with PBS and incubated with DAPI (Invitrogen, 1.5 pM). Plates were 
examined using In Cell Analyser and High Content Analysis was performed to discriminate 
positive BrdU nuclei and total nuclei.
4.4.6 Colony formation assay
Cells were plated at a density of lx l0 5 and 5xl04 per 10-cm dish. After 7 or 15 days cells 
were washed with PBS and fixed with 0.5% glutaraldehyde (w/v) in PBS for 30 minutes. 
Finally, plates were stained with 0.2% crystal violet (w/v)
4.4.7 Senescence-associated P-galactosidase (SA-P-gal) assay
Cells were washed once with PBS, fixed with 0.5% glutaraldehyde (w/v), and washed in 
PBS (pH 6.0) supplemented with ImM MgCU Cells were stained in X-gal solution (1 
mg/ml 5-bromo-chloro-3-indolyl-beta-D-galacto-pyranoside [Boehringer], 0.12 mM 
K3Fe[CN]6, 1 mM MgCl2 in PBS at pH 6.0) for 7 hours at 37°C. After staining, cells were
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washed with PBS and stored at 4°C, in the dark. Images were taken using the Olympus 
CKX41 inverted fluorescence microscope, supplied with a DP20 digital camera. The 
percentage of SA-p-gal positive cells were determined upon counting of at least 100 cells.
4.4.8 Immunofluorescence and high content analysis
For immunofluorescence, cells were fixed with 4% PFA (w/v) for 30 min, washed with 
PBS and permeabilised with 0.2% Triton X-100 (v/v) for 5 minutes. To block unspecific 
binding of primary antibody, cells were incubated for 30 minutes in blocking solution 
(0.5% BSA (w/v) and 0.2% fish skin gelatin (v/v) in PBS). Cells were then incubated with 
the primary antibody, diluted in blocking buffer for 30 minutes at room temperature. Three 
washes with the blocking buffer for removing unbound primary antibody were performed. 
Cells were subsequently incubated with the secondary antibody, diluted in blocking buffer 
for 30 minutes. Cells were washed with PBS three times before adding 3pM DAPI for 30 
minutes for nuclear staining.
The antibodies used for immunofluorescence were: anti-pl6 (JC8, 1:100, Santa Cruz 
Biotechnology); anti-p21 (P1484, 1:100, Sigma Aldrich); anti-p53 (DO-1, 1:100, Santa 
Cruz Biotechnolgy), anti-IL8 (1:100, BD), anti-CXCR2 (1:100, BD), anti-IL6 (1:100, BD). 
Secondary antibody used was anti-mouse Alexa488-conjugated antibody (1:500, 
Invitrogen).
Acquisition of immunofluorescence images was performed using the IN Cell Analyzer 
1000 automated high-throughput microscope (GE Healthcare) with lOx objective. Image 
processing was performed using the IN Cell Investigator (vl.7) software (GE Healthcare). 
High Content Analysis (HCA) was used for quantification of immunofluorescence images. 
Two fluorescence images corresponding to DAPI and primary/antibody/Alexa Fluor® 488-
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secondary were acquired for each condition. HCA was performed using the IN Cell 
Investigator (vl.7) software (GE Healthcare). For the analysis, DAPI staining of the nuclei 
was used to identify nuclear area and number of cells. The nuclei were defined by using 
top-hat segmentation, specifying a minimum nucleus area of 100 pm2. To define the cell 
segmentation, a collar segmentation routine was used with a ratio of 1 pm. To determine 
the cellular expression of the analysed protein, the average intensity of pixels in the 
reference channel (Alexa Fluor® 488) within the specified nuclear region (Object Nuclear 
Intensity) was measured. Each cells was assigned a nuclear intensity value for the specific 
protein expression and that value was used to set up a threshold filter, which determined 
high levels (positive) and low levels (negative) expressing cells. The threshold filter used a 
histogram for data visualisation. In order to set the filter cut-off, expression in the control 
was measured to define the negative population. Next, the analysis of the positive control 
was performed to determine the high-expressing population. Once the cut-off was set up, 
the analysis of the whole experiment was carried out. As a result, the software classified 
each cell as either positive or negative for the expression of the analysed protein and 
negative and generated a percentage of both cell population (positive and negative) per 
well. The mean of the nuclear intensity was also routinely analysed and equivalent results 
were obtained.
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CHAPTER 5
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Chapter 5 - Conclusions
Oncogene-induced senescence (OIS) is regarded as an important anti-cancer mechanism 
that restricts uncontrolled proliferation of cells and prevents neoplastic transformation in 
vitro and in vivo, and is recognized as a tumour suppressor mechanism. While its 
importance is beyond doubt, there are many key questions yet to be answered:
• How do cells decide whether to undergo senescence or apoptosis in response to 
stress signals?
• How homogenous is this response in different cellular contexts?
® Which features of senescent phenotype are of fundamental importance?
• Which is the relative contribution of OIS to tumour suppression?
• Is senescence a common trait, across different tissue types, at the early stage of 
tumorigenesis?
In this study we have demonstrated for the first time the involvement of OIS in thyroid 
carcinogenesis. We found that all the oncogenes activated in thyroid tumours (BRAF, RAS, 
RET, and TRK) have the potential to drive senescence in human primary thyrocytes. The 
comparative characterization in their capability to induce senescence in human primary 
thyrocytes revealed interesting similarities and differences in the phenotypes and pathways 
regulating this cellular program.
Translating our in vitro observations in an in vivo setting we found senescent cells at early 
stages of papillary thyroid tumour namely PTMC, as judged by the presence of OIS 
markers, whereas their gradual lost was observed during tumour progression suggesting 
that in thyroid cancer the senescence response may act as an initial barrier that restricts a 
full blown transformation.
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Firstly, it was interesting to detect OIS in human primary thyrocytes with different 
oncogenes transfected with different methods and thus expressed at different levels.
We also established an OIS inducible system in our cellular model and again upon
p  1 o voncogene activation (H-RAS ) cells underwent senescence.
PTC-associated oncogenes triggered senescence by a distinct set of alterations in cellular 
phenotype, changes in chromatin structure and gene expression. Upon oncogenic stress 
human primary thyrocytes became large, flat and multinucleated. Moreover, PTC- 
associated oncogenes drove senescence by increased SA-p-Gal activity, the most widely 
used senescence marker (Dimri et al., 1995) and by formation of bright, punctate DNA foci 
through the cell nucleus, the so called SAHF (Narita et al., 2003).
Regardless of the senescence initiating signals, tumour suppressor pathways are critical for 
initiation and maintenance of the senescent phenotype. These pathways are controlled by 
the tumour suppressor proteins p53 and pRb (Shay et al., 1991). In our cellular model, 
PTC-associated oncogenes triggered a strong and persistent induction of p lb 1^ 4* and p53, 
whereas we failed to observe any significant upregulation of p21cn>1, with exception of H- 
RASG12V expressing thyrocytes.
In light of this specific regulation, we examined the relative function of p53 and pRb in the 
initiation of senescence by assessing the outcomes of their inactivation. To this end, we 
focused on BRAFV600E and inducible H-RASG12v-driven senescence.
As reported in several studies the critical role of p53 and pRb differs in mouse and human 
cells. In mouse embryo fibroblasts, disruption of p53 alone is sufficient to prevent 
senescence (Dirac and Bernards, 2003). Likewise, inactivation of pRb gene together with 
other members of Rb family such as p i07 and p i30, but not pRb alone, is sufficient to 
escape senescence (Dannenberg et al., 2000; Sage et al., 2000).
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This implies that both p53 and pRb pathways are required for the induction of senescence. 
Inactivation of either of these genes in senescent MEFs is enough for proliferation to 
resume (Dannenberg et al., 2000; Sage et al., 2000). These observations suggested a model 
of linear signalling, whereby a stress signal activates p53 which in turn activates pRb. 
Unlike the behaviour of mouse cells, the inactivation of both p53 and pRb is essential to 
prevent to onset of replicative senescence in human cells (Smogorzewska and de Lange, 
2002), whereas disruption of only one of these proteins delays the onset of senescence. This 
indicates that in human cells, p53 and pRb operate in two parallel pathways.
From the observations made in this study it emerges that suppression of p l6INK4a in 
BRAFv600b lentivirally transduced in human primary thyrocytes did not influence the onset
C* 19Vof senescence, whereas cells retrovirally infected with inducible H-RAS vector 
bypassed senescence upon disruption of p l6INK4a. These results are in harmony with 
models previously proposed by others (Michaloglou et al., 2005; Serrano et al., 1997). To 
better understand these differences in the pathways executing OIS by BRAFV600E versus H- 
RASG12V, we also investigated the role of p 16INK4a in human primary thyrocytes transduced 
with retroviral carrying BRAFV600E. Here, it was interesting to discover a strict correlation 
between p l6INK4a expression and cell cycle arrest. Thus, it is possible that different 
oncogenic levels due to the different oncogene delivery may trigger different responses 
upon p 16mK4a abrogation.
While p ld 1^ 43 plays a dominant role in H-RASG12V mediated senescence, p53 is not 
required for the onset of senescence as its inactivation was not sufficient to re-enter the cell 
cycle.
In the last few years, growing body of evidence suggests that OIS is tightly connected with 
inflammation.
151
Cells undergoing senescence display profound changes in their secretome, termed the 
senescence-associated secretory phenotype (SASP) or senescence-messaging secretome 
(SMS) (Coppe et al., 2008; Kuilman and Peeper, 2009): they produce a wide range of 
inflammatory cytokines and growth factors which reinforce senescence (Acosta et al., 
2008; Kuilman et al., 2008; Wajapeyee et al., 2008) or promote carcinogenesis. These 
opposite effects of SASP factors may depend on the cellular context and genetic make-up 
of target cells.
Among SASP factors IGFBP7 is a secreted protein recently proposed as a mediator of 
BRAFV600E induced senescence in melanocytes (Wajapeyee et al., 2008).
Firstly, it was important to find out that IGFBP7 is downregulated in a consistent fraction 
of PTC with respect to normal thyroid. We addressed the functional consequences of 
IGFBP7 downregulation in PTC-derived NIM1 cell line, in which the expression of 
IGFBP7 is lacking. We provided evidence that the restoration of IGFBP7 reduced the 
growth rate, migration, anchorage independent growth of NIM1 cells and all these effects 
were related to apoptosis. This was also recapitulated in vivo: re-expression of IGFBP7 
reduced the NIM1 cells capability to induce tumour formation in mouse xenografts. In 
nutshell, our results suggest that IGFBP7 exerts an oncosuppressor role in thyroid tumour, 
this in agreement with different human cancer models proposed by others. (Akaogi et al., 
1996; Sprenger et al., 1999; Wilson et al., 2002; Burger et al., 2005; Ruan et al., 2006; 
Chen et al., 2007; Sato et al., 2007).
Given the involvement of IGFBP7 in BRAFV600E mediated senescence in melanocytes by
Wajapeyee and colleagues it was of particular interest to determine whether the IGFBP7
expression is changed in BRAFV600E senescent thyrocytes. Surprisingly, we did not detect
any significant upregulation of IGFBP7 in response to oncogenic BRAF: we saw a
reduction in IGFBP7 levels in BRAFV600E infected cells compared with the controls.
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Meanwhile, Scurr and co-workers observed similar IGFBP7 regulation in melanocytes, 
they also reported that BRAFV600E induced senescence in melanocytes irrespective of the 
presence of IGFBP7 (Scurr et al., 2010).
Shifting towards others SASP factors, the finding that H-RASG12V induces senescence in 
human primary thyrocytes through activation of inflammatory network including IL8 and 
its receptor CXCR2 as well as IL6 was exciting. This specific regulation prompted us to 
explore the requirement for CXCR2 receptor and IL8 in OIS. Upon either CXCR2 or IL8 
abrogation senescent thyrocytes expressing H-RASG12V were able bypass OIS and to 
continue proliferating, suggesting that the activation of chemokine signalling via CXCR2 
plays an important role for the senescence establishment.
We wished to extend our findings obtained in vitro in humans by the analysis of thyroid 
tumours characterized by different aggressiveness (including PTMC, PTC NOS, PDTC and 
ATC). It was important to discover that the expression of OIS markers such as p l6 INK4a, 
p21CIP1 and IGFBP7 is upregulated at early stages, and lost during tumour progression. The 
highest expression of all OIS markers analyzed observed in PTMCs would suggest that OIS 
may play a role in the generally indolent clinical course of this PTC variant by keeping 
proliferation under control. Thus, OIS is a mechanism involved in the pathogenesis of 
thyroid carcinoma by constraining neoplastic transformation.
In sum, in this thesis we have established the role of oncogene-induced senescence in 
thyroid carcinogenesis in vitro and in vivo. We have used the oncogene-induced cell system 
in vitro to unravel what mechanisms are important for senescence induction and 
maintenance. Furthermore, we have tried to use the in vitro cell system to identify and 
study some genes involved in OIS, and to link them to cancer progression.
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